US20040235774A1 - Immunostimulatory nucleic acids for the treatment of asthma and allergy - Google Patents

Abstract

The invention involves administration of an immunostimulatory nucleic acid alone or in combination with an asthma/allergy medicament for the treatment or prevention of asthma and allergy in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of drugs.

Description

PRIORITY OF THE INVENTION
• This application claims priority under Title 35 § 119(e), of U.S. Provisional Application No. 60/179,991, filed Feb. 3, 2000, entitled IMMUNOSTIMULATORY NUCLEIC ACIDS FOR THE TREATMENT OF ASTHMA AND ALLERGY, the entire contents of which are incorporated herein by reference.[0001]
BACKGROUND OF THE INVENTION
• Asthma is a chronic inflammatory disease effecting 14-15 million persons in the U.S. alone. Symptoms of asthma include recurrent episodes of wheezing, breathlessness, and chest tightness, and coughing, resulting from airflow obstruction. Airway inflammation associated with asthma can be detected through observation of a number of physiological changes, such as, denudation of airway epithelium, collagen deposition beneath basement membrane, edema, mast cell activation, inflammatory cell infiltration, including neutrophils, eosinophils, and lymphocytes. As a result of the airway inflammation, asthma patients often experience airway hyper-responsiveness, airflow limitation, respiratory symptoms, and disease chronicity. Airflow limitations include acute bronchoconstriction, airway edema, mucous plug formation, and airway remodeling, features which often lead to bronchial obstruction. In some cases of asthma, subbasement membrane fibrosis may occur, leading to persistent abnormalities in lung function.[0002]
• Research over the past several years has revealed that asthma likely results from complex interactions among inflammatory cells, mediators, and other cells and tissues resident in the airway. Mast cells, eosinophils, epithelial cells, macrophage, and activated T-cells all play an important role in the inflammatory process associated with asthma (Djukanovic et al.,[0003]Am. Rev. Respir. Dis;142:434-457; 1990). It is believed that these cells can influence airway function through secretion of preformed and newly synthesized mediators which can act directly or indirectly on the local tissue. It has also been recognized that subpopulations of T-lymphocytes (TH-2) play an important role in regulating allergic inflammation in the airway by releasing selective cytokines and establishing disease chronicity (Robinson, et al.N. Engl. J. Med.;326:298-304; 1992).
• Asthma is a complex disorder which arises at different stages in development and can be classified based on the degree of symptoms of acute, subacute or chronic. An acute inflammatory response is associated with an early recruitment of cells into the airway. The subacute inflammatory response involves the recruitment of cells as well as the activation of resident cells causing a more persistent pattern of inflammation. Chronic inflammatory response is characterized by a persistent level of cell damage and an ongoing repair process, which may result in permanent abnormalities in the airway.[0004]
• Medications for the treatment of asthma are generally separated into two categories, quick-relief medications and long-term control medications. Asthma patients take the long-Jo term control medications on a daily basis to achieve and maintain control of persistent asthma. Long-term control medications include anti-inflammatory agents such as corticosteroids, chromolyn sodium and medacromil; long-acting bronchodilators, such as long-acting β[0005]₂-agonists and methylxanthines; and leukotriene modifiers. The quick-relief medications include short-acting β₂agonists, anti-cholinergics, and systemic corticosteroids. There are many side effects associated with each of these drugs and none of the drugs alone or in combination is capable of preventing or completely treating asthma.
• Allergy is a disease associated with the production of antibodies from a particular class of immunoglobulin, IgE, against allergens. The development of an IgE-mediated response to common aeroallergens is also a factor which indicates predisposition towards the development of asthma. If an allergen encounters a specific IgE which is bound to an Fc IgE receptor on the surface of a basophil (circulating in the blood) or mast cell (dispersed throughout solid tissue), the cell becomes activated, resulting in the production and release of mediators such as histamine, scrotonin, and lipid mediators. Allergic diseases include but are not limited to rhinitis (hay fever) asthma, urticaria and atopic dermatitis.[0006]
• Conventional methods for treating or preventing allergy have involved the use of anti-histamines or desensitization therapies. Anti-histamines and other drugs which block the effects of chemical mediators of the allergic reaction help to regulate the severity of the allergic symptoms but do not prevent the allergic reaction and have no effect on subsequent allergic responses. Desensitization therapies are performed by giving small doses of an allergen, usually by injection under the skin, in order to induce an IgG-type response against the allergen. The presence of IgG antibody helps to neutralize the production of mediators resulting from the induction of IgE antibodies, it is believed. Initially, the subject is treated with a very low dose of the allergen to avoid inducing a severe reaction and the dose is slowly increased. This type of therapy is dangerous because the subject is actually administered the compounds which cause the allergic response and severe allergic reactions can result.[0007]
SUMMARY OF THE INVENTION
• Improved methods and products for the prevention and/or treatment of asthma and allergy are provided according to the invention. The invention is based, in some aspects, on the finding that when immunostimulatory nucleic acid molecules are used in conjunction with medicaments for the treatment of asthma and allergy, some unexpected and improved results are observed. For instance, the efficacy of the combination of immunostimulatory nucleic acids and asthma and allergy medicaments is profoundly improved over the use of each of the medicaments alone. The results are surprising in part because the drugs act through different mechanisms and would not necessarily be expected to improve the efficacy of one another in a synergistic manner.[0008]
• In some aspects, the invention is a method for preventing or treating asthma or allergy by administering a synergistic combination of an immunostimulatory nucleic acid and an asthma/allergy medicament, wherein the combination is administered in an effective amount for synergistically reducing the immune or inflammatory response caused by a mediator of asthma or allergy. It was surprisingly discovered according to the invention that the combination of the immunostimulatory nucleic acid and the asthma/allergy medicament worked synergistically to reduce the immune or inflammatory response initiated when a mediator of asthma or allergy is encountered.[0009]
• In other aspects, the invention is a method for altering the dosage of the asthma/allergy medicament that is required to treat a subject suffering from asthma or allergy. The invention in one aspect is a method for increasing the dose of an asthma/allergy medicament without inducing the level of side effects ordinarily observed with that dose of an asthma/allergy medicament. The method is accomplished by administering to a subject suffering from asthma or allergy or at risk of developing asthma or allergy, an asthma/allergy medicament in a dose which would ordinarily induce side effects, administering an immunostimulatory nucleic acid to the subject, wherein administration of the immunostimulatory nucleic acid prevents the side effects associated with the high dose of the asthma/allergy medicament. The method provides a basis for administering higher therapeutic doses of an asthma/allergy medicament to a subject in order to prevent or reduce the symptoms associated with an asthmatic or an allergic response more sufficiently than a lower dose. It is not desirable to administer such high doses alone, in the absence of the immunostimulatory nucleic acid, because of the side effects resulting from the high dose.[0010]
• In another aspect, the invention includes a method for decreasing the dose of an asthma/allergy medicament by administering to a subject having asthma or allergy or at risk of developing asthma or allergy an asthma/allergy medicament in a sub-therapeutic dosage and an immunostimulatory nucleic acid, wherein the combination of the sub-therapeutic dose of the asthma/allergy medicament and the immunostimulatory nucleic acid produce a therapeutic result in the prevention or treatment of asthma or allergy in the subject. The method allows a lower dose of the asthma/allergy medicament to be used. This provides several advantages, including lower costs associated with using less drugs and less chances of inducing side effects resulting from the medications by using lower doses.[0011]
• According to other aspects, the invention involves methods for treating or preventing asthma and/or allergy by administering an immunostimulatory nucleic acid and an asthma/allergy medicament in different dosing schedules. In one aspect, the invention is a method for preventing or treating asthma or allergy by administering to a subject an effective amount of an immunostimulatory nucleic acid in an effective amount for producing the immune response and subsequently administering to the subject an asthma/allergy medicament. In other aspects, the invention is a method for preventing or treating asthma or allergy by administering to a subject an allergy/asthma medicament in an effective amount for providing some symptomatic relief and subsequently administering an immunostimulatory nucleic acid to the subject. In some embodiments, the immunostimulatory nucleic acid is administered in an effective amount for redirecting the immune response from a Th2 to a Th1 immune response. In some embodiments, the immunostimulatory nucleic acid is administered consistently over a period of time, such as, for instance, in a sustained release vehicle.[0012]
• In another aspect of the invention is a method for treating asthma or allergy by administering to a subject having asthma or allergy or at risk of developing asthma or allergy an immunostimulatory nucleic acid and an asthma/allergy medicament, wherein the immunostimulatory nucleic acid is administered systemically and the asthma/allergy medicament is administered locally. In yet another aspect, the immunostimulatory nucleic acid is administered locally and the asthma/allergy medicament is administered systemically.[0013]
• According to yet another aspect of the invention, a method for treating or preventing asthma/allergy is provided. The method is accomplished by administering to a subject having asthma or allergy or at risk of developing asthma or allergy, an immunostimulatory nucleic acid and an asthma/allergy medicament on a routine schedule. In some embodiments, the routine schedule is a daily, weekly, monthly, or quarterly administration of the medicaments. In other embodiments, the immunostimulatory nucleic acid and/or the asthma/allergy medicament is administered in two or more doses.[0014]
• The immunostimulatory nucleic acid can be administered on a recurring basis, such as daily, weekly, or monthly in one or more doses. Alternatively, it can be administered on a non-regular basis e.g. whenever symptoms being. In yet other embodiments, the asthma/allergy medicament is a quick relief asthma/allergy medicament and in other embodiments it is a long-lasting asthma/allergy medicament.[0015]
• According to yet another aspect of the invention, methods for treating or preventing asthma or allergy using specific immunostimulatory nucleic acid molecules are provided. The method in one aspect involves a method for preventing or treating asthma or allergy by administering to a subject suffering from asthma or allergy or at risk of developing asthma or allergy, an immunostimulatory nucleic acid having a sequence selected from the group consisting of SEQ ID NO: 1 through to SEQ ID NO: 1093 and administering to the subject an asthma/allergy medicament.[0016]
• In yet another aspect of the invention, a method for preventing or treating asthma or allergy utilizing different routes of administration is provided. In one aspect, the method involves the step of administering toga subject having asthma or allergy or at risk of developing asthma or allergy, an immunostimulatory nucleic acid, wherein the immunostimulatory is administered systemically and wherein the asthma/allergy medicament is administered locally. In a related embodiment, the immunostimulatory nucleic acid molecule may be administered locally and the asthma/allergy medicament is administered systemically. In still other embodiments, the immunostimulatory nucleic acid and the asthma/allergy medicament are administered by the same route (i.e., both delivered locally or both delivered systemically), and optionally at the same time.[0017]
• The invention according to another aspect is a method of preventing or treating asthma or allergy by administering a poly-G nucleic acid, in an effective amount for treating or preventing asthma or allergy. In some embodiments the poly-G nucleic acid is administered alone and in other embodiments the poly-G nucleic acid is administered in conjunction with an asthma/allergy medicament. The poly-G nucleic acid in preferred embodiments comprises one of the following formulas: 5′ X[0018]₁X₂GGGX₃X₄3′, wherein X₁, X₂, X₃, and X₄are nucleotides, 5′ GGGNGGG 3′ or 5′ GGGNGGGNGGG 3′, wherein N represents between 0 and 20 nucleotides. In some embodiments at least one of X₃and X₄are a G and in other embodiments both of X₃and X₄are a G. Accordingly, in some embodiments, the poly-G nucleic acid may comprise a sequence of 5′ X₁X₂GGGGX₄3′. In still other embodiments, the poly-G nucleic acid is one which is rich in G (e.g., six out of seven bases are G, or six out of eight bases are G).
• The poly-G may be free of unmethylated CG dinucleotides, or may include at least one unmethylated CG dinucleotide.[0019]
• The poly G nucleic acid in some embodiments is selected from the group consisting of SEQ ID NO: 5, 6, 73, 215, 267-269, 276, 282, 288, 297-299, 355, 359, 386, 387, 444, 476, 531, 557-559, 733, 768, 795, 796, 914-925, 928-931, 933-936, and 938. In other embodiments the poly G nucleic acid includes a sequence selected from the group consisting of SEQ ID NO: 67, 80-82, 141, 147, 148, 173, 178, 183, 185, 214, 224, 264, 265, 315, 329, 434, 435, 475, 519, 521-524, 526, 527, 535, 554, 565, 609, 628, 660, 661, 662, 725, 767, 825, is 856, 857, 876, 892, 909, 926, 927, 932, and 937.[0020]
• The invention provides, in yet another aspect, a method for treating or preventing asthma or allergy in a hypo-responsive subject. The method involves administering to a hypo-responsive subject having asthma or allergy or at risk of developing asthma or allergy an immunostimulatory nucleic acid. In one embodiment, the method further comprises administering to the hypo-responsive subject an asthma/allergy medicament. If the asthma/allergy medicament is not administered to the hypo-responsive subject, then the immunostimulatory nucleic acid is administered in an amount to treat or prevent the asthma or allergy. If the asthma/allergy medicament is administered to the hypo-responsive subject, then the immunostimulatory nucleic acid and the asthma/allergy medicament are administered in an effective amount to treat or prevent the asthma or allergy. In this latter instance, the amount of the immunostimulatory nucleic acid and the amount of the asthma/allergy medicament may be insufficient (i.e., ineffective) in treating or preventing the asthma or allergy if administered alone. In other words, in some embodiments, the immunostimulatory nucleic acid may be administered to the hypo-responsive subject in a sub-therapeutic amount. Similarly, the asthma/allergy medicament may also be administered in a sub-therapeutic amount. However, the combination of the immunostimulatory nucleic acid and the asthma/allergy medicament allows for lower doses of one or both in order to treat or prevent the asthma or allergy. The immunostimulatory nucleic acid may be administered concurrently with the asthma/allergy medicament, but need not be.[0021]
• The hypo-responsive subject may be one who is hypo-responsive to an asthma/allergy medicament. In one embodiment, the hypo-responsive subject is selected from the group consisting of a subject who is refractory to an asthma/allergy medicament, a subject who is a non-responder to an asthma/allergy medicament, an elderly subject and a neonatal subject.[0022]
• According to yet another aspect of the invention, a method is provided for preventing asthma or allergy in a subject at risk of developing asthma or allergy which involves administering to a subject at risk of developing asthma or allergy an effective amount of an immunostimulatory nucleic acid substantially prior to an asthmatic or an allergic event.[0023]
• In one embodiment, the immunostimulatory nucleic acid is administered at least three months, at least two months, at least one month, or at least 20 days prior to the asthmatic or allergic event. In another embodiment, the immunostimulatory nucleic acid is administered at least two weeks prior to the asthmatic or allergic event. In yet another embodiment, the immunostimulatory nucleic acid is administered at least 10 days, at least 5 days or at least 2 days prior to the asthmatic or allergic event.[0024]
• In one embodiment, the asthmatic or allergic event is selected from the group consisting of an asthma attack, seasonal allergic rhinitis, and perennial allergic rhinitis.[0025]
• In one embodiment, the immunostimulatory nucleic acid is administered in a routine schedule. In a related embodiment, the routine schedule is selected from the group consisting of a daily routine, a weekly routine, a bi-weekly routine, a monthly routine, and a bi-monthly routine.[0026]
• In a further aspect, the invention provides another method for decreasing a dose of an asthma/allergy medicament. The method involves administering to a subject at risk of developing asthma or allergy, substantially prior to an asthmatic or allergic event, an immunostimulatory nucleic acid in an amount to decrease an effective amount of an asthma/allergy medicament subsequently administered to the subject in order to treat the asthma or allergy.[0027]
• In one embodiment, the immunostimulatory nucleic acid is administered at least three months, at least two months, at least one month or at least 20 days prior to the asthmatic or allergic event. In another embodiment, the immunostimulatory nucleic acid is administered at least two weeks, at least 10 days, at least one week, at least 5 days or at least 2 days prior to the asthmatic or allergic event.[0028]
• In one embodiment, the asthmatic or allergic event is selected from the group consisting of an asthma attack, seasonal allergic rhinitis, and perennial allergic rhinitis.[0029]
• In one embodiment, the immunostimulatory nucleic acid is administered in a routine schedule. The routine schedule may be selected from the group consisting of a daily routine, a weekly routine, a bi-weekly routine, a monthly routine, and a bimonthly routine.[0030]
• The method may further comprise administering to the subject the asthma/allergy medicament subsequent to the administration of the immunostimulatory nucleic acid. In one embodiment, the asthma/allergy medicament is administered immediately prior to, concurrently with, or following the asthmatic or allergic event. The method may further comprise administering the immunostimulatory nucleic acid concurrently with or following the asthmatic or allergic event. In one embodiment, the immunostimulatory nucleic acid is administered concurrently with the asthma/allergy medicament. In one embodiment, the asthma/allergy medicament is administered in a sub-therapeutic dose.[0031]
• In these and other aspects of the invention, the immunostimulatory nucleic acids have a number of attributes. The immunostimulatory nucleic acids may have a modified backbone. In some embodiments, the modified backbone is a phosphate modified backbone, and in related embodiments, the phosphate modified backbone is a phosphorothioate backbone. In certain embodiments, the immunostimulatory nucleic acid is a CpG nucleic acid, in other embodiments, the immunostimulatory nucleic acid is a T-rich nucleic acid, while in still other embodiments, the immunostimulatory nucleic acid is a poly-G nucleic acid. Preferably, the T-rich and poly-G nucleic acids are also CpG nucleic acids. In still other embodiments, the immunostimulatory nucleic acid comprises a poly-G motif (e.g., 5′ GGGG 3′) and a palindrome. Preferably, the immunostimulatory nucleic acid comprises two poly-G motifs, one 5′ and one 3′ to a centrally located palindrome sequence. Even more preferably, the backbone of these latter immunostimulatory nucleic acids is chimeric (i.e., it is partially, but riot completely, composed of phosphorothioate linkages). In some embodiments, a plurality of immunostimulatory nucleic acids is administered, wherein the plurality comprises CpG nucleic acids and T-rich nucleic acids, or CpG nucleic acids and poly-G nucleic acids, or T-rich nucleic acids and poly-G nucleic acids.[0032]
• In these and other aspects of the invention, the asthma/allergy medicaments have a number of attributes. In some embodiments, the asthma/allergy medicament is an asthma medicament, while in still other embodiments, the asthma/allergy medicament is an allergy medicament.[0033]
• In some embodiments, the asthma/allergy medicament is selected from the group consisting of a steroid and an immunomodulator. In certain embodiments, the steroid may be selected from the group consisting of beclomethasone, fluticasone, tramcinolone, budesonide, and budesonide. In certain embodiments, the immunomodulator may be selected from the group consisting of an anti-inflammatory agent, a leukotriene antagonist, an IL-4 mutein, a soluble IL-4 receptor, an immunosuppressant, anti-IL-4 antibody, an IL-4 antagonist, an anti-IL-5 antibody, a soluble IL-13 receptor-Fc fusion protein, an anti-IL-9 antibody, a CCR3 antagonist, a CCR5 antagonist, a VLA-4 inhibitor, and a downregulator of IgE. The downregulator of IgE may be an anti-Ig antibody or a fragment thereof, but need not be so limited. The immunosuppressant may be a tolerizing peptide vaccine, but need not be so limited.[0034]
• In some embodiments, the asthma/allergy medicament is a medicament selected from the group consisting of a PDE-4 inhibitor, a bronchodilator/beta-2 agonist, a K+ channel opener, a VLA-4 antagonist, a neurokin antagonist, a TXA2 synthesis inhibitor, Xanthanine, an arachidonic acid antagonist, a 5 lipoxygenase inhibitor, a thromboxin A2 receptor antagonist, a thromboxane A2 antagonist, an inhibitor of 5-lipox activation-protein, and a protease inhibitor. In certain embodiments, the bronchodilator/beta-2 agonist may be selected from the group consisting of salmeterol, salbutamol, terbutaline, D2522/formoterol, fenoterol and orciprenaline.[0035]
• In some embodiments, the asthma/allergy medicament is a medicament selected from the group consisting of an anti-histamine and a prostaglandin inducer. In certain embodiments, the anti-histamine is selected from the group consisting of loratidine, cetirizine, buclizine, ceterizine analogues, fexofenadine, terfenadine, desloratadine, norastemizole, epinastine, ebastine, ebastine, astemizole, levocabastine, azelastine, tranilast, terfenadine, mizolastine, betatastine, CS 560 and HSR 609. The prostaglandin inducer may-be S-5751, but is not so limited.[0036]
• In still other embodiments, the asthma/allergy medicament is a prostaglandin inhibitor in the form of a cyclooxygenase-2 (COX-2) inhibitor. The COX-2 inhibitor may be selected from the group consisting of celecoxib, rofecoxib, NS-398, 1-745,337, meloxicam, nimesulide, SC236, and C-phycocyanin.[0037]
• A composition comprising a poly-G nucleic acid in an aerosol formulation is provided according to other aspects of the invention.[0038]
• A kit is provided according to another aspect of the invention. The kit in one aspect includes a sustained-release vehicle containing an immunostimulatory nucleic acid and at least one container housing an asthma/allergy medicament, and instructions for timing of administration of the immunostimulatory nucleic acid and the asthma/allergy medicament. In another aspect, the kit includes containers for multiple administrations of immunostimulatory nucleic acid and/or multiple administrations of immunostimulatory nucleic acid and at least one container housing an asthma/allergy medicament.[0039]
• A composition is provided according to another aspect of the invention. The composition includes an immunostimulatory nucleic acid and an asthma/allergy medicament, formulated in a pharmaceutically-acceptable carrier and in an effective amount for preventing or treating an immune response associated with exposure to a mediator of asthma or allergy.[0040]
• Formulations of poly-G nucleic acids are also encompassed by the invention. For instance the invention includes a pharmaceutical composition of a poly-G nucleic acid in an aerosol formulation.[0041]
• The immunostimulatory nucleic acid may be any of the immunostimulatory nucleic acids described above, and may have any of the attributes of the immunostimulatory nucleic acids described above which are useful in other aspects of the invention.[0042]
• The asthma/allergy medicament may be any of the asthma medicaments-or allergy medicaments described above which are useful in other aspects of the invention.[0043]
• Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention.[0044]
DETAILED DESCRIPTION OF THE INVENTION
• The invention relates to methods and products for the treatment of asthma/allergy using a combination of immunostimulatory nucleic acids and asthma/allergy medicaments. The compositions can be administered in higher doses without as many side effects as are ordinarily achieved at those dosage levels or in lower doses with higher efficacy than is ordinarily achieved with those doses. The compositions can also be administered on-fixed schedules or in different temporal relationships to one another. The various combinations have many advantages over the prior art methods of treating asthma and allergy.[0045]
• One method for treating or preventing asthma or allergy includes the step of administering a synergistic combination of an immunostimulatory nucleic acid and an asthma/allergy medicament in an effective amount to treat or prevent the asthma or allergy.[0046]
• An “immunostimulatory nucleic acid” as used herein is any nucleic acid containing an immunostimulatory motif or backbone that induces a Th1 immune response and/or suppresses a Th2 immune response. Immunostimulatory motifs include, but are not limited to, CpG motifs, poly-G motifs, and T-rich motifs. Immunostimulatory backbones include, but are not limited to, phosphate modified backbones, such as phosphorothioate backbones. Immunostimulatory nucleic acids have been described extensively in the prior art and a brief summary of these nucleic acids is presented below.[0047]
• The immunostimulatory nucleic acids when combined with the asthma/allergy medicaments have many advantages over each composition alone for the treatment of asthma so and allergy. The immunostimulatory nucleic acid functions in some aspects by simultaneously suppressing Th2-type immune responses (IL-4, IgE production, histamine release) that can result in airway inflammation and bronchial spasm, and/or inducing Th1-type immune responses (IFN-γ and IL-12 production) that promote harmless antibody and cellular responses. This creates an environment inside the body that safely and effectively prevents hypersensitive reactions from occurring, thereby eliminating symptoms.[0048]
• The immunostimulatory nucleic acids eliminate/reduce bronchial hyperreactivity, bronchoconstriction, bronchial obstruction, airway inflammation and atopy (which improves asthma control, normalizes lung function, prevents irreversible airway injury); and may also inhibit acute response to exercise, cold dry air, and SO[0049]₂. The nucleic acids provide long-lasting effects, thus reducing dosing regimes, improving compliance and maintenance therapy, reducing emergency situations; and improving quality of life. These compounds are also useful because they provide early anti-infective activity, which leads to decreasing infectious episodes, which further reduces hyperreactive immune responses. This is especially true in subjects like children or immuno-compromised subjects. Furthermore, use of the immunostimulatory nucleic acids reduces/eliminates use of inhalers, which can exacerbate hypersensitive reactions by providing simpler and safer delivery and by allowing less drugs to be used.
• Immunostimulatory nucleic acids stimulate the immune system to prevent or treat allergy and/or asthma. The strong yet balanced, cellular and humoral immune-responses that result from the nucleic acid's stimulation reflect the body's own natural defense system against invading allergens and initiators.[0050]
• The terms “nucleic acid” and “oligonucleotide” are used interchangeably to mean multiple nucleotides (i.e. molecules comprising a sugar (e.g. ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g. cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g. adenine (A) or guanine (G)). As used herein, the terms refer to oligoribonucleotides as well as oligodeoxyribonucleotides. The terms shall also include polynucleosides (i.e. a polynucleotide minus the phosphate) and any other organic base containing polymer. Nucleic acids include vectors, e.g., plasmids as well as oligonucleotides. Nucleic acid molecules can be obtained from existing nucleic acid sources (e.g. genomic or cDNA), but are preferably synthetic (e.g. produced by oligonucleotide synthesis).[0051]
• Exemplary immunostimulatory nucleic acids as those described herein as well as various control nucleic acids include but are-not limited to those presented in Table 1.[0052]

  TABLE 1
  SEQ ID NO:	ODN SEQUENCE	BACKBONE

  1	tctcccagcgtgcgccat	s
  2	ataatccagcttgaaccaag	s
  3	ataatcgacgttcaagcaag	s
  4	taccgcgtgcgaccctct	s
  5	ggggagggt	s
  6	ggggagggg	s
  7	ggtgaggtg	s
  8	tccatgtzgttcctgatgct	o
  9	gctaccttagzgtga	o
  10	tccatgazgttcctgatgct	o
  11	tccatgacgttcztgatgct	o
  12	gctagazgttagtgt	o
  13	agctccatggtgctcactg	s
  14	ccacgtcgaccctcaggcga	s
  15	gcacatcgtcccgcagccga	s
  16	gtcactcgtggtacctcga	s
  17	gttggatacaggccagactttgttg	o
  18	gattcaacttgcgatcatcttaggc	o
  19	accatggacgaactgtttcccctc	s
  20	accatggacgagctgtttcccctc	s
  21	accatggacgacctgtttcccctc	s
  22	accatggacgtactgtttcccctc	s
  23	accatggacggtctgtttcccctc	s
  24	accatggacgttctgtttcccctc	s
  25	ccactaacatctgctgctccacaag	o
  26	acttctcatagtccctttggtccag	o
  27	tccatgagcttcctgagtct	o
  28	gaggaaggigiggaigacgt	o
  29	gtgaaticgttcicgggict	o
  30	aaaaaa	s
  31	cccccc	s
  32	ctgtca	s
  33	tcgtag	s
  34	tcgtgg	s
  35	cgtcgt	s
  36	tccatgtcggtcctgagtct	sos
  37	tccatgccggtcctgagtct	sos
  38	tccatgacggtcctgagtct	sos
  39	tccatgacggtcctgagtct	sos
  40	tccatgtcgatcctgagtct	sos
  41	tccatgtcgctcctgagtct	sos
  42	tccatgtcgttcctgagtct	sos
  43	tccatgacgttcctgagtct	sos
  44	tccataacgttcctgagtct	sos
  45	tccatgacgtccctgagtct	sos
  46	tccatcacgtgcctgagtct	sos
  47	tccatgctggtcctgagtct	sos
  48	tccatgtzggtcctgagtct	sos
  49	ccgcttcctccagatgagctcatgggtttctccaccaag	o
  50	cttggtggagaaacccatgagctcatctggaggaagcgg	o
  51	ccccaaagggatgagaagtt	o
  52	agatagcaaatcggctgacg	o
  53	ggttcacgtgctcatggctg	o
  54	tctcccagcgtgcgccat	s
  55	tctcccagcgtgcgccat	s
  56	taccgcgtgcgaccctct	s
  57	ataatccagcttgaaacaag	s
  58	ataatcgacgttcaagcaag	s
  59	tccatgattttcctgatttt	o
  60	ttgtttttttgtttttttgttttt	s
  61	ttttttttgtttttttgttttt	o
  62	tgctgcttttgtgcttttgtgctt	s
  63	tgctgcttgtgcttttgtgctt	o
  64	gcattcatcaggcgggcaagaat	o
  65	taccgagcttcgacgagatttca	o
  66	gcatgacgttgagct	s
  67	cacgttgaggggcat	s
  68	ctgctgagactggag	s
  69	tccatgacgttcctgacgtt	s
  70	gcatgagcttgagctga	o
  71	tcagcgtgcgcc	s
  72	atgacgttcctgacgtt	s
  73	ttttggggttttggggtttt	s
  74	tctaggctttttaggcttcc	s
  75	tgcattttttaggccaccat	s
  76	tctcccagcgtgcgtgcgccat	s
  77	tctcccagcgggcgcat	s
  78	tctcccagcgagcgccat	s
  79	tctcccagcgcgcgccat	s
  80	ggggtgacgttcagggggg	sos
  81	ggggtcaagcgtgcgccatggggg	sos
  82	ggggtgtcgttcagggggg	sos
  83	tccatgtcgttcctgtcgtt	s
  84	tccatagcgttcctagcgtt	s
  85	tcgtcgctgtctccgcttctt	s
  86	gcatgacgttgagct	sos
  87	tctcccagcgtgcgccatat	sos
  88	tccatgazgttcctgazgtt	s
  89	gcatgazgttgagct	o
  90	tccagcgtgcgccata	sos
  91	tctcccagcgtgcgccat	o
  92	tccatgagcttcctgagtct	o
  93	gcatgtcgttgagct	sos
  94	tcctgacgttcctgacgtt	s
  95	gcatgatgttgagct	o
  96	gcatttcgaggagct	o
  97	gcatgtagctgagct	o
  98	tccaggacgttcctagttct	o
  99	tccaggagcttcctagttct	o
  100	tccaggatgttcctagttct	o
  101	tccagtctaggcctagttct	o
  102	tccagttcgagcctagttct	o
  103	gcatggcgttgagct	sos
  104	gcatagcgttgagct	sos
  105	gcattgcgttgagct	sos
  106	gcttgcgttgcgttt	sos
  107	tctcccagcgttgcgccatat	sos
  108	tctcccagcgtgagttatat	sos
  109	tctccctgcgtgcgccatat	sos
  110	tctgcgtgcgtgcgccatat	505
  111	tctcctagcgtgcgccatat	sos
  112	tctcccagcgtgcgcctttt	sos
  113	gctandcghhagc	o
  114	tcctgacgttccc	o
  115	ggaagacgttaga	o
  116	tcctgacgttaga	o
  117	tcagaccagctggtcgggtgttcctga	o
  118	tcaggaacacccgaccagctggtctga	o
  119	gctagtcgatagc	o
  120	gctagtcgctagc	o
  121	gcttgacgtctagc	o
  122	gcttgacgtttagc	o
  123	gcttgacgtcaagc	o
  124	gctagacgtttagc	o
  125	tccatgacattcctgatgct	o
  126	gctagacgtctagc	o
  127	ggctatgtcgttcctagcc	o
  128	ggctatgtcgatcctagcc	o
  129	ctcatgggtttctccaccaag	o
  130	cttggtggagaaacccatgag	o
  131	tccatgacgttcatagttct	o
  132	ccgcttcctccagatgagctcatg	o
  133	catgagctcatctggaggaagcgg	o
  134	ccagatgagctcatgggtttctcc	o
  135	ggagaaacccatgagctcatctgg	o
  136	agcatcaggaacgacatgga	o
  137	tccatgacgttcctgacgtt	rna
  138	gcgcgcgcgcgcgcgcgcg	o
  139	ccggccggccggccggccgg	o
  140	ttccaatcagccccacccgctctggccccaccctcaccctcca	o
  141	tggagggtgagggtggggccagagcgggtggggctgattggaa	o
  142	tcaaatgtgggattttcccatgagtct	o
  143	agactcatgggaaaatcccacatttga	o
  144	tgccaagtgctgagtcactaataaaga	o
  145	tctttattagtgactcagcacttggca	o
  146	tgcaggaagtccgggttttccccaacccccc	o
  147	ggggggttggggaaaacccggacttcctgca	o
  148	ggggactttccgctggggactttccagggggactttcc	sos
  149	tccatgacgttcctctccatgacgttcctctccatgacgttaatc	o
  150	gaggaacgtcatggagaggaacgtcatggagaggaacgtcatgga	o
  151	ataatagagcttcaagcaag	s
  152	tccatgacgttcctgacgtt	s
  153	tccatgacgttcctgacgtt	sos
  154	tccaggactttcctcaggtt	s
  155	tcttgcgatgctaaaggacgtcacattgcacaatcttaataaggt	o
  156	accttattaagattgtgcaatgtgacgtcctttagcatcgcaaga	o
  157	tcctgacgttcctggcggtcctgtcgct	o
  158	tcctgtcgctcctgtcgct	o
  159	tcctgacgttgaagt	o
  160	tcctgtcgttgaagt	o
  161	tcctggcgttgaagt	o
  162	tcctgccgttgaagt	o
  163	tccttacgttgaagt	o
  164	tcctaacgttgaagt	o
  165	tcctcacgttgaagt	o
  166	tcctgacgatgaagt	o
  167	tcctgacgctgaagt	o
  168	tcctgacggtgaagt	o
  169	tcctgacgtagaagt	o
  170	tcctgacgtcgaagt	o
  171	tcctgacgtggaagt	o
  172	tcctgagcttgaagt	o
  173	gggggacgttggggg	o
  174	tcctgacgttccttc	o
  175	tctcccagcgagcgagcgccat	s
  176	tcctgacgttcccctggcggtcccctgtcgct	o
  177	tcctgtcgctcctgtcgctcctgtcgct	o
  178	tcctggcggggaagt	o
  179	tcatgazgttgaagt	o
  180	tcztgacgttgaagt	o
  181	tcctagcgttgaagt	o
  182	tccagacgttgaagt	o
  183	tcctgacggggaagt	o
  184	tcctggcggtgaagt	o
  185	ggctccggggagggaatttttgtctat	o
  186	atagacaaaaattccatccccggagcc	o
  187	tccatgagcttccttgagtct	rna
  188	tcgtcgctgtctccgcttctt	so
  189	tcgtcgctgtctccgcttctt	s20
  190	tcgagacattgcacaatcatctg	o
  191	cagattgtgcaatgtctcga	o
  192	tccatgtcgttcctgatgcg	o
  193	gcgatgtcgttcctgatgct	o
  194	gcgatgtcgttcctgatgcg	o
  195	tccatgtcgttccgcgcgcg	o
  196	tccatgtcgttcctgccgct	o
  197	tccatgtcgttcctgtagct	o
  198	gcggcgggcggcgcgcgccc	o
  199	atcaggaacgtcatgggaagc	o
  200	tccatgagcttcctgagtct	p-ethoxy
  201	tcaacgtt	p-ethoxy
  202	tcaagctt	p-ethoxy
  203	tcctgtcgttcctgtcgtt	s
  204	tccatgtcgtttttgtcgtt	s
  205	tcctgtcgttccttgtcgtt	s
  206	tccttgtcgttcctgtcgtt	s
  207	btccattccatgacgttcctgatgcttcca	os
  208	tcctgtcgttttttgtcgtt	s
  209	tcgtcgctgtctccgcttctt	s
  210	tcgtcgctgtctgcccttctt	s
  211	tcgtcgctgttgtcgtttctt	s
  212	tcctgtcgttcctgtcgttggaacgacagg	o
  213	tcctgtcgttcctgtcgtttcaacgtcaggaacgacagga	o
  214	ggggtctgtcgttttgggggg	sos
  215	ggggtctgtgcttttgggggg	sos
  216	tccggccgttgaagt	o
  217	tccggacggtgaagt	o
  218	tcccgccgttgaagt	o
  219	tccagaaggtgaagt	o
  220	tcccgacggtgaagt	o
  221	tccagagcttgaagt	o
  222	tccatgtzgttcctgtzgtt	s
  223	tccatgacgttcctgacgtt	sos
  224	ggggttgacgttttgggggg	sos
  225	tccaggacttctctcaggtt	s
  226	tttttttttttttttttttt	s
  227	tccatgccgttcctgccgtt	s
  228	tccatggcgggcctggcggg	s
  229	tccatgacgttcctgccgtt	s
  230	tccatgacgttcctggcggg	s
  231	tccatgacgttcctgcgttt	s
  232	tccatgacggtcctgacggt	s
  233	tccatgcgtgcgtgcgtttt	s
  234	tccatgcgttgcgttgcgtt	s
  235	btccattccattctaggcctgagtcttccat	os
  236	tccatagcgttcctagcgtt	o
  237	tccatgtcgttcctgtcgtt	o
  238	tccatagcgatcctagcgat	o
  239	tccattgcgttccttgcgtt	o
  240	tccatagcggtcctagcggt	o
  241	tccatgattttcctgcagttcctgatttt
  242	tccatgacgttcctgcagttcctgacgtt	s
  243	ggcggcggcggcggcggcgg	o
  244	tccacgacgttttcgacgtt	s
  245	tcgtcgttgtcgttgtcgtt	s
  246	tcgtcgttttgtcgttttgtcgtt	s
  247	tcgtcgttgtcgttttgtcgtt	s
  248	gcgtgcgttgtcgttgtcgtt	s
  249	czggczggczgggczccgg	o
  250	gcggcgggcggcgcgcgccc	s
  251	agicccgigaacgiattcac	o
  252	tgtcgtttgtcgtttgtcgtt	s
  253	tgtcgttgtcgttgtcgttgtcgtt	s
  254	tgtcgttgtcgttgtcgttgtcgtt	s
  255	tcgtcgtcgtcgtt	s
  256	tgtcgttgtcgtt	s
  257	cccccccccccccccccccc	s
  258	tctagcgtttttagcgttcc	sos
  259	tgcatcccccaggccaccat	s
  260	tcgtcgtcgtcgtcgtcgtcgtt	sos
  261	tcgtcgttgtcgttgtcgtt	sos
  262	tcgtcgttttgtcgttttgtcgtt	sos
  263	tcgtcgttgtcgttttgtcgtt	sos
  264	ggggagggaggaacttcttaaaattcccccagaatgttt	o
  265	aaacattctgggggaattttaagaagttcctccctcccc	o
  266	atgtttacttcttaaaattcccccagaatgttt	o
  267	aaacattctgggggaattttaagaagtaaacat	o
  268	atgtttactagacaaaattcccccagaatgttt	o
  269	aaacattctgggggaattttgtctagtaaacat	o
  270	aaaattgacgttttaaaaaa	sos
  271	ccccttgacgttttcccccc	sos
  272	ttttcgttgtttttgtcgtt
  273	tcgtcgttttgtcgttttgtcgtt	sos
  274	ctgcagcctgggac	o
  275	acccgtcgtaattatagtaaaaccc	o
  276	ggtacctgtggggacattgtg	o
  277	agcaccgaacgtgagagg	o
  278	tccatgccgttcctgccgtt	o
  279	tccatgacggtcctgacggt	o
  280	tccatgccggtcctgccggt	o
  281	tccatgcgcgtcctgcgcgt	o
  282	ctggtctttctggtttttttctgg	s
  283	tcaggggtggggggaacctt	sos
  284	tacatgazgttcctagttct	o
  285	tccatgatgttcctagttct	o
  286	cccgaagtcatttcctcttaacctgg	o
  287	ccaggttaagaggaaatgacttcggg	o
  288	tcctggzggggaagt	o
  289	gzggzgggzggzgzgzgccc	x
  290	tccatgtgcttcctgatgct	o
  291	tccatgtccttcctgatgct
  292	tccatgtcgttcctagttct
  293	tccaagtagttcctagttct	o
  294	tccatgtagttcctagttct	o
  295	tcccgcgcgttccgcgcgtt	s
  296	tcctggcggtcctggcggtt	s
  297	tcctggaggggaagt	o
  298	tcctgggggggaagt	o
  299	tcctggtggggaagt	o
  300	tcgtcgttttgtcgttttgtcgtt	o
  301	ctggtctttctggtttttttctgg	o
  302	tccatgacgttcctgacgtt	o
  303	tccaggacttctctcaggtt	sos
  304	tzgtzgttttgtzgttttgtzgtt	o
  305	btcgtcgttttgtcgttttgtcgttttttt	os
  306	gctatgacgttccaaggg	s
  307	tcaacgtt	s
  308	tccaggactttcctcaggtt	o
  309	ctctctgtaggcccgcttgg	s
  310	ctttccgttggacccctggg	s
  311	gtccgggccaggccaaagtc	s
  312	gtgcgcgcgagcccgaaatc	s
  313	tccatgaigttcctgaigtt	s
  314	aatagtcgccataacaaaac	o
  315	aatagtcgccatggcggggc	o
  316	btttttccatgtcgttcctgatgcttttt	os
  317	tcctgtcgttgaagtttttt	o
  318	gctagctttagagctttagagctt	o
  319	tgctgcttcccccccccccc	o
  320	tcgacgttcccccccccccc	o
  321	tcgtcgttcccccccccccc	o
  322	tcgtcgttcccccccccccc	o
  323	tcgccgttcccccccccccc	o
  324	tcgtcgatcccccccccccc	o
  325	tcctgacgttgaagt	s
  326	tcctgccgttgaagt	s
  327	tcctgacggtgaagt	s
  328	tcctgagcttgaagt	s
  329	tcctggcggggaagt	s
  330	aaaatctgtgcttttaaaaaa	sos
  331	gatccagtcacagtgacctggcagaatctggat	o
  332	gatccagattctgccaggtcactgtgactggat	o
  333	gatccagtcacagtgactcagcagaatctggat	o
  334	gatccagattctgctgagtcactgtgactggat	o
  335	tcgtcgttccccccczcccc	o
  336	tzgtggttccccccaccccc	o
  337	tzgtcgttcccccccccccc	o
  338	tcgtzgttcccccacccccc	o
  339	tcgtcgctccaccccccccc	o
  340	tcgtcggtcccccccccccc	o
  341	tcggcgttcccccccccccc	o
  342	ggccttttcccccccccccc	o
  343	tcgtcgttttgacgttttgtcgtt	s
  344	tcgtcgttttgacgttttgacgtt	s
  345	ccgtcgttcccccccccccc	o
  346	gcgtcgttcccccccccccc	o
  347	tcgtcattcccccccccccc	o
  348	acgtcgttcccccccccccc	o
  349	ctgtcgttcccccccccccc	o
  350	btttttcgtcgttcccccccccccc	os
  351	tcgtcgttccccccccccccb	o
  352	tcgtcgttttgtcgttttgtcgttb	o
  353	tccagttccttcctcagtct	o
  354	tzgtcgttttgtcgttttgtcgtt	o
  355	tcctggaggggaagt	s
  356	tcctgaaaaggaagt	s
  357	tcgtcgttccccccccc	s
  358	tzgtzgttttgtzgttttgtzgtt	s
  359	ggggtcaagcttgagggggg	sos
  360	tgctgcttcccccccccccc	s
  361	tcgtcgtcgtcgtt	s2
  362	tcgtcgtcgtagtt	s20
  363	tcgtcgtcgtcgtt	os2
  364	tcaacgttga	s
  365	tcaacgtt	s
  366	atagttttccatttttttac
  367	aatagtcgccatcgcgcgac	o
  368	aatagtcgccatcccgggac	o
  369	aatagtcgccatcccccccc	o
  370	tgctgcttttgtgcttttgtgctt	o
  371	ctgtgctttctgtgtttttctgtg	s
  372	ctaatctttctaatttttttctaa	s
  373	tcgtcgttggtgtcgttggtgtcgtt	s
  374	tcgtcgttggttgtcgttttggtt	s
  375	accatggacgagctgtttcccctc
  376	tcgtcgttttgcgtgcgttt	s
  377	ctgtaagtgagcttggagag
  378	gagaacgctggaccttcc
  379	cgggcgactcagtctatcgg
  380	gttctcagataaagcggaaccagcaacagacacagaa
  381	ttctgtgtctgttgctggttccgctttatctgagaac
  382	cagacacagaagcccgatagacg
  383	agacagacacgaaacgaccg
  384	gtctgtcccatgatctcgaa
  385	gctggccagcttacctcccg
  386	ggggcctctatacaacctggg
  387	ggggtccctgagactgcc
  388	gagaacgctggaccttccat
  389	tccatgtcggtcctgatgct
  390	ctcttgcgacctggaaggta
  391	aggtacagccaggactacga
  392	accatggacgacctgtttcccctc
  393	accatggattacctttttcccctt
  394	atggaaggtccagcgttctc	o
  395	agcatcaggaccgacatgga	o
  396	ctctccaagctcacttacag
  397	tccctgagactgccccacctt
  398	gccaccaaaacttgtccatg
  399	gtccatggcgtgcgggatga
  400	cctctatacaacctgggac
  401	cgggcgactcagtctatcgg
  402	gcgctaccggtagcctgagt
  403	cgactgccgaacaggatatcggtgatcagcactgg
  404	ccagtgctgatcaccgatatcctgttcggcagtcg
  405	ccaggttgtatagaggc
  406	tctcccagcgtacgccat	s
  407	tctcccagcgtgcgtttt	s
  408	tctcccgacgtgcgccat	s
  409	tctcccgtcgtgcgccat	s
  410	ataatcgtcgttcaagcaag	s
  411	tcgtcgttttgtcgttttgtcgt	s2
  412	tcgtcgttttgtcgttttgtcgtt	s2
  413	tcgtcgttttgtcgttttgtcgtt	s2
  414	tcntcgtnttntcgtnttntcgtn	s
  415	tctcccagcgtcgccat	s
  416	tctcccatcgtcgccat	s
  417	ataatcgtgcgttcaagaaag	s
  418	ataatcgacgttcccccccc	s
  419	tctatcgacgttcaagcaag	s
  420	tcc tga cgg gg agt	s
  421	tccatgacgttcctgatcc
  422	tccatgacgttcctgatcc
  423	tccatgacgttcctgatcc
  424	tcc tgg cgt gga agt	s
  425	tccatgacgttcctgatcc
  426	tcgtcgctgttgtcgtttctt	s
  427	agcagctttagagctttagagctt	s
  428	cccccccccccccccccccccccc	s
  429	tcgtcgttttgtcgttttgtcgttttgtcgtt	s
  430	tcgtcgttttttgtcgttttttgtcgtt	s
  431	tcgtcgtttttttttttttt	s
  432	tttttcaacgttgatttttt	sos
  433	tttttttttttttttttttttttt	s
  434	ggggtcgtcgttttgggggg
  435	tcgtcgttttgtcgttttgggggg
  436	tcgtcgctgtctccgcttcttcttgcc	s
  437	tcgtcgctgtctccg	s
  438	ctgtaagtgagcttggagag
  439	gagaacgctggaccttccat
  440	ccaggttgtatagaggc
  441	gctagacgttagcgtga
  442	ggagctcttcgaacgccata
  443	tctccatgatggttttatcg
  444	aaggtggggcagtctcaggga
  445	atcggaggactggcgcgccg
  446	ttaggacaaggtctagggtg
  447	accacaacgagaggaacgca
  448	ggcagtgcaggctcaccggg
  449	gaaccttccatgctgtt
  450	gctagacgttagcgtga
  451	gcttggagggcctgtaagtg
  452	gtagccttccta
  453	cggtagccttccta
  454	cacggtagccttccta
  455	agcacggtagccttccta
  456	gaacgctggaccttccat
  457	gaccttccat
  458	tggaccttccat
  459	gctggaccttccat
  460	acgctggaccttccat
  461	taagctctgtcaacgccagg
  462	gagaacgctggaccttccatgt
  463	tccatgtcggtcctgatgct
  464	ttcatgccttgcaaaatggcg
  465	tgctagctgtgcctgtacct
  466	agcatcaggaccgacatgga
  467	gaccttccatgtcggtcctgat
  468	acaaccacgagaacgggaac
  469	gaaccttccatgctgttccg
  470	caatcaatctgaggagaccc
  471	tcagctctggtactttttca
  472	tggttacggtctgtcccatg
  473	gtctatcggaggactggcgc
  474	cattttacgggcgggcgggc
  475	gaggggaccattttacgggc
  476	tgtccagccgaggggaccat
  477	cgggcttacggcggatgctg
  478	tggaccttctatgtcggtcc
  479	tgtcccatgtttttagaagc
  480	gtggttacggtcgtgcccat
  481	cctccaaatgaaagaccccc
  482	ttgtactctccatgatggtt
  483	ttccatgctgttccggctgg
  484	gaccttctatgtcggtcctg
  485	gagaccgctcgaccttcgat
  486	ttgccccatattttagaaac
  487	ttgaaactgaggtgggac
  488	ctatcggaggactggcgcgcc
  489	cttggagggcctcccggcgg
  490	gctgaaccttccatgctgtt
  491	tagaaacagcattcttcttttagggcagcaca
  492	agatggttctcagataaagcggaa
  493	ttccgctttatctgagaaccatct
  494	gtcccaggttgtatagaggctgc
  495	gcgccagtcctccgatagac
  496	atcggaggactggcgcgccg
  497	ggtctgtcccatatttttag
  498	tttttcaacgttgagggggg	sos
  499	tttttcaagcgttgatttttt	sos
  500	ggggtcaacgttgatttttt	sos
  501	ggggttttcaacgttttgagggggg	sos
  502	ggttacggtctgtcccatat
  503	ctgtcccatatttttagaca
  504	accatcctgaggccattcgg
  505	cgtctatcgggcttctgtgtctg
  506	ggccatcccacattgaaagtt
  507	ccaaatatcggtggtcaagcac
  508	gtgcttgaccaccgatatttgg
  509	gtgctgatcaccgatatcctgttcgg
  510	ggccaactttcaatgtgggatggcctc
  511	ttccgccgaatggcctcaggatggtac
  512	tatagtccctgagactgccccaccttctcaacaacc
  513	gcagcctctatacaacctgggacggga
  514	ctatcggaggactggcgcgccg
  515	tatcggaggactggcgcgccg
  516	gatcggaggactggcgcgccg
  517	ccgaacaggatatcggtgatcagcac
  518	ttttggggtcaacgttgagggggg
  519	ggggtcaacgttgagggggg	sos
  520	cgcgcgcgcgcgcgcgcgcg	s
  521	ggggcatgacgttcgggggg	ss
  522	ggggcatgacgttcaaaaaa	s
  523	ggggcatgagcttcgggggg	s
  524	ggggcatgacgttcgggggg	sos
  525	aaaacatgacgttcaaaaaa	sos
  526	aaaacatgacgttcgggggg	sos
  527	ggggcatgacgttcaaaaaa	sos
  528	accatggacgatctgtttcccctc	s
  529	gccatggacgaactgttccccctc	s
  530	cccccccccccccccccccc	sos
  531	gggggggggggggggggggg	sos
  532	gctgtaaaatgaatcggccg	sos
  533	ttcgggcggactcctccatt	sos
  534	tatgccgcgcccggacttat	sos
  535	ggggtaatcgatcagggggg	sos
  536	tttgagaacgctggaccttc	sos
  537	gatcgctgatctaatgctcg	sos
  538	gtcggtcctgatgctgttcc	sos
  539	tcgtcgtcagttcgctgtcg	sos
  540	ctggaccttccatgtcgg	sos
  541	gctcgttcagcgcgtct	sos
  542	ctggaccttccatgtc	sos
  543	cactgtccttcgtcga	sos
  544	cgctggaccttccatgtcgg	sos
  545	gctgagctcatgccgtctgc	sos
  546	aacgctggaccttccatgtc	sos
  547	tgcatgccgtacacagctct	sos
  548	ccttccatgtcggtcctgat	sos
  549	tactcttcggatcccttgcg	Sos
  550	ttccatgtcggtcctgat	sos
  551	ctgattgctctctcgtga	sos
  552	ggcgttattcctgactcgcc	o
  553	cctacgttgtatgcgcccagct	o
  554	ggggtaatcgatgagggggg	o
  555	ttcgggcggactcctccatt	o
  556	tttttttttttttttttttt	o
  557	gggggttttttttttggggg	o
  558	tttttggggggggggttttt	o
  559	ggggggggggggggggggt	o
  560	aaaaaaaaaaaaaaaaaaaa	o
  561	cccccaaaaaaaaaaccccc	o
  562	aaaaaccccccccccaaaaa	o
  563	tttgaattcaggactggtgaggttgag	o
  564	tttgaatcctcagcggtctccagtggc	o
  565	aattctctatcggggcttctgtgtctgttgctggttccgctttat	o
  566	ctagataaagcggaaccagcaacagacacagaagccccgatagag	o
  567	ttttctagagaggtgcacaatgctctgg	o
  568	tttgaattccgtgtacagaagcgagaagc	o
  569	tttgcggccgctagacttaacctgagagata	o
  570	tttgggcccacgagagacagagacacttc	o
  571	tttgggcccgcttctcgcttctgtacacg	o
  572	gagaacgctggaccttccat	s
  573	tccatgtcggtcctgatgct	s
  574	ctgtcg	s
  575	tcgtga	s
  576	cgtcga	s
  577	agtgct	s
  578	ctgtcg	o
  579	agtgct	o
  580	cgtcga	o
  581	tcgtga	o
  582	gagaacgctccagcttcgat	o
  583	gctagacgtaagcgtga	o
  584	gagaacgctcgaccttccat	o
  585	gagaacgctggacctatccat	o
  586	gctagaggttagcgtga	o
  587	gagaacgctggacttccat	o
  588	tcacgctaacgtctagc	o
  589	bgctagacgttagcgtga	o
  590	atggaaggtcgagcgttctc	o
  591	gagaacgctggaccttcgat	o
  592	gagaacgatggaccttccat	o
  593	gagaacgctggatccat	o
  594	gagaacgctccagcactgat	o
  595	tccatgtcggtcctgctgat	o
  596	atgtcctcggtcctgatgct	o
  597	gagaacgctccaccttccat	o
  598	gagaacgctggaccttcgta	o
  599	batggaaggtccagcgttctc	o
  600	tcctga	o
  601	tcaacgtt	o
  602	aacgtt	o
  603	aacgttga	o
  604	tcacgctaacctctagc	o
  605	gagaacgctggaccttgcat	o
  606	gctggaccttccat	o
  607	gagaacgctggacctcatccat	o
  608	gagaacgctggacgctcatccat	o
  609	aacgttgaggggcat	o
  610	atgcccctcaacgtt	o
  611	tcaacgttga	o
  612	gctggaccttccat	o
  613	caacgtt	o
  614	acaacgttga	o
  615	tcacgt	o
  616	tcaagctt	o
  617	tcgtca	o
  618	aggatatc	o
  619	tagacgtc	o
  620	gacgtcat	o
  621	ccatcgat	o
  622	atcgatgt	o
  623	atgcatgt	o
  624	ccatgcat	o
  625	agcgctga	o
  626	tcagcgct	o
  627	ccttcgat	o
  628	gtgccggggtctccgggc	s
  629	gctgtggggcggctcctg	s
  630	btcaacgtt	o
  631	ftcaacgtt	o
  632	faacgttga	o
  633	tcaacgt	s
  634	aacgttg	s
  635	cgacga	o
  636	tcaacgtt	o
  637	tcgga	o
  638	agaacgtt	o
  639	tcatcgat	o
  640	taaacgtt	s
  641	ccaacgtt	s
  642	gctcga	s
  643	cgacgt	s
  644	cgtcgt	s
  645	acgtgt	s
  646	cgttcg	s
  647	gagcaagctggaccttccat	s
  648	cgcgta	s
  649	cgtacg	s
  650	tcaccggt	s
  651	caagagatgctaacaatgca	s
  652	acccatcaatagctctgtgc	s
  653	ccatcgat	o
  654	tcgacgtc	o
  655	ctagcgct	o
  656	taagcgct	o
  657	tcgcgaattcgcg	o
  658	atggaaggtccagcgttct	o
  659	actggacgttagcgtga	o
  660	cgcctggggctggtctgg	o
  661	gtgtcggggtctccgggc	o
  662	gtgccggggtctccgggc	o
  663	cgccgtcgcggcggttgg	o
  664	gaagttcacgttgaggggcat	o
  665	atctggtgagggcaagctatg	s
  666	gttgaaacccgagaacatcat	s
  667	gcaacgtt	o
  668	gtaacgtt	o
  669	cgaacgtt	o
  670	gaaacgtt	o
  671	caaacgtt	o
  672	ctaacgtt	o
  673	ggaacgtt	o
  674	tgaacgtt	o
  675	acaacgtt	o
  676	ttaacgtt	o
  677	aaaacgtt	o
  678	ataacgtt	o
  679	aacgttct	o
  680	tccgatcg	o
  681	tccgtacg	o
  682	gctagacgctagcgtga	o
  683	gagaacgctggacctcatcatccat	o
  684	gagaacgctagaccttctat	o
  685	actagacgttagtgtga	o
  686	cacaccttggtcaatgtcacgt	o
  687	tctccatcctatggttttatcg	o
  688	cgctggaccttccat	o
  689	caccaccttggtcaatgtcacgt	o
  690	gctagacgttagctgga	o
  691	agtgcgattgcagatcg	o
  692	ttttcgttttgtggttttgtggtt
  693	ttttcgtttgtcgttttgtcgtt
  694	tttttgttttgtggttttgtggtt
  695	accgcatggattctaggcca	s
  696	gctagacgttagcgt	o
  697	aacgctggaccttccat	o
  698	tcaazgtt	o
  699	ccttcgat	o
  700	actagacgttagtgtga	s
  701	gctagaggttagcgtga	s
  702	atggactctccagcgttctc	o
  703	atcgactctcgagcgttctc	o
  704	gctagacgttagc	o
  705	gctagacgt	o
  706	agtgcgattcgagatcg	o
  707	tcagzgct	o
  708	ctgattgctctctcgtga	o
  709	tzaacgtt	o
  710	gagaazgctggaccttccat	o
  711	gctagacgttaggctga	o
  712	gctacttagcgtga	o
  713	gctaccttagcgtga	o
  714	atcgacttcgagcgttctc	o
  715	atgcactctgcagcgttctc	o
  716	agtgactctccagcgttctc	o
  717	gccagatgttagctgga	o
  718	atcgactcgagcgttctc	o
  719	atcgatcgagcgttctc	o
  720	bgagaacgctcgaccttcgat	o
  721	gctagacgttagctgga	sos
  722	atcgactctcgagcgttctc	sos
  723	tagacgttagcgtga	o
  724	cgactctcgagcgttctc	o
  725	ggggtcgaccttggagggggg	sos
  726	gctaacgttagcgtga	o
  727	cgtcgtcgt	o
  728	gagaacgctggaczttccat	o
  729	atcgacctacgtgcgttztc	o
  730	atzgacctacgtgcgttctc	o
  731	gctagazgttagagt	o
  732	atcgactctcgagzgttctc	o
  733	ggggtaatgcatcagggggg	sos
  734	ggctgtattcctgactgccc	s
  735	ccatgctaacctctaga	o
  736	gctagatgttagcgtga	o
  737	cgtaccttacggtga	o
  738	tccatgctggtcctgatgct	o
  739	atcgactctctcgagcgttctc	o
  740	gctagagcttagcgtga	o
  741	atcgactctcgagtgttctc	o
  742	aacgctcgaccttcgat	o
  743	ctcaacgctggaccttccat	o
  744	atcgacctacgtgcgttctc	o
  745	gagaatgctggaccttccat	o
  746	tcacgctaacctctgac	o
  747	bgagaacgctccagcactgat	o
  748	bgagcaagctggaccttccat	o
  749	cgctagaggttagcgtga	o
  750	gctagatgttaacgt	o
  751	atggaaggtccacgttctc	o
  752	gctagatgttagcgt	o
  753	gctagacgttagtgt	o
  754	tccatgacggtcctgatgct	o
  755	tccatggcggtcctgatgct	o
  756	gctagacgatagcgt	o
  757	gctagtcgatagcgt	o
  758	tccatgacgttcctgatgct	o
  759	tccatgtcgttcctgatgct	o
  760	gctagacgttagzgt	o
  761	gctaggcgttagcgt	o
  762	tccatgtzggtcctgatgct	o
  763	tccatgtcggtzctgatgct	o
  764	atzgactctzgagzgttctc	o
  765	atggaaggtccagtgttctc	o
  766	gcatgacgttgagct	o
  767	ggggtcaacgttgagggggg	s
  768	ggggtcaagtctgagggggg	sos
  769	cgcgcgcgcgcgcgcgcgcg	o
  770	cccccccccccccccccccccccccccc	s
  771	ccccccccccccccccccccccccccccccccccc	s
  772	tccatgtcgctcctgatcct	o
  773	gctaaacgttagcgt	o
  774	tccatgtcgatcctgatgct	o
  775	tccatgccggtcctgatgct	o
  776	aaaatcaacgttgaaaaaaa	sos
  777	tccataacgttcctgatgct	o
  778	tggaggtcccaccgagatcggag	o
  779	cgtcgtcgtcgtcgtcgtcgt	s
  780	ctgctgctgctgctgctgctg	s
  781	gagaacgctccgaccttcgat	s
  782	gctagatgttagcgt	s
  783	gcatgacgttgagct	s
  784	tcaatgctgaf	o
  785	tcaacgttgaf	o
  786	tcaacgttgab	o
  787	gcaatattgcb	o
  788	gcaatattgcf	o
  789	agttgcaact	o
  790	tcttcgaa	o
  791	tcaacgtc	o
  792	ccatgtcggtcctgatgct	o
  793	gtttttatataatttggg	o
  794	tttttgtttgtcgttttgtcgtt	o
  795	ttggggggggtt	s
  796	ggggttgggggtt	s
  797	ggtggtgtaggttttgg	o
  798	bgagaazgctcgaccttcgat	o
  799	tcaacgttaacgttaacgtt	o
  800	bgagcaagztggaccttccat	o
  801	bgagaazgctccagcactgat	o
  802	tcaazgttgax	o
  803	gzaatattgcx	o
  804	tgctgcttttgtcgttttgtgctt	o
  805	ctgcgttagcaatttaactgtg	o
  806	tccatgacgttcctgatgct	s
  807	tgcatgccgtgcatccgtacacagctct	s
  808	tgcatgccgtacacagctct	s
  809	tgcatcagctct	s
  810	tgcgctct	s
  811	cccccccccccccccccccc	s
  812	cccccccccccc	s
  813	cccccccc	s
  814	tgcatcagctct	sos
  815	tgcatgccgtacacagctct	o
  816	gagcaagctggaccttccat	s
  817	tcaacgttaacgttaacgttaacgttaacgtt	s
  818	gagaacgctcgaccttcgat	s
  819	gtccccatttcccagaggaggaaat	o
  820	ctagcggctgacgtcatcaagctag	o
  821	ctagcttgatgacgtcagccgctag	o
  822	cggctgacgtcatcaa	s
  823	ctgacgtg	o
  824	ctgacgtcat	o
  825	attcgatcggggcggggcgag	o
  826	ctcgccccgccccgatcgaat	o
  827	gactgacgtcagcgt	o
  828	ctagcggctgacgtcataaagctagc	s
  829	ctagctttatgacgtcagccgctagc	s
  830	ctagcggctgagctcataaagctagc	s
  831	ctagtggctgacgtcatcaagctag	s
  832	tccaccacgtggtctatgct	s
  833	gggaatgaaagattttattataag	o
  834	tctaaaaaccatctattattaaccct	o
  835	agctcaacgtcatgc	o
  836	ttaacggtggtagcggtattggtc	o
  837	ttaagaccaataccgctaccaccg	o
  838	gatctagtgatgagtcagccggatc	o
  839	gatccggctgactcatcactagatc	o
  840	tccaagacgttcctgatgct	o
  841	tccatgacgtccctgatgct	o
  842	tccaccacgtggctgatgct	o
  843	ccacgtggacctctagc	o
  844	tcagaccacgtggtcgggtgttcctga	o
  845	tcaggaacacccgaccacgtggtctga	o
  846	catttccacgatttccca	o
  847	ttcctctctgcaagagaat	o
  848	tgtatctctctgaaggact	o
  849	ataaagcgaaactagcagcagtttc	o
  850	gaaactgctgctagtttcgctttat	o
  851	tgcccaaagaggaaaatttgtttcatacag	o
  852	ctgtatgaaacaaattttactctttgggca	o
  853	ttagggttagggttagggtt	ss
  854	tccatgagcttcctgatgct	ss
  855	aaaacatgacgttcaaaaaa	ss
  856	aaaacatgacgttcgggggg	ss
  857	ggggcatgagcttcgggggg	sos
  858	ctaggctgacgtcatcaagctagt	o
  859	tctgacgtcatctgacgttggctgacgtct	o
  860	ggaattagtaatagatatagaagtt	o
  861	tttaccttttataaacataactaaaacaaa	o
  862	gcgtttttttttgcg	s
  863	atatctaatcaaaacattaacaaa	o
  864	tctatcccaggtggttcctgttag	o
  865	btccatgacgttcctgatgct	o
  866	btccatgagcttcctgatgct	o
  867	tttttttttttttf	o
  868	tttttttttttttf	so
  869	ctagcttgatgagctcagccgctag	o
  870	ttcagttgtcttggtgcttagctaa	o
  871	tccatgagcttcctgagtct	s
  872	ctagcggctgacgtcatcaatctag	o
  873	tgctagctgtgcctgtacct	s
  874	atgctaaaggacgtcacattgca	o
  875	tgcaatgtgacgtcctttagcat	o
  876	gtaggggactttccgagctcgagatcctatg	o
  877	cataggatctcgagctcggaaagtcccctac	o
  878	ctgtcaggaactgcaggtaagg	o
  879	cataacataggaatatttactcctcgc	o
  880	ctccagctccaagaaaggacg	o
  881	gaagtttctggtaagtcttcg	o
  882	tgctgcttttgtgcttttgtgctt	s
  883	tcgtcgttttgtggttttgtggtt	s
  884	tcgtcgtttgtcgttttgtcgtt	s
  885	tcctgacgttcggcgcgcgccc	s
  886	tgctgcttttgtgcttttgtgctt
  887	tccatgagcttcctgagctt	s
  888	tcgtcgtttcgtcgttttgacgtt	s
  889	tcgtcgtttgcgtgcgtttcgtcgtt	s
  890	tcgcgtgcgttttgtcgttttgacgtt	s
  891	ttcgtcgttttgtcgttttgtcgtt	s
  892	tcctgacggggaagt	s
  893	tcctggcgtggaagt	s
  894	tcctggcggtgaagt	s
  895	tcctggcgttgaagt	s
  896	tcctgacgtggaagt	s
  897	gcgacgttcggcgcgcgccc	s
  898	gcgacgggcggcgcgcgccc	s
  899	gcggcgtgcggcgcgcgccc	s
  900	gcggcggtcggcgcgcgccc	s
  901	gcgacggtcggcgcgcgccc	s
  902	gcggcgttcggcgcgcgccc	s
  903	gcgacgtgcggcgcgcgccc	s
  904	tcgtcgctgtctccg	s
  905	tgtgggggttttggttttgg	s
  906	aggggaggggaggggagggg	s
  907	tgtgtgtgtgtgtgtgtgtgt	s
  908	ctctctctctctctctctctct	chimeric
  909	ggggtcgacgtcgagggggg	s
  910	atatatatatatatatatatat	s
  911	ttttttttttttttttttttttttttt	s
  912	ttttttttttttttttttttt	s
  913	tttttttttttttttttt	s
  914	gctagaggggagggt
  915	gctagatgttagggg
  916	gcatgagggggagct
  917	atggaaggtccagggggctc
  918	atggactctggagggggctc
  919	atggaaggtccaaggggctc
  920	gagaaggggggaccttggat
  921	gagaaggggggaccttccat
  922	gagaaggggccagcactgat
  923	tccatgtggggcctgatgct
  924	tccatgaggggcctgatgct
  925	tccatgtggggcctgctgat
  926	atggactctccggggttctc
  927	atggaaggtccggggttctc
  928	atggactctggaggggtctc
  929	atggaggctccatggggctc
  930	atggactctggggggttctc
  931	tccatgtgggtggggatgct
  932	tccatgcgggtggggatgct
  933	tccatgggggtcctgatgct
  934	tccatggggtccctgatgct
  935	tccatggggtgcctgatgct
  936	tccatggggttcctgatgct
  937	tccatcgggggcctgatgct
  938	gctagagggagtgt
  939	tttttttttttttttttt	s
  940	gmggtcaacgttgagggmggg	s
  941	ggggagttcgttgaggggggg	s
  942	tcgtcgtttccccccccccc	s
  943	ttggggggttttttttttttttttt	s
  944	tttaaattttaaaatttaaaata	s
  945	ttggtttttttggtttttttttgg	s
  946	tttcccttttccccttttcccctc	s
  947	ggggtcatcgatgagggggg s	sos
  948	tccatgacgttcctgacgtt
  949	tccatgacgttcctgacgtt
  950	tccatgacgttcctgacgtt
  951	tccatgacgttcctgacgtt
  952	tccatgacgttcctgacgtt
  953	tccatgacgttcctgacgtt
  954	tccatgacgttcctgacgtt
  955	tccatgacgttcctgacgtt
  956	tccatgacgttcctgacgtt
  957	tccatgacgttcctgacgtt
  958	tccatgacgttcctgacgtt
  959	gggggacgatcgtcggggg	sos
  960	gggggtcgtacgacgggggg	sos
  961	tttttttttttttttttttttttt	po
  962	aaaaaaaaaaaaaaaaaaaaaaaa	po
  963	cccccccccccccccccccccccc	po
  964	tcgtcgttttgtcgttttgtcgtt
  965	tcgtcgttttgtcgttttgtcgtt
  966	tcgtcgttttgtcgttttgtcgtt
  967	tcgtcgttttgtcgttttgtcgtt
  968	ggggtcaacgttgagggggg
  969	ggggtcaacgttgagggggg
  970	ggggtcaagcttgagggggg
  971	tgctgcttcccccccccccc
  972	ggggacgtcgacgtgggggg	sos
  973	ggggtcgtcgacgagggggg	sos
  974	ggggtcgacgtacgtcgagggggg	sos
  975	ggggaccggtaccggtgggggg	sos
  976	gggtcgacgtcgagggggg	sos
  977	ggggtcgacgtogaggggg	sos
  978	ggggaacgttaacgttgggggg	sos
  979	ggggtcaccggtgagggggg	sos
  980	ggggtcgttcgaacgagggggg	sos
  981	ggggacgttcgaacgtgggggg	sos
  982	tcaactttga	s
  983	tcaagcttga	s
  984	tcacgatcgtga	s
  985	tcagcatgctga	s
  986	gggggagcatgctggggggg	sos
  987	gggggggggggggggggggg	sos
  988	gggggacgatatcgtcgggggg	sos
  989	gggggacgacgtcgtcgggggg	sos
  990	gggggacgagctcgtcgggggg	sos
  991	gggggacgtacgtcgggggg	sos
  992	tcaacgtt
  993	tccataccggtcctgatgct
  994	tccataccggtcctaccggt	s
  995	gggggacgatcgttgggggg	sos
  996	ggggaacgatcgtcgggggg	sos
  997	ggg ggg acg atc gtc ggg ggg	sos
  998	ggg gga cga tcg tcg ggg ggg	sos
  999	aaa gac gtt aaa	po
  1000	aaagagcttaaa	po
  1001	aaagazgttaaa	po
  1002	aaattcggaaaa	po
  1003	gggggtcatcgatgagggggg	sos
  1004	gggggtcaacgttgagggggg	sos
  1005	atgtagcttaataacaaagc	po
  1006	ggatcccttgagttacttct	po
  1007	ccattccacttctgattacc	po
  1008	tatgtattatcatgtagata	po
  1009	agcctacgtattcaccctcc	po
  1010	ttcctgcaactactattgta	po
  1011	atagaaggccctacaccagt	po
  1012	ttacaccggtctatggaggt	po
  1013	ctaaccagatcaagtctagg	po
  1014	cctagacttgatctggttag	po
  1015	tataagcctcgtccgacatg	po
  1016	catgtcggacgaggcttata	po
  1017	tggtggtggggagtaagctc	po
  1018	gagctactcccccaccacca	po
  1019	gccttcgatcttcgttggga	po
  1020	tggacttctctttgccgtct	po
  1021	atgctgtagcccagcgataa	po
  1022	accgaatcagcggaaagtga	po
  1023	tccatgacgttcctgacgtt
  1024	ggagaaacccatgagctcatctgg
  1025	accacagaccagcaggcaga
  1026	gagcgtgaactgcgcgaaga
  1027	tcggtacccttgcagcggtt
  1028	ctggagccctagccaaggat
  1029	gcgactccatcaccagcgat
  1030	cctgaagtaagaaccagatgt
  1031	ctgtgttatctgacatacacc
  1032	aattagccttaggtgattggg
  1033	acatctggttcttacttcagg
  1034	ataagtcatattttgggaactac
  1035	cccaatcacctaaggctaatt
  1036	ggggtcgtcgacgagggggg	sos
  1037	ggggtcgttcgaacgagggggg	sos
  1038	ggggacgttcgaacgtgggggg	sos
  1039	tcctggcggggaagt	s
  1040	ggggaacgacgtcgttgggggg	sos
  1041	ggggaacgtacgtcgggggg	sos
  1042	ggggaacgtacgtacgttgggggg	sos
  1043	ggggtcaccggtgagggggg	sos
  1044	ggggtcgacgtacgtcgagggggg	sos
  1045	ggggaccggtaccggtgggggg	sos
  1046	gggtcgacgtcgagggggg	sos
  1047	ggggtcgacgtcgagggg	sos
  1048	ggggaacgttaacgttgggggg	sos
  1049	ggggacgtcgacgtggggg	sos
  1050	gcactcttcgaagctacagccggcagcctctgat
  1051	cggctcttccatgaggtctttgctaatcttgg
  1052	cggctcttccatgaaagtctttggacgatgtgagc
  1053	tcctgcaggttaagt	s
  1054	gggggtcgttcgttgggggg	sos
  1055	gggggatgattgttgggggg	sos
  1056	gggggazgatzgttgggggg	sos
  1057	gggggagctagcttgggggg	sos
  1058	ggttcttttggtccttgtct	s
  1059	ggttcttttggtcctcgtct	s
  1060	ggttcttttggtccttatct	s
  1061	ggttcttggtttccttgtct	s
  1062	tggtcttttggtccttgtct	s
  1063	ggttcaaatggtccttgtct	s
  1064	gggtcttttgggccttgtct	s
  1065	tccaggacttctctcaggtttttt	s
  1066	tccaaaacttctctcaaatt	s
  1067	tactacttttatacttttatactt	s
  1068	tgtgtgtgtgtgtgtgtgtgtgtg	s
  1069	ttgttgttgttgtttgttgttgttg	s
  1070	ggctccggggagggaatttttgtctat	s
  1071	gggacgatcgtcggggggg	sos
  1072	gggtcgtcgacgaggggggg	sos
  1073	ggtcgtcgacgaggggggg	sos
  1074	gggtcgtcgtcgtggggggg	sos
  1075	ggggacgatcgtcggggggg	sos
  1076	ggggacgtcgtcgtgggggg	sos
  1077	ggggtcgacgtcgacgtcgaggggggg	sos
  1078	ggggaaccgcggttggggggg	sos
  1079	ggggacgacgtcgtggggggg	sos
  1080	tcgtcgtcgtcgtcgtggggggg	sos
  1081	tcctgccggggaagt	s
  1082	tcctgcaggggaagt	s
  1083	tcctgaaggggaagt	s
  1084	tcctggcgggcaagt	s
  1085	tcctggcgggtaagt	s
  1086	tcctggcgggaaagt	s
  1087	tccgggcggggaagt	s
  1088	tcggggcggggaagt	s
  1089	tcccggcggggaagt	s
  1090	gggggacgttggggg	s
  1091	ggggttttttttttgggggg	sos
  1092	ggggccccccccccgggggg	sos
  1093	ggggttgttgttgttgggggg	sos

• In some embodiments, the immunostimulatory nucleic acid is a CpG nucleic acid. CpG sequences, while relatively rare in human DNA are commonly found in the DNA of infectious organisms such as bacteria. The human immune system has apparently evolved to recognize CpG sequences as an early warning sign of infection and to initiate an immediate and powerful immune response against invading pathogens without causing adverse reactions frequently seen with other immune stimulatory agents. Thus CpG containing nucleic acids, relying on this innate immune defense mechanism can utilize a unique and natural pathway for immune therapy. The effects of CpG nucleic acids on immune modulation have been described extensively in published patent applications, such as PCT US95/01570), PCT/US97/19791, PCT/US98/03678; PCT/US98/10408; PCT/US98/04703; PCT/US99/07335; and PCT/US99/09863. The entire contents of each of these patent applications is hereby incorporated by reference.[0053]
• A CpG nucleic acid is a nucleic acid which includes at least one unmethylated CpG dinucleotide. A nucleic acid containing at least one unmethylated CpG dinucleotide is a nucleic acid molecule which contains an unmethylated cytosine in a cytosine-guanine dinucleotide sequence (i.e. “CpG DNA” or DNA containing a 5′ cytosine followed by 3′ guanosine and linked by a phosphate bond) and activates the immune system. The CpG nucleic acids can be double-stranded or single-stranded. Generally, double-stranded molecules are more stable in vivo, while single-stranded molecules have increased immune activity. Thus in some aspects of the invention it is preferred that the nucleic acid be single stranded and in other aspects it is preferred that the nucleic acid be double stranded. The terms CpG nucleic acid or CpG oligonucleotide as used herein refer to an immunostimulatory CpG nucleic acid or a nucleic acid unless otherwise indicated. The entire immunostimulatory nucleic acid can be unmethylated or portions may be unmethylated but at least the C of the 5′ CG 3′ must be unmethylated.[0054]
• In one preferred embodiment the invention provides an immunostimulatory nucleic acid which is a CpG nucleic acid represented by at least the formula:[0055]
• 5′X₁X₂CGX₃X₄3′
• wherein X[0056]₁, X₂, X₃, and X₄are nucleotides. In one embodiment X₂is adenine, guanine, cytosine, or thymine. In another embodiment X₃is cytosine, guanine, adenine, or thymine. In other embodiments X₂is adenine, guanine, or thymine and X₃is cytosine, adenine, or thymine.
• In another embodiment the immunostimulatory nucleic acid is an isolated CpG nucleic acid represented by at least the formula:[0057]
• 5′N₁X₁X₂CGX₃X₄N₂3′
• wherein X[0058]₁, X₂, X₃, and X₄are nucleotides and N is any nucleotide and N₁and N₂are nucleic acid sequences composed of from about 0-25 N's each. In one embodiment X₁X₂are nucleotides selected from the group consisting of: GpT, GpG, GpA, ApA, ApT, ApG, CpT, CpA, CpG, TpA, TpT, and TpG; and X₃X₄are nucleotides selected from the group consisting of: TpT, ApT, TpG, ApG, CpG, TpC, ApC, CpC, TpA, ApA, and CpA. Preferably X₁X₂are GpA or GpT and X₃X₄are TpT. In other embodiments X₁or X₂or both are purines and X₃or X₄or both are pyrimidines or X₁X₂are GpA and X₃or X₄or both are pyrimidines. In another preferred embodiment X₁X₂are nucleotides selected from the group consisting of: TpA, ApA, ApC, ApG, and GpG. In yet another embodiment X₃X₄are nucleotides selected from the group consisting of: TpT, TpA, TpG, ApA, ApG, ApC, and CpA. X₁X₂in another embodiment are nucleotides selected from the group consisting of: TpT, TpG, ApT, GpC, CpC, CpT, TpC, GpT and CpG.
• In another preferred embodiment the immunostimulatory nucleic acid has the sequence 5′TCN[0059]₁TX₁X₂CGX₃X₄3′. The immunostimulatory nucleic acids of the invention in some embodiments include X₁X₂selected from the group consisting of GpT, GpG, GpA and ApA and X₃X₄is selected from the group consisting of TpT, CpT and TpC.
• In other embodiments, the CpG oligonucleotide has a sequence selected from the group consisting of SEQ ID NO: 1, 3, 4, 14-16, 18-24, 28, 29, 33-46, 49, 50, 52-56, 58, 64-67, 69, 71, 72, 76-87, 90, 91, 93, 94, 96, 98, 102-124, 126-128, 131-133; 136-141, 146-150, 152-153, 155-171, 173-178, 180-186, 188-198, 201, 203-214, 216-220, 223, 224, 227-240, 242-256, 258, 260-265, 270-273, 275, 277-281, 286-287, 292, 295-296, 300, 302, 1305-307, 309-312, 314-317, 320-327, 329, 335, 337-341, 343-352, 354, 357, 361-365, 367-369, 373-376, 378-385, 388-392, 394, 395, 399, 401-404, 406-426, 429-433, 434-437, 439, 441-443, 445, 447, 448, 450, 453-456, 460-464, 466-469, 472-475, 477, 478, 480, 483-485, 488, 489, 492, 493, 495-502, 504-505, 507-509, 511, 513-529, 532-541, 543-555, 564-566, 568-576, 578, 580, 599, 601-605, 607-611, 613-615, 617, 619-622, 625-646, 648-650, 653-664, 666-697, 699-706, 708, 709, 711-716, 718-732, 736, 737, 739-744, 746, 747, 749-761, 763, 766-767, 769, 772-779, 781-783, 785-786, 7900792, 798-799, 804-808, 810, 815, 817, 818, 820-832, 835-846, 849-850, 855-859, 862, 865, 872, 874-877, 879-881, 883-885, 888-904, and 909-913.[0060]
• For facilitating uptake into cells, the immunostimulatory nucleic acids are preferably in the range of 6 to 100 bases in length. However, nucleic acids of any size greater than 6 nucleotides (even many kb long) are capable of inducing an immune response according to the invention if sufficient immunostimulatory motifs are present. Preferably the immunostimulatory nucleic acid is in the range of between 8 and 100 and in some embodiments between 8 and 50 or 8 and 30 nucleotides in size.[0061]
• “Palindromic sequence” shall mean an inverted repeat (i.e. a sequence such as ABCDEE′D′C′B′A′ in which A and A′ are bases capable of forming the usual Watson-Crick base pairs. In vivo, such sequences may form double-stranded structures. In one embodiment the CpG nucleic acid contains a palindromic sequence. A palindromic sequence used in this context refers to a palindrome in which the CpG is part of the palindrome, and preferably is the center of the palindrome. In another embodiment the CpG nucleic acid is free of a palindrome. An immunostimulatory nucleic acid that is free of a palindrome is one in which the CpG dinucleotide is not part of a palindrome. Such an oligonucleotide may include a palindrome in which the CpG is not the center of the palindrome.[0062]
• The CpG nucleic acid sequences of the invention are those broadly described above as well as disclosed in PCT Published Patent Applications PCT/US95/01570 and PCT/US97/19791 claiming priority to U.S. Ser. Nos. 08/386,063 and 08/960,774, filed on Feb. 7, 1995 and Oct. 30, 1997 respectively.[0063]
• The immunostimulatory nucleic acids of the invention also include nucleic acids having T-rich motifs. It was recently discovered by Dr. Arthur Krieg that T-rich nucleic acids were immunostimulatory. It was presented by Dr. Krieg at the International Workshop on “Immunobiology of Bacterial CpG-DNA” held in Upper Bavaria on Sep. 26-29, 1999 that poly-T nucleic acids of 24 bases in length are immunostimulatory, whereas the same length poly-C oligonucleotide is non-stimulatory. These concepts are also described and claimed in US Provisional Patent Application No. 60/156,113 filed on Sep. 25, 1999, which is hereby incorporated by reference.[0064]
• Poly-G containing nucleic acids are also immunostimulatory. PCT published patent application number WO 00/14217, which claims priority to German Patent Application No. 98 11 6652.3, filed on Sep. 3, 1998 describes poly-G-containing oligonucleotides and their uses. A variety of other references, including Pisetsky and Reich, 1993[0065]Mol. Biol. Reports,18:217-221; Krieger and Herz, 1994, Ann. Rev. Biochem.,63:601-637; Macaya et al., 1993, PNAS,90:3745-3749; Wyatt et al., 1994, PNAS,91:1356-1360; Rando and Hogan, 1998, In Applied Antisense Oligonucleotide Technology, ed. Krieg and Stein, p. 335-352; and Kimura et al., 1994, J. Biochem.116, 991-994 also describe the immunostimulatory properties of poly-G nucleic acids. Poly-G-containing nucleotides are useful for treating and preventing bacterial and viral infections.
• In some aspects of the invention the poly-G containing nucleic acids are administered alone for the treatment of asthma and allergy. It was previously suggested in the prior art that poly-G rich oligonucleotides inhibit the production of IFN-δ by compounds such as CpG oligonucleotides, concanavalin A, bacterial DNA, or the combination of PMA and the calcium ionophore A 23187 (Halperin and Pisetsky, 1995[0066], Immunopharmacol.,29:47-52, as well as block the downstream effects of IFN-δ. For instance, Ramanathan et al., 1994, Transplantation,57:612-615, has shown that a poly-G oligonucleotide inhibits the binding of IFN-δ to its receptor, which prevents the normal enhancement of MHC Class 1 and ICAM-1 in response to IFN-δ. Poly-G oligonucleotides were also found to be able to inhibit the secretion of IFN-δ from lymphocytes (Halperin and Pisetsky, 1995, Immunopharmacol.,29:47-52). It was surprisingly, discovered according to the invention that when poly-G nucleic acids are administered in vivo, they are useful for treating or preventing allergy or asthma. Thus, in this aspect of the invention, poly-G nucleic acids are administered alone or optionally with other asthma/allergy medicaments for the treatment of allergy and/or asthma.
• Poly-G nucleic acids preferably are nucleic acids having the following formulas:[0067]
• 5′X₁X₂GGGX₃X₄3′
• wherein X[0068]₁, X₂, X₃, and X₄are nucleotides. In preferred embodiments at least one of X₃and X₄are a G. In other embodiments both of X₃and X₄are a G. In yet other embodiments the preferred formula is 5′ GGGNGGG 3′, or 5′ GGGNGGGNGGG 3′ wherein N represents between 0 and 20 nucleotides. In other embodiments the poly-G nucleic acid is free of unmethylated CG dinucleotides, while in other embodiments the poly-G nucleic acid includes at least one unmethylated CG dinucleotide.
• The poly G nucleic acid in some embodiments is selected from the group consisting of SEQ ID NO: 5, 6, 73, 215, 267-269, 276, 282, 288, 297-299, 355, 359, 386, 387, 444, 476, 531, 557-559, 733, 768, 795, 796, 914-925, 928-931, 933-936, and 938. In other embodiments, the poly G nucleic acid includes a sequence selected from the group consisting of SEQ ID NO: 67, 80-82, 141, 147, 148, 173, 178, 183, 185, 214, 224, 264, 265, 315, 329, 434, 435, 475, 519, 521-524, 526, 527, 535, 554, 565, 609, 628, 660, 661, 662, 725, 767, 825, 856, 857, 876, 892, 909, 926, 927, 932, and 937. In some embodiments, the entire backbone of the poly-G nucleic acid is phosphorothioate.[0069]
• In related embodiments, the invention also contemplates the use of immunostimulatory nucleic acids that comprise one and preferably two poly-G motifs, even more preferably flanking a palindrome. Such immunostimulatory nucleic acids preferably have a chimeric backbone (i.e., their backbone is comprised of both phosphodiester and phosphorothioate linkages). Even more preferably, the phosphorothioate linkages in these latter immunostimulatory nucleic acids are located at the 5′ and 3′ ends of the nucleic acid. Examples of suitable palindromes include, but are not limited to AACGTT; AAGCTT; AGCGCT; TCGA; TTCGAA; ACGT; GACGTC; and CACGTG.[0070]
• Nucleic acids having modified-backbones, such as phosphorothioate backbones, fall within the class of immunostimulatory nucleic acids. U.S. Pat. Nos. 5,723,335 and 5,663,153 issued to Hutcherson, et al. and related PCT publication WO95/26204 describe immune stimulation using phosphorothioate oligonucleotide analogues. These patents describe the ability of the phosphorothioate backbone to stimulate an immune response in a non-sequence specific manner.[0071]
• The backbone characteristics of the nucleic acids listed in Table 1 are also shown. Some of the designations in the Table are as follows: o or po=phosphodiester, s=phosphorothioate, sos=chimeric.[0072]
• In the case when the immunostimulatory nucleic acid is administered in conjunction with a nucleic acid vector, it is preferred that the backbone of the immunostimulatory nucleic acid be a chimeric combination of phosphodiester and phosphorothioate (or other phosphate modification). The cell may have a problem taking up a plasmid vector in the presence of completely phosphorothioate oligonucleotide. Thus when both a vector and an oligonucleotide are delivered to a subject, it is preferred that the oligonucleotide have a chimeric backbone or have a phosphorothioate backbone but that the plasmid is associated with a vehicle that delivers it directly into the cell, thus avoiding the need for cellular uptake. Such vehicles are known in the art and include, for example, liposomes and gene guns.[0073]
• For use in the instant invention, the immunostimulatory nucleic acids can be synthesized de novo using any of a number of procedures well known in the art. Such compounds are referred to as “synthetic nucleic acids.” For example, the b-cyanoethyl phosphoramidite method (Beaucage, S. L., and Caruthers, M. H.,[0074]Tet. Let.22:1859, 1981); nucleoside H-phosphonate method (Garegg et al.,Tet. Let.27:4051-4054, 1986; Froehler et al.,Nucl. Acid. Res.14:5399-5407, 1986; Garegg et al.,Tet. Let.27:4055-4058, 1986, Gaffney et al.,Tet. Let.29:2619-2622, 1988). These chemistries can be performed by a variety of automated oligonucleotide synthesizers available in the market. These nucleic acids are referred to as synthetic nucleic acids. Alternatively, immunostimulatory nucleic acids can be produced on a large scale in plasmids, (see Sambrook, T., et al., “Molecular Cloning: A Laboratory Manual”, Cold Spring Harbor laboratory Press, New York, 1989) and separated into smaller pieces or administered whole. Nucleic acids can be prepared from existing nucleic acid sequences (e.g., genomic or cDNA) using known techniques, such as those employing restriction enzymes, exonucleases or endonucleases. Nucleic acids prepared in this manner are referred to as isolated nucleic acids. The term “immunostimulatory nucleic acid” encompasses both synthetic and isolated immunostimulatory nucleic acids.
• For use in vivo, nucleic acids are preferably: relatively resistant to degradation (e.g., are stabilized). A “stabilized nucleic acid molecule” shall mean a nucleic acid molecule that is relatively resistant to in vivo degradation (e.g. via an exo- or endo-nuclease). Stabilization can be a function of length or secondary structure. Immunostimulatory nucleic acids that are tens to hundreds of kbs long are relatively resistant to in vivo degradation. For shorter immunostimulatory nucleic acids, secondary structure can stabilize and increase their effect. For example, if the 3′ end of a nucleic acid has self-complementarity to an upstream region, so that it can fold back and form a sort of stem loop structure, then the o nucleic acid becomes stabilized and therefore exhibits more activity.[0075]
• Alternatively, nucleic acid stabilization-can be accomplished via backbone modifications. Preferred stabilized nucleic acids of the instant invention have a modified backbone. It has been demonstrated that modification of the nucleic acid backbone provides enhanced activity of the immunostimulatory nucleic acids when administered in vivo. One type of modified backbone is a phosphate backbone modification. Immunostimulatory nucleic acids, including at least two phosphorothioate linkages at the 5′ end of the oligonucleotide and multiple phosphorothioate linkages at the 3′ end, preferably 5, can in some circumstances provide maximal activity and protect the nucleic acid from degradation by intracellular exo- and endo-nucleases. Other phosphate modified nucleic acids include phosphodiester modified nucleic acids, combinations of phosphodiester and phosphorothioate nucleic acids, methylphosphonate, methylphosphorothioate, phosphorodithioate, and combinations thereof. Each of these combinations in CpG nucleic acids and their particular effects on immune cells is discussed in more detail in PCT Published Patent Applications PCT/US95/01570 and PCT/US97/19791, the entire contents of which are hereby incorporated by reference. Although Applicants are not bound by the theory, it is believed that these phosphate modified nucleic acids may show more stimulatory activity due to enhanced nuclease resistance, increased cellular uptake, increased protein binding, and/or altered intracellular localization.[0076]
• Modified backbones such as phosphorothioates may be synthesized using automated techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl- and alkyl-phosphonates can be made, e.g., as described in U.S. Pat. No. 4,469,863; and alkylphosphotriesters, (in which the charged oxygen moiety is alkylated as described in U.S. Pat. No. 5,023,243 and European Patent No. 092,574) can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described (Uhlmann, E. and Peyman, A.,[0077]Chem. Rev.90:544, 1990; Goodchild; J.,Bioconjugate Chem.1:165, 1990).
• Both phosphorothioate and phosphodiester nucleic acids containing immunostimulatory motifs are active in immune cells. However, based on the concentration needed to induce immunostimulatory nucleic acid specific effects, the nuclease resistant phosphorothioate backbone immunostimulatory nucleic acids are more potent (2 μg/ml for the phosphorothioate vs. a total of 90 μg/ml for phosphodiester).[0078]
• Another type of modified backbone, useful according to the invention, is a peptide nucleic acid. The backbone is composed of aminoethylglycine and supports bases which provide the DNA-character. The backbone does not include any phosphate and thus may optionally have no net charge. The lack of charge allows for stronger DNA-DNA binding because the charge repulsion between the two strands does not exist. Additionally, because the backbone has an extra methylene group, the oligonucleotides are enzyme/protease resistant. Peptide nucleic acids can-be purchased from various commercial sources, e.g., Perkin Elmer, C. A. or synthesized de novo.[0079]
• Another class of backbone modifications include 2′-O-methylribonucleosides (2′-Ome). These types of substitutions are described extensively in the prior art and in particular with respect to their immunostimulating properties in Zhao et al.,[0080]Bioorganic and Medicinal Chemistry Letters,1999, 9:24:3453. Zhao et al. describes methods of preparing 2′-Ome modifications to nucleic acids.
• The nucleic acid molecules of the invention may include naturally-occurring or synthetic purine or pyrimidine heterocyclic bases as well as modified backbones. Purine or pyrimidine heterocyclic bases include, but are not limited to, adenine, guanine, cytosine, thymidine, uracil, and inosine. Other representative heterocyclic bases are disclosed in U.S. Pat. No. 3,687,808, issued to Merigan, et al. The term purine or pyrimidine or bases are used herein to refer to both naturally-occurring or synthetic purines, pyrimidines or bases.[0081]
• Other stabilized nucleic acids include: nonionic DNA analogs, such as alkyl- and aryl-phosphates (in which the charged phosphonate oxygen is replaced by an alkyl or aryl group), phosphodiester and alkylphosphotriesters, in which the charged oxygen moiety is alkylated. Nucleic acids which contain diol, such as tetraethyleneglycol or hexaethyleneglycol, at either or both termini have also been shown to be substantially resistant to nuclease degradation.[0082]
• The immunostimulatory nucleic acids having backbone modifications useful according to the invention in some embodiments are S- or R-chiral immunostimulatory nucleic acids. An “S chiral immunostimulatory nucleic acid” as used herein is an immunostimulatory nucleic acid wherein at least two nucleotides have a backbone modification forming a chiral center and wherein a plurality of the chiral centers have S chirality. An “R chiral immunostimulatory nucleic acid” as used herein is an immunostimulatory nucleic acid wherein at least two nucleotides have a backbone modification forming a chiral center and wherein a plurality of the chiral centers have R chirality. The backbone modification may be any type of modification that-forms a chiral center. The modifications include but are not-limited to phosphorothioate, methylphosphonate, methylphosphorothioate, phosphorodithioate, 2′-Ome and combinations thereof.[0083]
• The chiral immunostimulatory nucleic acids must have at least two nucleotides within the nucleic acid that have a backbone modification. All or less than all of the nucleotides in the nucleic acid, however, may have a modified backbone. Of the nucleotides having a modified backbone (referred to as chiral centers), a plurality have a single chirality, S or R. A “plurality” as used herein within the context of modified backbones refers to an amount greater than 50%. Thus, less than all of the chiral centers may have S or R chirality as long as a plurality of the chiral centers have S or R chirality. In some embodiments at least 55%, 60%, 65%, 70%, 75%, 80,%, 85%, 90%, 95%, or 100% of the chiral-centers have S or R chirality. In other embodiments at least-55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% of the nucleotides have backbone modifications.[0084]
• The S- and R-chiral immunostimulatory nucleic acids may be prepared by any method known in the art for producing chirally pure oligonucleotides. The Stec et al reference teaches methods for producing stereopure phosphorothioate oligodeoxynucleotides using an oxathiaphospholane. (Stec, W. J., et al., 1995[0085], J. Am. Chem. Soc.,117:12019). Other methods for making chirally pure oligonucleotides have been described by companies such as ISIS Pharmaceuticals. US patents have also described these methods. For instance U.S. Pat. Nos. 5,883,237; 5,837,856; 5,599,797; 5,512,668; 5,856,465; 5,359,052; 5,506,212; 5,521,302; and 5,212,295, each of which is hereby incorporated by reference in its entirety, disclose methods for generating stereopure oligonucleotides.
• The immunostimulatory nucleic acids are useful for treating or preventing allergy or asthma in a subject. A “subject” shall mean a human or vertebrate mammal including but not limited to a dog, cat, horse, cow, pig, sheep, goat, or primate, e.g., monkey.[0086]
• The immunostimulatory nucleic acids are useful in some aspects of the invention as a prophylactic for the treatment of a subject at risk of developing an allergy or asthma where the exposure of the subject to an allergen or predisposition to asthma is known or suspected. A “subject at risk” of developing allergy or asthma as used herein is a subject who has any risk of exposure to an allergen or a risk of developing asthma, i.e. someone who has suffered from an asthmatic attack previously or has a predisposition to asthmatic attacks. For instance, a subject at risk may be a subject who is planning to travel to an area where a particular type of allergen or asthmatic initiator is found or it may even be any subject living in an area where an allergen has been identified. If the subject develops allergic responses to a particular antigen and the subject may be exposed to the antigen, i.e., during pollen season, then that subject is at risk of exposure to the antigen. A subject at risk of developing an allergy or asthma includes those subjects that have been identified as having an allergy or asthma but that don't have the active disease during the treatment of the invention as well as subjects that are considered to be at risk of developing these diseases because of genetic or environmental factors.[0087]
• In addition to the use of the immunostimulatory nucleic acid and the asthma/allergy medicament for prophylactic treatment, the invention also encompasses the use of the combination of drugs for the treatment of a subject having an allergy or asthma. A “subject having an allergy” is a subject that has an allergic reaction in response to an allergen. An “allergy” refers to acquired hypersensitivity to a substance (allergen).[0088]
• The allergic reaction in man and animals has been extensively studied and the basic immune mechanisms involved are well known. Allergic conditions or diseases in humans include but are not limited to eczema, allergic rhinitis or coryza, hay fever, conjunctivitis, bronchial or allergic asthma, urticaria (hives) and food allergies; atopic dermatitis; anaphylaxis; drug allergy; angioedema; and allergic conjunctivitis. Allergic diseases in dogs, include but are not limited to seasonal dermatitis; perennial dermatitis; rhinitis: conjunctivitis; allergic asthma; and drug reactions. Allergic diseases in cats include but are not limited to dermatitis and respiratory disorders; and food allergens. Allergic diseases in horses include but are not limited to respiratory disorders such as “heaves” and dermatitis. Allergic diseases in non-human primates include but are not limited to allergic asthma and allergic dermatitis.[0089]
• The generic name for molecules that cause an allergic reaction is allergen. There are numerous species of allergens. The allergic reaction occurs when tissue-sensitizing immunoglobulin of the IgE type reacts with foreign allergen. The IgE antibody is bound to mast cells and/or basophils, and these specialized cells release chemical mediators (vasoactive amines) of the allergic reaction when stimulated to do so by allergens bridging the ends of the antibody molecule. Histamine, platelet activating factor, arachidonic acid metabolites, and serotonin are among the best known mediators of allergic reactions in man. Histamine and the other vasoactive amines are normally stored in mast cells and basophil leukocytes. The mast cells are dispersed throughout animal tissue and the basophils circulate within the vascular system. These cells manufacture and store histamine within the cell unless the specialized sequence of events involving IgE binding occurs to trigger its release.[0090]
• The symptoms of the allergic reaction vary, depending on the location within the body where the IgE reacts with the antigen. If the reaction occurs along the respiratory epithelium the symptoms are sneezing, coughing and asthmatic reactions. If the interaction-occurs in the digestive tract, as in the case of food allergies, abdominal pain and diarrhea are common. Systematic reactions, for example following a bee sting, can be severe and often life threatening.[0091]
• Delayed type hypersensitivity, also known as type IV allergy reaction is an allergic so reaction characterized by a delay period of at least 12 hours from invasion of the antigen into the allergic subject until appearance of the inflammatory or immune reaction. The T lymphocytes (sensitized T lymphocytes) of individuals in an allergic condition react with the antigen, triggering the T lymphocytes to release lymphokines (macrophage migration inhibitory factor (MIF), macrophage activating factor (MAF), mitogenic factor (MF), skin-reactive factor (SRF), chemotactic factor, neovascularization-accelerating factor, etc.), which function as inflammation mediators, and the biological activity of these lymphokines, together with the direct and indirect effects of locally appearing lymphocytes and other inflammatory immune cells, give rise to the type IV allergy reaction. Delayed allergy reactions include tuberculin type reaction, homograft rejection reaction, cell-dependent type protective reaction, contact dermatitis hypersensitivity reaction, and the like, which are known to be most strongly suppressed by steroidal agents. Consequently, steroidal agents are effective against diseases which are caused by delayed allergy reactions. Long-term use of steroidal agents at concentrations currently being used can, however, lead to the serious side-effect known as steroid dependence. The methods of the invention solve some of these problems, by providing for lower and fewer doses to be administered.[0092]
• Immediate hypersensitivity (or anaphylactic response) is a form of allergic reaction which develops very quickly, i.e. within seconds or minutes of exposure of the patient to the causative allergen, and it is mediated by IgE antibodies made by B lymphocytes. In nonallergic patients, there is no IgE antibody of clinical relevance; but, in a person suffering with allergic diseases, IgE antibody mediates immediate hypersensitivity by sensitizing mast cells which are abundant in the skin, lymphoid organs, in the membranes of the eye, nose and mouth, and in the respiratory tract and intestines.[0093]
• Mast cells have surface receptors for IgE, and the IgE antibodies in allergy-suffering patients become bound to them. As discussed briefly above, when the bound IgE is subsequently contacted by the appropriate allergen, the mast cell is caused to degranulate and to release various substances called bioactive mediators, such as histamine, into the surrounding tissue. It is the biologic activity of these substances which is responsible for the clinical symptoms typical of immediate hypersensitivity; namely, contraction of smooth muscle in the airways or the intestine, the dilation of small blood vessels and the increase in their permeability to water and plasma proteins, the secretion of thick sticky mucus, and in the skin, redness, swelling and the stimulation of nerve endings that results in itching or pain.[0094]
• Many allergies are caused by IgE antibody generation against harmless allergens. The cytokines that are induced by administration of immunostimulatory nucleic acids are predominantly of a class called “Th1” (examples are IL-12 and IFN-γ). Cytokine production by helper CD4[0095]⁺(and also in CD8⁺) T cells frequently fall into one of two phenotypes, Th1 and Th2, in both murine and human systems (Romagnani, 1991, Immunol Today 12: 256-257, Mosmann, 1989, Annu-Rev Immunol, 7: 145-173). Th1 cells produce interleukin 2 (IL-2), tumor necrosis factor (TNFα) and interferon gamma (IFNγ) and they are responsible primarily for cell-mediated immunity such as delayed type hypersensitivity. Th2 cells produce interleukins, IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13 and are primarily involved in providing optimal help for humoral immune responses such as IgE and IgG4 antibody isotype switching (Mosmann, 1989, Annu Rev Immunol, 7: 145-173).
• The types of antibodies associated with a Th1 response are generally more protective because they have high neutralization and opsonization capabilities. Th2 responses involve predominately antibodies and these have less protective effect against infection and some Th2 isotypes (e.g., IgE) are associated with allergy. Strongly polarized. Th1 and Th2 responses not only play different roles in protection, they can promote different immunopathological reactions. Th1-type responses are involved organ specific autoimmunity-such as experimental autoimmune uveoretinitis (Dubeyet al, 1991, Eur Cytokine Network 2: 147-152), experimental autoimmune encephalitis (EAE) (Beraud et al, 1991, Cell Immunol 133: 379-389) and insulin dependent diabetes mellitus (Hahnet al, 1987[0096], Eur. J. Immunol.18: 2037-2042), in contact dermatitis (Kapsenberg et al, Immunol Today 12: 392-395), and in some chronic inflammatory disorders. In contrast Th2-type responses are responsible for triggering allergic atopic disorders (against common environmental allergens) such as allergic asthma (Walker et al, 1992, Am Rev Resp Dis 148: 109-115) and atopic dermatitis (van der Heijden et al, 1991, J Invest Derm 97: 389-394), are thought to exacerbate infection with tissue-dwelling protozoa such as helminths (Finkelman et al, 1991, Immunoparasitol Today 12: A62-66) andLeishmania major(Caceres-Dittmar et al, 1993, Clin Exp Immunol 91: 500-505), are preferentially induced in certain primary immunodeficiencies such as hyper-IgE syndrome (Del Prete et al, 1989, J Clin Invest 84: 1830-1835) and Omenn's syndrome (Schandene et al, 1993, Eur J Immunol 23: 56-60), and are associated with reduced ability to suppress HIV replication (Barker et al, 1-995, Proc Soc Nat Acad Sci USA 92: 11135-11139).
• Thus, in general, it appears that allergic diseases are mediated by Th2 type immune responses. Based on the ability of the immunostimulatory nucleic acid to shift the immune response in a subject from a Th2 (which is associated with production of IgE antibodies and allergy and asthma) to a Th1 response (which is protective against allergic and asthmatic reactions), an effective dose for inducing an immune response of a immunostimulatory nucleic acid can be administered to a subject to treat or prevent an allergy or asthma.[0097]
• Th2 cytokines, especially IL-4 and IL-5 are elevated in the airways of asthmatic, subjects. These cytokines promote important aspects of the asthmatic inflammatory response, including IgE isotype switching, eosinophil chemotaxis and activation, and mast cell growth. Th1 cytokines, especially IFN-g and IL-12, can suppress the formation of Th2 clones and production of Th2 cytokines. Thus, the immunostimulatory nucleic acid has significant therapeutic utility in the treatment of allergic conditions and asthma.[0098]
• An “allergen” as used herein is a molecule capable of provoking an immune response characterized by production of IgE. Thus, in the context of this invention, the term allergen means a specific type of antigen which can trigger an allergic response which is mediated by IgE antibody. The method and preparations of this invention extend to a broad class of such allergens and fragments of allergens or haptens acting as allergens. Allergens include but are not limited to Environmental Aeroallergens; plant pollens such as Ragweed/hayfever (affects 10% of pop., 25 million ppl); Weed pollen allergens; Grass pollen allergens (grasses affect 10% of pop., 25 million ppl); Johnson grass; Tree pollen allergens; Ryegrass; House dust mite allergens (affects 6% of pop., 15 million ppl); Storage mite allergens; Japanese cedar pollen/hay fever (affects 10% of pop. In Japan, 13 million ppl); Mold spore allergens; Animal allergens (cat (affects 2% of pop., 5 million ppl), dog, guinea pig, hamster, gerbil, rat, mouse); Food Allergens (e.g., Crustaceans; nuts, such-as peanuts; citrus fruits); Insect Allergens (Other than mites, listed above); Venoms: ([0099]Hymenoptera, yellow jacket, honey bee, wasp, hornet, fire ant); Other environmental insect allergens from cockroaches, fleas, mosquitoes, etc.; Bacteria such as streptococcal antigens; Parasites such asAscarisantigen; Viral Antigens; Fungal spores; Drug Allergens; Antibiotics; penicillins and related compounds; other antibiotics; Whole Proteins such-as hormones (insulin), enzymes (Streptokinase); all drugs and their metabolites capable of acting as incomplete antigens or haptens; Industrial Chemicals and metabolites capable of acting as haptens and stimulating the immune system (Examples are the acid anhydrides (such as trimellitic anhydride) and the isocyanates (such as toluene diisocyanate)); Occupational Allergens such as flour (ie. Baker's asthma), castor bean, coffee bean, and industrial chemicals described above; flea allergens; and human proteins in non-human animals.
• Allergens include but are not limited to cells, cell extracts, proteins, polypeptides, peptides, polysaccharides, polysaccharide conjugates, peptide and non-peptide mimics of polysaccharides and other molecules, small molecules, lipids, glycolipids, and carbohydrates. Many allergens, however, are protein or polypeptide in nature, as proteins and polypeptides are generally more antigenic than carbohydrates or fats.[0100]
• Examples of specific natural, animal and plant allergens include but are not limited to proteins specific to the following genuses: Canine ([0101]Canis familiaris);Dermatophagoides(e.g.Dermatophagoides farinae);Felis(Felis domesticus);Ambrosia(Ambrosia artemiisfolia; Lolium(e.g.Lolium perenneorLolium multiflorum);Cryptomeria(Cryptomeria japonica);Alternaria(Alternaria alternata);Alder; Alnus(Alnus gultinoasa);Betula(Betula verrucosa);Quercus(Quercus alba);Olea(Olea europa);Artemisia(Artemisia vulgaris);Plantago(e.g.Plantago lanceolata);Parietaria(e.g.Parietaria officinalisorParietaria judaica);Blattella(e.g.Blattella germanica);Apis(e.g.Apis multiflorum);Cupressus(e.g.Cupressus sempervirens, Cupressus arizonicaandCupressus macrocarpa);Juniperus(e.g.Juniperus sabinoides, Juniperus virginiana, Juniperus communisandJuniperus ashei);Thuya(e.g.Thuya orientalis);Chamaecyparis(e.g.Chamaecyparis obtusa);Periplaneta(e.g.Periplanetaamericana);Agropyron(e.g.Agropyron repens); -Secale(e.g.Secale cereale);Triticum(e.g.Triticum aestivum);Dactylis(e.g.Dactylis glomerata);Festuca(e.g.Festuca elatior);Poa(e.g.Poa pratensisorPoa compressa);Avena(e.g.Avena sativa);Holcus(e.g.Holcus lanatus);Anthoxanthum(e.g.Anthoxanthum odoratum);Arrhenatherum(e.g.Arrhenatherum elatius);Agrostis(e.g.Agrostis alba);Phleum(e.g.Phleum pratense);Phalaris(e.g.Phalarisaruindinacea);Paspalum(e.g.Paspalum notatum);Sorghum(e.g. Sor-ghum halepensis); andBromus(e.g.Bromus inermis).
• A “subject having asthma” is a subject that has a disorder of the respiratory system characterized by inflammation, narrowing of the airways and increased reactivity of the airways to inhaled agents. Asthma is frequently, although not exclusively associated with atopic or allergic symptoms. An “initiator” as used herein refers to a composition or environmental condition which triggers asthma. Initiators include, but are not limited to, allergens, cold temperatures, exercise, viral infections, SO[0102]₂.
• In another aspect the invention provides methods for treating or preventing asthma or allergy in a hypo-responsive subject. As used herein, a hypo-responsive subject is one who has previously failed to respond to a treatment directed at treating or preventing asthma or allergy or one who is at risk of not responding to such a treatment. The treatment directed at treating or preventing asthma or allergy may began asthma/allergy medicarnent, in which case the hypo-responsive subject is one who is hypo-responsive to an asthma/allergy medicament.[0103]
• Other subjects who are hypo-responsive include those who are refractory to an asthma/allergy medicament. As used herein, the term “refractory” means resistant or failure to yield to treatment. Such subjects may be those who never responded to an asthma/allergy medicament (i.e., subjects who are non-responders), or alternatively, they may be those who at one time responded to an asthma/allergy medicament, but have since that time have become refractory to the medicament. In some embodiments, the subject is one who is refractory to a subset of medicaments. A subset of medicaments is at least one medicament. In some embodiments, a subset refers to 2, 3, 4, 5, 6, 7, 8, 9, or 10 medicaments.[0104]
• In other embodiments, hypo-responsive subjects are elderly subjects, regardless of whether they have or have not previously responded to a treatment directed at treating or preventing asthma or allergy. Elderly subjects, even those who have previously responded to such treatment, are considered to be at risk of not responding to a future administration of this treatment. Similarly, neonatal subjects are also considered to be at risk of not responding to treatment directed at treating or preventing asthma or allergy.[0105]
• In some embodiments, an immunostimulatory nucleic acid is administered to the hypo-responsive subject without the further administration of an asthma/allergy medicament. In yet other embodiments, an asthma/allergy medicament is administered to the hypo-responsive subject, in which case it may be administered substantially simultaneously (i.e., concurrently) with, or following the administration of the immunostimulatory nucleic acid.[0106]
• An “asthma/allergy medicament” as used herein is a composition of matter which reduces the symptoms, inhibits the asthmatic or allergic reaction, or prevents the development of an allergic or asthmatic reaction. Various types of medicaments for the treatment of asthma and allergy are described in the Guidelines For The Diagnosis and Management of Asthma, Expert Panel Report 2, NIH Publication No. 97/4051, Jul. 19, 1997, the entire contents of which are incorporated herein by reference. The summary of the medicaments as described in the NIH publication is presented below.[0107]
• In most embodiments the asthma/allergy medicament is useful to some degree for treating both asthma and allergy. Some asthma/allergy medicaments are preferably used in combination with the immunostimulatory nucleic acids to treat asthma. These are referred to as asthma medicaments. Asthma medicaments include, but are not limited PDE-4 inhibitors, bronchodilator/beta-2 agonists, K+ channel openers, VLA-4 antagonists, neurokin antagonists, TXA2 synthesis inhibitors, xanthanines, arachidonic acid antagonists, 5 lipoxygenase inhibitors, thromboxin A2 receptor antagonists, thromboxane A2 antagonists, inhibitor of 5-lipox activation proteins, and protease inhibitors.[0108]
• Bronchodilator/beta-2 agonists are a class of compounds which cause bronchodilation or smooth muscle relaxation. Bronchodilator/beta-2-agonists include, but are not limited to, salmeterol, salbutamol, albuterol, terbutaline, D2522/formoterol, fenoterol, bitolterol, pirbuerol methylxanthines and orciprenaline. Long-acting β[0109]₂-agonists and bronchodilators-are compounds which are used for long-term prevention of symptoms in addition to the anti-inflammatory therapies. They function by causing bronchodilation, or smooth muscle relaxation, following adenylate cyclase activation and increase in cyclic AMP producing functional antagonism of bronchoconstriction. These compounds also inhibit mast cell mediator release, decrease vascular permeability and increase mucociliary clearance. Long-acting β₂agonists include, but are not limited to, salmeterol and albuterol. These compounds are usually used in combination with corticosteroids and generally are not used without any inflammatory therapy. They have been associated with side effects such as tachycardia, skeletal muscle tremor, hypokalemia, and prolongation of QTc interval in overdose.
• Methylxanthines, including for instance theophylline, have been used for long-term control and prevention of symptoms. These compounds cause bronchodilation resulting from phosphodiesterase inhibition and likely adenosine antagorni. It is also believed that these compounds may effect eosinrophilic infiltration into bronchial mucosa and decrease T-lymphocyte numbers in the epithelium. Dose-related acute toxicities are a particular problem with these types of compounds. As a result, routine serum concentration must be monitored in order to account for the toxicity and narrow therapeutic range arising from individual differences in metabolic clearance. Side effects include tachycardia, nausea and vomiting, tachyarrhythmias, central nervous system stimulation, headache, seizures, hematemesis, hyperglycemia and hypokalemia. Short-acting β[0110]₂agonists/bronchodilators relax airway smooth muscle, causing the increase in air flow. These types of compounds are a preferred drug for the treatment of acute asthmatic systems. Previously, short-acting β₂agonists had been prescribed on a regularly-scheduled basis in order to improve overall asthma symptoms. Later reports, however, suggested that regular use of this class of drugs produced significant diminution in asthma control and pulmonary function (Sears, et al.Lancet;336:1391-6, 1990). Other studies showed that regular use of some types of β₂agonists produced no harmful effects over a four-month period but also produced no demonstrable effects (Drazen, et al.,N. Eng. J. Med.,335:841-7, 1996). As a result of these studies, the daily use of short-acting β2 agonists is not generally recommended. Short-acting β₂agonists include, but are not limited to, albuterol, bitolterol, pirbuterol, and terbutaline. Some of the adverse effects associated with the mastration of short-acting β₂agonists include tachycardia, skeletal muscle tremor, hypokalemia, increased lactic acid, headache, and hyperglycemia.
• Other asthma/allergy medicaments are preferably used in combination with the imminostimulatory nucleic acids to treat allergy. These are referred to as allergy medicaments. Allergy medicaments include, but are not limited to, anti-histamines, steroids, and prostaglandin inducers. Anti-histamines are compounds which counteract histamine released by mast cells or basophils. These compounds are well known in the art and commonly used for the treatment of allergy. Anti-histamines include, but are not limited to, loratidine, cetirizine, buclizine, ceterizine analogues, fexofenadine, terfenadine, desloratadine, norastemizole, epinastine, ebastine, ebastine, astemizole, levocabastine, azelastine, tranilast, terfenadine, mizolastine, betatastine, CS 560, and HSR 609. Prostaglandin inducers are compounds which induce prostaglandin activity. Prostaglandins function by regulating smooth muscle relaxation. Prostaglandin inducers include, but are not limited to, S-5751.[0111]
• The asthma/allergy medicaments useful in combination with the immunostimulatory nucleic acids also include steroids and immunomodulators.[0112]
• The steroids include, but are not limited to, beclomethasone, fluticasone, tramcinolone, budesonide, corticosteroids and budesonide. The combination of immunostimulatory nucleic acids and steroids are particularly well suited to the treatment of young subjects (e.g., children). To date, the use of steroids in children has been limited by the observation that some steroid treatments have been reportedly associated with growth retardation. Thus, according to the present invention, the immunostimulatory nucleic acids can be used in combination with growth retarding steroids, and can thereby provide a “steroid sparing effect.” The combination of the two agents can result in lower required doses of steroids.[0113]
• Corticosteroids are used long-term to prevent development of the symptoms, and suppress, control, and reverse inflammation arising from an initiator. Some corticosteroids can be administered by inhalation and others are administered systemically. The corticosteroids that are inhaled have an anti-inflammatory function by blocking late-reaction allergen and reducing airway hyper-responsiveness. These drugs also inhibit cytokine production, adhesion protein activation, and inflammatory cell migration and activation.[0114]
• Corticosteroids include, but are not limited to, beclomethasome dipropionate, budesonide, flunisolide, fluticaosone, propionate, and triamcinoone acetonide. Although dexamethasone is a corticosteroid having anti-inflammatory action, it is not regularly used for the treatment of asthma/allergy in an inhaled form because it is highly absorbed, it has long-term suppressive side effects at an effective dose. Dexamethasone, however, can be used according to the invention for the treating of asthma/allergy because when administered in combination with immunostimulatory nucleic acids it can be administered at a low dose to reduce the side effects. Additionally, the immunostimulatory nucleic acid can be administered to reduce the side effects of dexamethasone at higher concentrations. Some of the side effects associated with corticosteroid include cough, dysphonia, oral thrush (candidiasis), and in higher doses, systemic-effects, such as adrenal suppression, osteoporosis, growth suppression, skin thinning and easy bruising. (Barnes & Peterson,[0115]Am. Rev. Respir. Dis.;148:S1-S26, 1993; and Kamada et al.,Am. J. Respir. Crit. Care Med.;153:1739-48, 1996)
• Systemic corticosteroids include, but are not limited to, methylprednisolone,[0116]
• prednisolone and prednisone. Cortosteroids are used generally for moderate to severe exacerbations to prevent the progression, reverse inflammation and speed recovery. These anti-inflammatory compounds include, but are hot limited to, methylprednisolone, prednisolone, and prednisone. Cortosteroids are associated with reversible abnormalities in glucose metabolism, increased appetite, fluid retention, weight gain, mood alteration, hypertension, peptic ulcer, and rarely asceptic necrosis of femur. These compounds are useful for short-term (3-10 days) prevention of the inflammatory reaction in inadequately-controlled persistent asthma. They also function in a long-term prevention of symptoms in severe persistent asthma to suppress and control- and actually reverse inflammation. The side effects associated with systemic corticosteroids are even greater than those associated with inhaled corticosteroids. Side effects include, for instance, reversible abnormalities in glucose metabolism, increased appetite, fluid retention, weight gain, mood alteration, hypertension, peptic ulcer and asceptic necrosis of femur, which are associated with short-term use. Some side effects associated with longer term use include adrenal axis suppression, growth suppression, dermal thinning, hypertension, diabetes, Cushing's syndrome, cataracts, muscle weakness, and in rare instances, impaired immune function. It is recommended that these types of compounds be used at their lowest effective dose (guidelines for the diagnosis and management of asthma; expert panel report to; NIH Publication No. 97-4051; July 1997). The inhaled corticosteroids are believed to function by blocking late reaction to allergen and reducing airway hyper-responsiveness. Their also believed to reverse β[0117]₂-receptor downregulation and to inhibit microvascular leakage.
• The immunomodulators include, but are not limited to, the group consisting of anti-inflammatory agents, leukotriene antagonists, IL-4 muteins, soluble IL-4 receptors, immunosuppressants (such as tolerizing peptide vaccine), anti-IL-4 antibodies, IL-4 antagonists, anti-IL-5 antibodies, soluble IL-13 receptor-Fc fusion proteins, anti-IL-9 antibodies, CCR3 antagonists, CCR5 antagonists, VLA-4 inhibitors, and, and downregulators of IgE.[0118]
• Leukotriene modifiers are often used for long-term control and prevention of symptoms in mild persistent asthma. Leukotriene modifiers function as leukotriene receptor antagonists by selectively competing for LTD-4 and LTE-4 receptors. These compounds include, but are not limited to, zafirlukast tablets and zileuton tablets. Zileuton tablets function as 5-lipoxygenase inhibitors. These drugs have been associated with the elevation of liver enzymes and some cases of reversible hepatitis and hyperbilirubinemia. Leukotrienes are biochemical mediators that are released from mast cells, eosinophils, and basophils that cause contraction of airway smooth muscle and increase vascular permeability, mucous secretions and activate inflammatory cells in the airways of patients with asthma.[0119]
• Other immunomodulators include neuropeptides that have been shown, to have immunomodulating properties. Functional studies have shown that substance P, for instance, can influence lymphocyte function by specific receptor mediated mechanisms. Substance P also has been shown to modulate distinct immediate hypersensitivity responses by stimulating the generation of arachidonic acid-derived mediators from mucosal mast cells. J. McGillies, et al., Substance P and Immunoregulation, Fed. Proc. 46:196-9 (1987). Substance P is a neuropeptide first identified in 1931 by Von Euler and Gaddum. An unidentified depressor substance in certain tissue extracts, J. Physiol. (London) 72:74-87 (1931). Its amino acid sequence, Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH.sub.2 (Sequence Id. No. 1) was reported by Chang et al. in 1971. Amino acid sequence of substance P, Nature (London) New Biol. 232:86-87 (1971). The immunoregulatory activity of fragments of substance P has been studied by Siemion, et al. Immunoregulatory Activity of Substance P Fragments, Molec. Immunol. 27:887-890 (1990).[0120]
• Another class of compounds is the down-regulators of IgE. These compounds include peptides or other molecules with the ability to bind to the IgE receptor and thereby prevent binding of antigen-specific IgE. Another type of downregulator of IgE is a monoclonal antibody directed against the IgE receptor-binding region of the human IgE molecule. Thus, one type of downregulator of IgE is an anti-IgE antibody or antibody fragment. Anti-IgE is being developed by Genentech. One of skill in the art could prepare functionally active antibody fragments of binding peptides which have the same function. Other types of IgE downregulators are polypeptides capable of blocking the binding of the IgE antibody to the Fc receptors on the cell surfaces and displacing IgE from binding sites upon which IgE is already bound.[0121]
• One problem associated with downregulators of IgE is that many molecules don't have a binding strength to the receptor corresponding to the very strong interaction between the native IgE molecule and its receptor. The molecules having this strength tend to bind irreversibly to the receptor. However, such substances are relatively toxic since they can bind covalently and block other structurally similar molecules in the body. Of interest in this context is that the alpha chain of the IgE receptor belongs to a larger gene family where i.e. several of the different IgG Fc receptors are contained. These receptors are absolutely essential for the defense of the body against i.e. bacterial infections. Molecules activated for covalent binding are, furthermore, often relatively unstable and therefore they probably have to be administered several times a day and then in relatively high concentrations in order to make it possible to block completely the continuously renewing pool of IgE receptors on mast cells and basophilic leukocytes.[0122]
• These types of asthma/allergy medicaments are sometimes classified as long-term control medications or quick-relief medications. Long-term control medications include compounds such as corticosteroids (also referred to as glucocorticoids), methylprednisolone, prednisolone, prednisone, cromolyn sodium, nedocromil, long-acting β[0123]₂-agonists, methylxanthines, and leukotriene modifiers. Quick relief medications are useful for providing quick relief of symptoms arising from allergic or asthmatic responses. Quick relief medications include short-acting β₂agonists, anticholinergics and systemic corticosteroids.
• Chromolyn sodium and medocromil are used as long-term control medications for preventing primarily asthma symptoms arising from exercise or allergic symptoms arising from allergens. These compounds are believed to block early and late reactions to allergens by interfering with chloride channel function. They also stabilize mast cell membranes and inhibit activation and release of mediators from eosinophils and epithelial cells. A four to six week period of administration is generally required to achieve a maximum benefit.[0124]
• Anticholinergics are generally used for the relief of acute bronchospasm. These compounds are believed to function by competitive inhibition of muscarinic cholinergic receptors. Anticholinergics include, but are not limited to, ipratrapoium bromide. These compounds reverse only cholinerigically-mediated bronchospasm and do not modify any reaction to antigen. Side effects include drying of the mouth and respiratory secretions, increased wheezing in some individuals, blurred vision if sprayed in the eyes.[0125]
• In addition to standard asthma/allergy medicaments other methods for treating asthma/allergy have been used either alone or in combination with established medicaments. One preferred, but frequently impossible, method of relieving allergies is allergen or initiator avoidance. Another method currently used for treating allergic disease involves the injection of increasing doses of allergen to induce tolerance to the allergen and to prevent further allergic reactions.[0126]
• Allergen injection therapy (allergen immunotherapy) is known to reduce the severity of allergic rhinitis. This treatment has been theorized to involve the production of a different form of antibody, a protective antibody which is termed a “blocking antibody”. Cooke, R A et al., Serologic Evidence of Immunity with Coexisting Sensitization in a Type of Human Allergy, Exp. Med. 62-733 (1935). Other attempts to treat allergy involve modifying the allergen chemically so that its ability to cause an immune response in the patient is unchanged, while its ability to cause an allergic reaction is substantially altered.[0127]
• These methods, however, can take several years to be effective and are associated with the risk of side effects such as anaphylactic shock. The use of an immunostimulatory nucleic acid and asthma/allergy medicament in combination with an allergen avoids many of the side effects etc.[0128]
• Commonly used allergy and asthma drugs which are currently in development or on the market are shown in Tables 1 and 2 respectively.[0129]

  TABLE 1
  Allergy Drugs in Development or on the Market

  	BRAND NAME
  MARKETER	(GENERIC NAME)	MECHANISM
  Schering-	Claritin + Claritin D (loratidine)	Anti-histamine
  Plough
  	Vancenase (beclomethasone)	Steroid
  UCB	Reactine (cetirizine)(US)	Anti-histamine
  	Zyrtec (cetirizine)(ex US)
  	Longifene (buclizine)	Anti-histamine
  	UCB 28754 (ceterizine alalogue)	Anti-histamine
  Glaxo	Beconase (beclomethasone	Steroid
  	Flonase (fluticasone)	Steroid
  Aventis	Allegra (fexofenadine)	Anti-histamine
  	Seldane (terfenadine)	Anti-histamine
  Pfizer	Reactine (cetirizine) (US)	Anti-histamine
  	Zyrtec/Reactine (cetirizine)(ex US)
  	(both licensed from UCB)
  Sepracor	Allegra (fexofenadine)	Anti-histamine
  	Desloratadine (lic to Schering-	Anti-histamine
  	Plough) Cetirizine (−) (lic to UCB)	Anti-histamine
  	Norastemizole (option to J&J not	Anti-histamine
  	exercised, 10-17-99)
  B. Ingelheim	Alesion (epinastine)	Anti-histamine
  Aventis	Kestin (ebastine) (US)	Anti-histamine
  	Bastel (ebastine) (Eu/Ger)
  	Nasacort (tramcinolone)	Steroid
  Johnson &	Hismanol (astemizole)	Anti-histamine
  Johnson
  	Livostin/Livocarb (levocabastine)	Anti-histamine
  AstraZeneca	Rhinocort (budesonide) (Astra)	Steroid
  Merck	Rhinocort (budesonide)	Steroid
  Eisai	Azeptin (azelastine)	Anti-histamine
  Kissei	Rizaben (tranilast)	Anti-histamine
  Shionogi	Triludan (terfenadine).	Anti-histamine
  	S-5751	Prostaglandin
  		inducer
  Schwarz	Zolim (mizolastine)	Anti-histamine
  Daiichi	Zyrtec (cetirizine)	Anti-histamine
  Tanabe	Talion/TAU-284 (betatastine)	Anti-histamine
  Seiyaku
  Sankyo**	CS 560 (Hypersensitizaion	Other
  	therapy for cedar pollen allergy)
  Asta Medica	Azelastine-MDPI (azelastine)	Anti-histamine
  BASF	HSR 609	Anti-histamine
  SR Pharma	SRL 172	Immunomodulation
  Peptide	Allergy vaccine (allergy (hayfever,	Downregulates
  Therapeutics	anaphylaxis, atopic asthma)	specific IgE
  	Tolerizing peptide vaccine (rye	Immuno-
  	grass peptide (T cell epitope))	suppressant
  Coley	CpG DNA	Immunomodulation
  Pharmaceutical
  Group
  Genetech	Anti-IgE	Down-regulator of
  		IgE
  SR Pharma	SRL 172	Immunomodulation

• [0130]

  TABLE 2
  Asthma Drugs in Development or on the Market

  MARKETER	BRAND NAME (GENERIC NAME)	MECHANISM
  Glaxo	Serevent (salmeterol)	Bronchodilator/beta-2 agonist
  	Flovent (fluticasone)	Steroid
  	Flixotide (fluticasone)
  	Becotide (betamethasone)	Steroid
  	Ventolin (salbutamol)	Bronchodilator/beta-2 agonist
  	Seretide (salmeterol + fluticasone)	Beta agonist + steroid
  	GW215864	Steroid, hydolysable
  	GW250495	Steroid, hydolysable
  	GW328267	Adenosine A2 agonist
  AstraZeneca	Bambec (bambuterol) (Astra)
  	Pulmicort (budesonide) (Astra)	Steroid
  	Bricanyl Turbuhaler (terbutaline) (Astra)	Bronchodilator/beta-2 agonist
  	Accolate (zafirlukast) (Zeneca)	Leukotriene antagonist Slo-
  		Phyllin (theophylline)
  	Inspiryl (salbutamol) (Astra)	Bronchodilator/beta-2 agonist
  	Oxis Turbuhaler (D2522/formoterol)	Bronchodilator/beta-2 agonist
  	Symbicort (pulmicort-oxis combination)	Steroid
  	Roflepanide (Astra)	Steroid
  	Bronica (seratrodast)	TXA2 synthesis inhibitor
  	ZD 4407 (Zeneca)	5 lipoxygenase inhibitor
  B. Ingelheim	Atrovent (ipratropium)	Bronchodilator/anti-
  		cholinergic
  	Berodual (ipratropium + fenoterol)	Bronchodilator/anti-
  		cholinergic
  	Berotec (fenoterol)	Bronchodilator/beta-2 agonist
  	Alupent (orciprenaline)	Bronchodilator/beta-2 agonist
  	Ventilat (oxitropium)	Bronchodilator/anti-
  		cholinergic
  	Spiropent (clenbuterol)	Bronchodilator/beta-2 agonist
  	Inhacort (flunisolide)	Steroid
  	BI679/tiotropium bromide
  	RPR 106541	Steroid
  	BIIX 1	Potassium channel
  	BIIL284	LTB-4 antagonist
  Schering-	Proventil (salbutamol)	Bronchodilator/beta-2 agonist
  Plough
  	Vanceril (beclomethasone)	Steroid
  	Mometasone furoate	Steroid
  	Theo-Dur (theophylline (w/Astra)
  	Uni-Dur (theophylline)
  	Asmanex (mometasone)	Steroid
  	CDP 835 (lic from Celltech)	Anti-IL-5 Mab
  RPR	Intal (disodium cromoglycate)	Anti-inflammatory
  (Aventis)	Intal/Aarane (disodium cromoglycate)
  	Tilade (nedocromil sodium)	Anti-inflammatory
  	Azmacort (triamcinolone acetonide)	Steroid
  	RP 73401	PDE-4 inhibitor
  Novartis	Zaditen (ketotifen)	Anti-inflammatory
  	Azmacort (triamcinolone)	Steroid
  	Foradil (formoterol) (lic fromYamanouchi)	Bronchodilator/beta-2 agonist
  	E25	Anti-IgE
  	KCO 912	K+ channel opener
  Merck	Singulair (montelukast)	Leukotriene antagonist
  	Pulmicort Turbuhaler (budesonide)	Steroid
  	Slo-Phyllin (theophylline)
  	Symbicort (Pulmicort-Oxis combination)	Steroid
  	Oxis Turbuhaler (D2522/formoterol)	Bronchodilator/beta-2 agonist
  	Roflepanide	Steroid
  	VLA-4 antagonist (lic from Biogen)	VLA-4 antagonist
  ONO	Onon (pranlukast)	Leukotriene antagonist
  	Vega (ozagrel)	TXA2 synthesis inhibitor
  Fujisawa	Intal (chromoglycate)	Anti-inflammatory
  	FK 888	Neurokin antagonist
  Forest Labs	Aerobid (flunisolide)	Steroid
  IVAX	Ventolin (salbutamol)	Bronchodilator/beta-2 agonist
  	Becotide (beclomethasone Easi-Breathe)	Steroid
  	Serevent (salmeterol)	Bronchodilator/beta-2 agonist
  	Flixotide (fluticasone)	Steroid
  	Budesonide Dry Powder Inhaler	Steroid
  	Salbutamol Dry Powder Inhaler	Bronchodilator/beta-2 agonist
  Alza	Volmax (salbutamol)	Bronchodilator/beta-2 agonist
  Altana	Euphyllin (theophylline)	Xanthanine
  	Ciclesonide	Arachidonic acid antagonist
  	BY 217	PDE 4 inhibitor
  	BY 9010N (ciclesonide)	Steroid (nasal)
  Tanabe	Flucort (fluocinolone acetonide	Steroid
  Seiyaku
  Kissei	Domenan (ozagrel)	TXA2 synthesis inhibitor
  Abbott	Zyflo (zileuton) (4X/day dosing, not competitive w/	5 lipoxygenase inhibitor
  	Singulair or Accolate, no further interest in this area)
  Asta Medica	Aerobec (beclomethasone dipropionate) (w/3M)
  	Allergodil (azelastine)
  	Allergospasmin (sodium cromoglycate reproterol)
  	Bronchospasmin (reproterol)
  	Salbulair (salbutamol sulphate) (w/3M)
  	TriNasal (triamcinolone)	Steroid
  	Formoterol-MDPI	Beta 2 adrenoceptor agonist
  	Budesonide-MDPI
  UCB	Atenos/Respecal (tulobuerol)	Bronchodilator/beta-2 agonist
  Recordati	Theodur (theophylline)	Xanthine
  Medeva	Clickhalers Asmasal, Asmabec (salbutamol	Steroid
  	beclomethasone diproprionate, dry inhaler)
  Eisai	E 6123	PAF receptor antagonist
  Sankyo	Zaditen (ketotifen)	Anti-inflammatory
  	CS 615	Leukotriene antagonist
  Shionogi	Anboxan/S 1452 (domitroban)	Thromboxin A2 receptor
  		antagonist
  Yamanouchi	YM 976	PDE 4 inhibitor
  	YM 158	Leukotriene D4/thromboxan 2
  		dual antagonist
  3M Pharma	Exirel (pirbuterol)
  Hoechst	Autoinhalers (3M albuterol projects)	Bronchodilator/beta-2 agonist
  (Aventis)
  SmithKline	Ariflo	PDE-4 inhibitor
  Beecham
  	SB 240563	Anti-IL5 MAb (humanized)
  	SB 240683	Anti-IL4 Mab
  	IDEC 151/clenoliximab	Anti-CD4 MAb, primatised
  Roche	Anti-IgE(GNE)/CGO51901	Down-regulator of IgE
  Sepracor	Fomoterol (R,R)	Beta 2 adrenoceptor agonist
  	Xopenex (levalbuterol)	Bet 2 adrenoceptor agonist
  Bayer	BAY U 3405 (ramatroban)	Thromboxane A2 antagonist
  	BAY 16-9996 (once monthly dosing)	IL4 mutein
  	BAY 19-8004	PDE-4 inhibitor
  SR Pharma	SRL 172	Immunomodulation
  Immunex	Nuvance	Soluble IL-4 receptor
  		(immunomodulator)
  Biogen	Anti-VLA-4	Immunosuppressant
  Vanguard	VML 530	Inhibitor of 5-lipox activation
  		protein
  Recordati	Respix (zafirlukast)	Leukotriene antagonist
  Genentech	Anti-IgE MAb	Down-regulator of IgE
  Warner	CI-1018	PDE 4 inhibitor
  Lambert
  Celltech/	CDP 835/SCH 55700 (anti-IL-5) (lic to Schering-	IL-5 antagonist Mab
  Chiroscience	Plough)
  	D 4418 (w/Schering-Plough)	PDE 4 inhibitor
  	CDP 840 (Celltech)	PDE 4 inhibitor
  AHP	Pda-641 (asthma steroid replacement)
  Peptide	RAPID Technology Platform	Protease inhibitors
  Therapeutics
  Coley	CpG DNA	Immunomodulation
  Pharmaceutical
  Group

• In some cases the subject is exposed to an allergen in addition to being treated with the immunostimulatory nucleic acid and the asthma/allergy medicament. In this case the subject is said to be exposed to the allergen. As used herein, the term “exposed to” refers to either the active step of contacting the subject with an allergen or the passive exposure of the subject to the allergen in vivo. Methods for the active exposure of a subject to an allergen are well-known in the art. In general, an allergen is administered directly to the subject by any means such as intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal, or subcutaneous administration. The allergen can be-administered systemically or locally. Methods for administering the allergen and the immunostimulatory nucleic acid/asthma/allergy medicament are described in more detail below. A subject is passively exposed to an allergen if an allergen becomes available for exposure to the immune cells in the body. A subject may be passively exposed to an allergen, for instance, by entry of an allergen into the body when the allergen is present in the environment surrounding the subject, i.e. pollen.[0131]
• The methods in which a subject is passively exposed to an allergen can be particularly dependent on timing of administration of the immunostimulatory nucleic acid and the asthma/allergy medicament. For instance, in a subject at risk of developing an allergic or asthmatic response, the subject may be administered the immunostimulatory-nucleic acid and the asthma/allergy medicament on a regular basis when that risk is greatest, i.e., during pollen allergy season. Additionally the immunostimulatory nucleic acid and the asthma/allergy medicament may be administered to travelers before they travel to a destination where they are at risk of exposure to a particular allergen.[0132]
• As used herein, the term “prevent”, “prevented”, or “preventing” when used with respect to the treatment of an allergic or asthmatic disorder refers to a prophylactic treatment which increases the resistance of a subject to an allergen or initiator or, in other words, decreases the likelihood that the subject will develop an allergic or asthmatic response to the allergen or initiator as well as a treatment after the allergic or asthmatic disorder has begun in order to fight the allergy/asthma, e.g., reduce or eliminate it altogether or prevent it from becoming worse.[0133]
• The term “substantially purified” as used herein refers to a molecular species which is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated. One skilled in the art can purify allergenic polypeptides using standard techniques for protein purification. The substantially pure polypeptide will often yield a single major band on a non-reducing polyacrylamide gel. In the case of partially glycosylated polypeptides or those that have several start codons, there may be several bands on a non-reducing polyacrylamide gel, but these will form a distinctive pattern for that polypeptide. The purity of the allergenic polypeptide can also be determined by amino-terminal amino acid sequence analysis.[0134]
• The allergen and/or polypeptide asthma/allergy medicament may be in the form of a polypeptide when administered to the subject or it may be encoded by a nucleic acid vector. If the nucleic acid vector is administered to the subject the protein is expressed in vivo. Minor modifications of the primary amino acid sequences of polypeptide allergens may also result in a polypeptide which has substantially equivalent allergenic activity as compared to the unmodified counterpart polypeptide. Such modifications may be deliberate, as by site-directed mutagenesis, or may be spontaneous.[0135]
• The nucleic acid encoding the allergen or asthma/allergy medicament is operatively linked to a gene expression sequence which directs the expression of the protein within a eukaryotic cell. The “gene expression sequence” is any regulatory-nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the protein which it is operatively linked. The gene expression sequence may, for example, be a mammalian or viral promoter, such as a constitutive or inducible promoter. Constitutive mammalian promoters include, but are not limited to, the promoters for the following genes: hypoxanthine phosphoribosyl transferase-(HPTR), adenosine deaminase, pyruvate kinase, b-actin promoter and other constitutive promoters. Exemplary viral promoters which function constitutively in eukaryotic cells include, for example, promoters from the cytomegalovirus (CMV), simian virus (e.g., SY40), papilloma virus, adenovirus, human immunodeficiency virus (HIV), Rous sarcoma virus, cytomegalovirus, the long terminal repeats (LTR) of Moloney leukemia virus and other retroviruses, and the thymidine kinase promoter of herpes simplex virus. Other constitutive promoters are known to those of ordinary skill in the art. The promoters useful as gene expression sequences of the invention also include inducible promoters. Inducible promoters are expressed in the presence of an inducing agent. For example, the metallothionein promoter is induced to promote transcription and translation in the presence of certain metal ions. Other inducible promoters are known to those of ordinary skill in the art.[0136]
• In general, the gene expression sequence shall include, as necessary, 5′ non-transcribing and 5′ non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5′ non-transcribing sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined antigen nucleic acid. The gene expression sequences optionally include enhancer sequences or upstream activator sequences as desired.[0137]
• As used herein, the nucleic acid sequence encoding the protein and the gene expression sequence are said to be “operably linked” when they are covalently linked in such a way as to place the expression or transcription and/or translation of the antigen coding sequence under the influence or control of the gene expression sequence. Two DNA sequences are said to be operably linked if induction of a promoter in the 5′ gene expression sequence results in the transcription of the gene sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the antigen sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a gene expression sequence would be operably linked to a; specific nucleic acid sequence if the gene expression sequence were capable of effecting transcription of that nucleic acid sequence such that the resulting transcript is translated into the desired-protein or polypeptide.[0138]
• The immunostimulatory nucleic acids may also be delivered to the subject in the form of a plasmid vector. In some embodiments, one plasmid vector could include both the immunostimulatory nucleic acid and a nucleic acid encoding a protein asthma/allergy medicament and/or an allergen. In other embodiments, separate plasmids could be used. In yet other embodiments, no plasmids could be used.[0139]
• The compositions of the invention-may be delivered to the immune system or other target cells alone or in association with a vector. In its broadest sense, a “vector” is any vehicle capable of facilitating the transfer of the compositions to the target cells. The vector generally transports the nucleic acid to the immune cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector.[0140]
• In general, the vectors useful in the invention are divided into two classes: biological vectors and chemical/physical vectors. Biological vectors and chemical/physical vectors are useful for delivery/uptake of nucleic acids, asthma/allergy medicaments, and/or allergens to/by a target cell.[0141]
• Biological vectors include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of nucleic acid sequences, and free nucleic acid fragments which can be attached to nucleic acid sequences. Viral vectors are a preferred type of biological vector and include, but are not limited to, nucleic acid sequences from the following viruses: retroviruses, such as: Moloney murine leukemia-virus; Harvey murine sarcoma virus; murine mammary tumor virus; Rous sarcoma virus; adenovirus; adeno-associated virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes viruses; vaccinia viruses; polio viruses; and RNA viruses such as any retrovirus. One can readily employ other viral vectors not named but known in the art.[0142]
• Preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with a nucleic acid of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. Retroviruses have been approved for human gene therapy trials. In general, the retroviruses are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes in vivo. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell lined with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kriegler, M., “Gene Transfer and Expression, A Laboratory Manual,” W.H. Freeman Co., New-York (1990) and Murry, E. J. Ed. “Methods in Molecular Biology,” vol. 7, Humana Press, Inc., Cliffton, N.J. (1991).[0143]
• Another preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus can be engineered to be replication-deficient and is capable of infecting a wide range of cell types and species. It further has advantages, such as heat and lipid solvent stability; high transduction frequencies in cells of diverse lineages; and lack of superinfection inhibition thus allowing multiple series of transductions. Reportedly, the adeno-associated virus can integrate into human insertional mutagenesis and variability of inserted gene expression. In addition, wild-type adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.[0144]
• Other biological vectors include plasmid vectors. Plasmid vectors have been extensively described in the art and are well-known to those of skill in the art. See e.g., Sambrook et al., “Molecular Cloning: A Laboratory Manual,” Second Edition, Cold Spring Harbor Laboratory Press, 1989. In the last few years, plasmid vectors have been found to be particularly advantageous for delivering genes to cells in vivo because of their inability to replicate within and integrate into a host genome. These plasmids, however, having a promoter compatible with the host cell, can express a peptide from a gene operatively encoded within the plasmid. Some commonly used plasmids include pBR322, pUC18, pUC19, pRC/CMV, SV40, and pBlueScript. Other plasmids are well-known to those of ordinary skill in the art. Additionally, plasmids may be custom designed using restriction enzymes and ligation reactions to remove and add specific fragments of DNA.[0145]
• It has recently been discovered that gene carrying plasmids can be delivered to the immune system using bacteria. Modified forms of bacteria such as[0146]Salmonellacan be transfected with the plasmid and used as delivery vehicles. The bacterial delivery vehicles can be administered to a host subject orally or by other administration means. The bacteria deliver the plasmid to immune cells, e.g. B cells, dendritic cells, likely by passing through the gut barrier. High levels of immune protection have been established using this methodology. Such methods of delivery are useful for the aspects of the invention utilizing systemic delivery of allergen, immunostimulatory nucleic acid and/or other therapeutic agent.
• In addition to the biological vectors, chemical/physical vectors may be used to deliver a nucleic acid, asthma/allergy medicament, and/or allergen to a target cell and facilitate uptake thereby. As used herein, a “chemical/physical vector” refers to a natural or synthetic molecule, other than those derived from bacteriological or viral sources, capable of delivering the nucleic acid, asthma/allergy medicament, and/or allergen to a cell.[0147]
• A preferred chemical/physical vector of the invention is a colloidal dispersion system. Colloidal dispersion systems include lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system of the, invention is a liposome. Liposomes are artificial membrane vessels which are useful as a delivery vector in vivo or in vitro. It has been shown that large unilamellar vessels (LUV), which range in size from 0.2-4.0 μm can encapsulate large macromolecules. RNA, DNA, and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, et al.,[0148]Trends Biochem. Sci., (1981) 6:77).
• Liposomes may be targeted to a particular tissue by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein. Ligands which may be useful for targeting a liposome to an immune cell include, but are not limited to: intact or fragments of molecules which interact with immune cell specific receptors and molecules, such as antibodies, which interact with the cell surface markers of immune cells. Such ligands may easily be identified by binding assays well known to those of skill in the art. Additionally, the vector may be coupled to a nuclear targeting peptide, which will direct the vector to the nucleus of the host cell.[0149]
• Lipid formulations for transfection are commercially available from QIAGEN, for example, as EFFECTENE™ (a non-liposomal lipid with a special DNA condensing enhancer) and SUPERFECT™ (a novel acting dendrimeric technology).[0150]
• Liposomes are commercially available from Gibco BRL, for example, as LIPOFECTIN™ and LIPOFECTACE™, which are formed of cationic lipids such as N-[1-(2, 3 dioleyloxy)-propyl]-N,N, N-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Methods for making liposomes are well known in the art and have been described in many publications. Liposomes also have been reviewed by Gregoriadis, G. in[0151]Trends in Biotechnology, (1985) 3:235-241.
• In one embodiment, the vehicle is a biocompatible microparticle or implant that is suitable for implantation or administration to the mammalian recipient. Exemplary bioerodible implants that are useful in accordance with this method are described in PCT International application no. PCT/US/03307 (Publication No. WO95/24929, entitled “Polymeric Gene Delivery System”. PCT/US/0307 describes a biocompatible, preferably biodegradable polymeric matrix for containing an exogenous gene under the control of an appropriate promoter. The polymeric matrix can be used to achieve sustained release of the exogenous gene in the patient.[0152]
• The polymeric matrix preferably is in the form of a microparticle-such as a microsphere (wherein the a nucleic acid, asthma/allergy medicament, and/or allergen is dispersed throughout a solid polymeric matrix) or a microcapsule (wherein the a nucleic acid, asthma/allergy medicament, and/or allergen is stored in the core of a polymeric shell). Other forms of the polymeric matrix for containing the a nucleic acid, asthma/allergy medicament, and/or allergen include films, coatings, gels, implants, and stents. The size and composition of the polymeric matrix device is selected to result in favorable release kinetics in the tissue into which the matrix is introduced. The size of the polymeric matrix further is selected according to the method of delivery which is to be used, typically injection into a tissue or administration of a suspension by aerosol into the nasal and/or pulmonary areas. Preferably when an aerosol route is used the polymeric matrix and the nucleic acid, asthma/allergy medicament, and/or allergen are encompassed in a surfactant vehicle. The polymeric matrix composition can be selected to have both favorable degradation rates and also to be formed of a material which is bioadhesive, to further increase the effectiveness of transfer when the matrix is administered to a nasal and/or pulmonary surface that has sustained an injury. The matrix composition also can be selected not to degrade, but rather, to release by diffusion over an extended period of time.[0153]
• In another embodiment the chemical/physical vector is a biocompatible microsphere that is suitable for delivery, such as oral or mucosal delivery. Such microspheres are disclosed in Chickering et al.,[0154]Biotech. And Bioeng., (1996) 52:96-101 and Mathiowitz et al.,Nature, (1997) 386:410-414 and PCT Patent Application WO97/03702.
• Both non-biodegradable and biodegradable polymeric matrices can be-used to deliver the nucleic acid, asthma/allergy medicament, and/or allergen to the subject. Biodegradable matrices are preferred. Such polymers may be natural or synthetic polymers. The polymer is selected based on the period of time over which release is desired, generally in the order of a few hours to a year or longer. Typically, release over a period ranging from between a few hours and three to twelve months is most desirable. The polymer optionally is in the form of a hydrogel that can absorb up to about 90% of its weight in water and further, optionally is cross-linked with multi-valent ions or other polymers.[0155]
• Bioadhesive polymers of particular interest include bioerodible hydrogels described by H. S. Sawhney, C. P. Pathak and J. A. Hubell in[0156]Macromolecules, (1993) 26:581-587, the teachings of which are incorporated herein, polyhyaluronic acids, casein, gelatin, glutin, polyanhydrides, polyacrylic acid, alginate, chitosan, poly(methyl methacrylates), poly(ethyl methacrylates), poly(butylmethacrylate), poly(isobutyl methacrylate), poly(hexylmethacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), and poly(octadecyl acrylate).
• Compaction agents also can be used alone, or in combination with, a biological or chemical/physical vector. A “compaction agent”, as used herein, refers to an agent, such as a histone, that neutralizes the negative charges on the nucleic acid and thereby permits compaction of the nucleic acid into a fine granule. Compaction of the nucleic acid facilitates the uptake of the nucleic acid by the target cell. The compaction agents can be used alone, i.e., to deliver a nucleic acid in a form that is more efficiently taken up by the cell or, more preferably, in combination with one or more of the above-described vectors.[0157]
• Other exemplary compositions that can be used to facilitate uptake by a target cell of the nucleic acid, asthma/allergy medicament, and/or allergen include calcium phosphate and other chemical mediators of intracellular transport, microinjection compositions, electroporation and homologous recombination compositions (e.g., for integrating a nucleic acid into a preselected location within the target cell chromosome).[0158]
• The immunostimulatory nucleic acid and/or the asthma/allergy medicament the antigen and/or other therapeutics may be administered alone (e.g. in saline or buffer) or using any delivery vectors known in the art. For instance the following delivery vehicles have been described: Cochleates (Gould-Fogerite et al., 1994, 1996); Emulsomes (Vancott et al., 1998, Lowell et al., 1997); ISCOMs (Mowat et al., 1993, Carlsson et al., 1991, Hu et., 1998, Morein et al., 1999); Liposomes (Childers et al., 1999, Michalek et al., 1989, 1992, de-Haan 1995a, 1995b); Live bacterial vectors (e.g.,[0159]Salmonella, Escherichia coli, Bacillus calmatte-guerin, Shigella, Lactobacillus) (Hone et al., 1996, Pouwels et al., 1998, Chatfield et al., 1993, Stover et al., 1991, Nugent et al., 1998); Live viral vectors (e.g., Vaccinia, adenovirus, Herpes Simplex) (Gallichan et al., 1993, 1995, Moss et al., 1996, Nugent et al., 1998, Flexner et al., 1988, Morrow et al., 1999), Microspheres (Gupta et al., 1998, Jones et al., 1996, Maloy et al., 1994, Moore et al., 1995, O'Hagan et al., 1994, Eldridge et al., A989); Nucleic acid vaccines (Fynan et al., 1993, Kuklin et al., 1997, Sasaki et al., 1998, Okada et al., 1997, Ishii et al., 1997); Polymers (e.g. carboxymethylcellulose, chitosan) (Hamajima et al., 1998, Jabbal-Gill et al., 1998); Polymer rings (Wyatt et al., 1998); Proteosomes (Vancott et al., 1998, Lowell et al., 1988, 1996, 1997); Sodium Fluoride (Hashi et al., 1998); Transgenic plants (Tacket et al., 1998, Mason et al., 1998, Haq et al., 1995); Virosomes (Gluck et al., 1992, Mengiardi et al., 1995, Cryz et al., 1998); Virus-like particles (Jiang et al., 1999, Leibi et al., 1998).
• The immunostimulatory nucleic acid and asthma/allergy medicament can be combined with other therapeutic agents such as adjuvants to enhance immune responses even further. The immunostimulatory nucleic acid, asthma/allergy medicament and other therapeutic agent may be administered simultaneously or sequentially. When the other therapeutic agents are administered simultaneously they can be administered in the same or separate formulations, but are administered at the same time. The other therapeutic agents are administered sequentially with one another and with the immunostimulatory nucleic acid and asthma/allergy medicament, when the administration of the other therapeutic agents and the immunostimulatory-nucleic acid and asthma/allergy medicament is temporally separated. The separation in time between the administration of these compounds may be a matter of minutes or it may be longer. Other therapeutic agents include but are not limited to non-nucleic acid adjuvants, cytokines, antibodies, antigens, etc.[0160]
• A “non-nucleic acid adjuvant” is any molecule or compound except for the immunostimulatory nucleic acids described herein which can stimulate the humoral and/or cellular immune response. Non-nucleic acid adjuvants include, for instance, adjuvants that create a depo effect, immune stimulating adjuvants, adjuvants that create a depo effect and stimulate the immune system and mucosal adjuvants.[0161]
• An “adjuvant that creates a depo effect” as used herein is an adjuvant that causes an antigen or allergen to be slowly released in the body, thus prolonging the exposure of immune cells to the antigen or allergen. This Class of adjuvants includes but is not limited to alum (e.g., aluminum hydroxide, aluminum phosphate); or emulsion-based formulations including mineral oil, non-mineral oil, water-in-oil or oil-in-water-in oil emulsion, oil-in-water emulsions such as Seppic ISA series of Montanide adjuvants (e.g., Montanide ISA 720, AirLiquide, Paris, France); MF-59 (a squalene-in-water emulsion stabilized with Span 85 and Tween 80; Chiron Corporation, Emeryville, Calif.; and PROVAX (an oil-in-water emulsion containing a stabilizing detergent and a micelle-forming agent; IDEC, Pharmaceuticals Corporation, San Diego, Calif.).[0162]
• An “immune stimulating adjuvant” is an adjuvant that causes activation of a cell of the immune system. It may, for instance, cause an immune cell to produce and secrete cytokines. This class of adjuvants includes but is not limited to saponins purified from the bark of the[0163]Q. saponariatree, such as QS21 (a glycolipid that elutes in the 21^stpeak with HPLC fractionation; Aquila Biopharmaceuticals, Inc., Worcester, Mass.); poly[di(carboxylatophenoxy)phosphazene (PCPP polymer; Virus Research Institute, USA); derivatives of lipopolysaccharides such as monophosphoryl lipid A (MPL; Ribi ImmunoChem Research, Inc., Hamilton, Mont.), muramyl dipeptide (MDP; Ribi) andthreonyl-muramyl dipeptide (t-MDP; Ribi); OM-174 (a glucosamine disaccharide related to lipid A; OM Pharma SA, Meyrin, Switzerland); andLeishmaniaelongation factor (a purifiedLeishmaniaprotein; Corixa Corporation, Seattle, Wash.).
• “Adjuvants that create a depo effect and stimulate the immune system” are those compounds which have both of the above-identified functions. This class of adjuvants includes but is not limited to ISCOMS (Immunostimulating complexes which contain mixed saponins, lipids and form virus-sized particles with pores that can hold antigen; CSL, Melbourne, Australia); SB-AS2 (SmithKline Beecham adjuvant system #2 which is an oil-in-water emulsion containing MPL and QS21: SmithKline Beecham Biologicals [SBB], Rixensart, Belgium); SB-AS4 (SmithKline Beecham adjuvant system #4 which contains alum and MPL; SBB, Belgium); non-ionic block copolymers that form micelles such as CRL 1005 (these contain a linear chain of hydrophobic polyoxpropylene flanked by chains of polyoxyethylene; Vaxcel, Inc., Norcross, Ga.); and Syntex Adjuvant Formulation (SAF, an oil-in-water emulsion containing Tween 80 and a nonionic block copolymer; Syntex Chemicals, Inc., Boulder, Colo.).[0164]
• A “non-nucleic acid mucosal adjuvant” as used herein is an adjuvant-other than an immunostimulatory nucleic acid that is capable of inducing a mucosal immune response in a subject when administered to a mucosal surface in conjunction with an antigen or allergen. Mucosal adjuvants include but are not limited to Bacterial toxins: e.g., Cholera toxin (CT), CT derivatives including but not limited to CT B subunit (CTB) (Wu et al., 1998, Tochikubo et al., 1998); CTD53 (Val to Asp) (Fontana et al., 1995); CTK97 (Val to Lys) (Fontana et al., 1995); CTK104 (Tyr to Lys) (Fontana et al., 1995); CTD53/K63 (Val to Asp, Ser to Lys) (Fontana et al., 1995); CTH54 (Arg to His) (Fontana et al., 1995); CTN[0165]₁O₇(His to Asn) (Fontana et al., 1995); CTE114 (Ser to Glu) (Fontana et al., 1995); CTE112K (Glu to Lys) (Yamamoto et al., 1997a); CTS61F (Ser to Phe) (Yamamoto et al., 1997a, 1997b); CTS106 (Pro to Lys) (Douce et al., 1997, Fontana et al. 1995); and CTK63 (Ser to Lys) (Douce et al., 1997, Fontana et al., 1995), Zonula occludens toxin, zot,Escherichia coliheat-labile enterotoxin, Labile Toxin (LT), LT derivatives including but not limited to LT B subunit (LTB) (Verweij et al., 1998); LT7K (Arg to Lys) (Komase et al., 1998, Douce et al., 1995); LT61F (Ser to Phe) (Komase et al., 1998); LT112K (Glu to Lys) (Komase et al., 1998); LT118E (Gly to Glu) (Komase et al., 1998); LT146E (Arg to Glu) (Komase et al., 1998); LT192G (Arg to Gly) (Komase et al., 1998); LTK63 (Ser to Lys) (Marchetti et al., 1998, Douce et al., 1997, 1998, Di Tommaso et al., 1996); and LTR72 (Ala to Arg) (Giuliani et al., 1998), Pertussis toxin, PT. (Lycke et al., 1992, Spangler B D, 1992, Freytag and Clemments, 1999, Roberts et al., 1995, Wilson et al., 1995) including PT-9K/129G (Roberts et al., 1995, Cropley et al., 1995); Toxin derivatives (see below) (Holmgren et al., 1993, Verweij et al., 1998, Rappuoli et al., 1995, Freytag and Clements, 1999); Lipid A derivatives (e.g., monophosphoryl lipid A, MPL) (Sasaki et al. 1998, Vancott et al., 1998; Muramyl Dipeptide (MDP) derivatives (Fukushima et al., 1996, Ogawa et al., 1989, Michalek et al., 1983, Morisaki et al., 1983); Bacterial outer membrane proteins (e.g., outer surface protein A (OspA) lipoprotein ofBorrelia burgdorferi, outer membrane protine ofNeisseria meningitidis)(Marinaro et al., 1999, Van de Verg et al., 1996); Oil-in-water emulsions (e.g., MF59) (Barchfield et al., 1999, Verschoor et al., 1999, O'Hagan, 1998); Aluminum salts (Isaka et al., 1998, 1999); and Saponins (e.g., QS21) Aquila Biopharmaceuticals, Inc., Worster, Mass.) (Sasaki et al., 1998, MacNeal-et al., 1998), ISCOMS, MF-59 (a squalene-in-water emulsion stabilized with Span 85 and Tween 80; Chiron Corporation, Emeryville, Calif.); the Seppic ISA series of Montanide adjuvants (e.g., Montanide ISA 720; AirLiquide, Paris, France); PROVAX (an oil-in-water emulsion containing a stabilizing detergent and a micell-forming agent; IDEC Pharmaceuticals Corporation, San Diego, Calif.); Syntext Adjuvant Formulation (SAF; Syntex Chemicals, Inc., Boulder, Colo.); poly[di(carboxylatophenoxy)phosphazene (PCPP polymer; Virus Research Institute, USA) andLeishmaniaelongation factor (Corixa Corporation, Seattle, Wash.).
• Immune responses can also be induced or augmented by the co-administration or co-linear expression of cytokines (Bueler & Mulligan, 1996; Chow et al., 1997; Geissler et. al., 1997; Iwasaki et al., 1997; Kim et al., 1997) or B-7 co-stimulatory molecules (Iwasaki et al., 1997; Tsuji et al., 1997) with the immunostimulatory nucleic acids and asthma/allergy medicaments. The cytokines can be administered directly with immunostimulatory nucleic acids or may be administered in the form of a nucleic acid vector that encodes the cytokine, such that the cytokine can be expressed in vivo. In one embodiment, the cytokine is administered in the form of a plasmid expression vector. The term “cytokine” is used as a generic name for a diverse group of soluble proteins and peptides which act as humoral regulators at nano- to picomolar concentrations and which, either under normal- or pathological conditions, modulate the functional activities of individual cells and tissues. These proteins also mediate interactions between cells directly and regulate processes taking place in the extracellular environment. Examples of cytokines include, but are not limited to IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-15, IL-18-granulocyte-macrophage colony stimulating factor (GM-CSF); granulocyte colony stimulating factor (GCSF), interferon-γ (γ-IFN), IFN-a, tumor necrosis factor (TNF), TGF-β, FLT-3 ligand, and CD40 ligand. Cytokines play a role in directing the T cell response. Helper (CD4+) T cells orchestrate the immune response of mammals through production of soluble factors that-act on other immune system cells, including other T cells. Most mature CD4+ T helper cells express one of two cytokine profiles: Th1 or Th2. In some embodiments it is preferred that the cytokine be a Th1 cytokine.[0166]
• The term “effective amount” of an immunostimulatory nucleic acid and an asthma/allergy medicament refers to the amount necessary or sufficient to realize a desired biologic effect. For example, an effective amount of an immunostimulatory nucleic acid and an asthma/allergy medicament for treating or preventing asthma or preventing is that amount necessary, to prevent the development of IgE in response to an allergen or initiator upon exposure to the allergen or initiator is that amount necessary to cause the shift from Th2 to Th1 response in response to an allergen or initiator.[0167]
• Combined with the teachings provided herein, by choosing among the various active compounds and weighing factors such as potency, relative bioavailability, patient body weight, severity of adverse side-effects and preferred mode of administration, an effective prophylactic or therapeutic treatment regimen can be planned which does not cause substantial toxicity and yet is entirely effective to treat the particular subject. The effective amount for any particular application can vary depending on such factors as the disease or condition being treated, the particular immunostimulatory nucleic acid or asthma/allergy medicament being administered (e.g. the type of nucleic acid, i.e. a CpG nucleic acid, the number of unmethylated CpG motifs or their location in the nucleic acid, the degree of modification of the backbone to the oligonucleotide the type of medicament), the size of the subject, or the severity of the disease or condition. One of ordinary skill in the art can empirically determine the effective amount of a particular-immunostimulatory nucleic acid and/or asthma/allergy medicament and/or other therapeutic agent without necessitating undue experimentation.[0168]
• Depending upon the aspect of the invention, the immunostimulatory nucleic acid and asthma/allergy medicament may be administered in a: synergistic amount effective to treat or prevent asthma or allergy. A synergistic amount is that amount which produces a physiological response that is greater than the sum of the individual effects of either the immunostimulatory nucleic acid or the asthma/allergy medicament alone. For instance, in some embodiments of the invention, the physiological effect is a reduction in IgE levels. A synergistic amount is that amount which produces a reduction in IgE that is greater than the sum of the IgE reduced by either the immunostimulatory nucleic acid or the asthma/allergy medicament alone. In other embodiments, the physiological result is a shift from Th2 cytokines, such as IL-4 and Il-5, to Th1 cytokines, such as IFN-γ and IL-12. The synergistic amount in this case is that-amount which produces the shift to a Th1 cytokine that is greater than the sum of the shift produced by either the immunostimulatory nucleic acid or the asthma/allergy medicament alone. In other embodiments the physiological result is a decrease in eosinophilia, hyperreactivity, or lung function.[0169]
• In some embodiments of the invention, the immunostimulatory nucleic acid is administered in an effective amount for preventing bacterial or viral infection. Immunostimulatory nucleic acids are known to be useful for preventing bacterial and viral infections. Bacterial and viral infections exacerbate and/or induce allergy and/or asthma. In this aspect of the invention, the immunostimulatory nucleic acid is administered to the subject in an amount effective to prevent bacterial and viral infection and the asthma/allergy medicament is administered to the subject when symptoms of allergy or asthma appear. Thus, the immunostimulatory nucleic acid is administered to the subject and then the asthma/allergy medicament is subsequently administered to the subject or they are administered together at the same time. This method is particularly useful in subjects such as children and immunocompromised subjects, or elderly subjects, who are particularly susceptible to bacterial or viral disease.[0170]
• In aspects of the invention directed at treating subjects in anticipation of an asthmatic or allergic event or season (e.g., in anticipation of the hay-fever season), the subjects may be administered an immunostimulatory nucleic acid in an effective amount for preventing the asthma or allergy. In related embodiments of this method, an asthma/allergy medicament is also administered to the subject. In these latter instances, the amount of the immunostimulatory nucleic acid administered may be that amount necessary to reduce the effective dose of the asthma/allergy medicament which is required to treat or prevent the asthma or allergy.[0171]
• Thus, in these embodiments, the immunostimulatory nucleic acid potentiates the effect of the asthma/allergy medicament. The ability to potentiate the effect of an asthma/allergy medicament is useful since it allows for a reduction in the administered dose of an asthma/allergy medicament with the same or better therapeutic result. As an example, if the dose of the medicament is lowered, then so too are the side-effects of the medicament such as, for example, drowsiness, nervousness, dizziness or, in some instances, sleeplessness. Similarly, the administration of a lowered dose of the asthma/allergy medicament may make the medicament more compatible with the administration of other medicaments such as those which are currently not simultaneously prescribed or administered with asthma or allergy medicaments. In some instances, these include certain medicaments which are prescribed for depression, psychiatric or emotional conditions or Parkinson's disease and which contain monoamine oxidase inhibitor (MAOI). Similarly, the ability to potentiate the effect of the asthma/allergy medicament, thereby leading to a decreased effective dose, is useful for treating a wide range of subjects who have previously been contraindicated for such treatment, including subjects with heart disease or diabetes, subjects who have difficulty in urinating due to prostate gland enlargement, and subjects who are pregnant or who are nursing (i.e., breast-feeding). Thus, the invention provides a method for administering to a subject a dose of an asthma/allergy medicament which if administered alone, or if administered without previous administration of an immunostimulatory nucleic acid to the same subject, would be ineffective (and would be considered sub-therapeutic).[0172]
• Subject doses of the compounds described herein typically range from about 0.1 μg to 10,000 mg, more typically from about 1 μg/day to 8000 mg, and most typically from about 10 μg to 100 μg. Stated in terms of subject body weight, typical dosages range from about 0.1 μg to 20 mg/kg/day, more typically from about 1 to 0.10 mg/kg/day, and most typically from about 1 to 5 mg/kg/day.[0173]
• In some instances, a sub-therapeutic dosage of the immunostimulatory nucleic acid and the asthma/allergy medicament are used. It has been discovered according to the invention, that when the two classes of drugs are used together, they can be administered in sub-therapeutic doses and still produce a desirable therapeutic-result, a “sub-therapeutic dose” as used herein refers to a dosage which is less than that dosage which would produce a therapeutic result in the subject, if administered alone. Thus, the sub-therapeutic dose of an asthma/allergy medicament is one which would not produce the desired therapeutic result in the subject. Therapeutic doses of asthma/allergy medicaments are well known in the field of medicine for the treatment of asthma and allergy. These dosages have been extensively described in references such as Remington's Pharmaceutical Sciences, 18th ed., 1990; as well as many other medical references relied upon by the medical profession as guidance for the treatment of asthma and allergy. Therapeutic dosages of immunostimulatory nucleic acids, have also been described in the art and methods for identifying therapeutic dosages in subjects are described in more detail above.[0174]
• In other aspects, the method of the invention involves administering a high dose of an asthma/allergy medicament to a subject, without inducing side effects. Ordinarily, when an asthma/allergy medicament is administered in a high dose, a variety of side effects can occur. (Discussed in more detail above, as well as in the medical literature). As a result of these side effects, the asthma/allergy medicament is not administered in such high doses, no matter what therapeutic benefits are derived. It was discovered, according to the invention, that such high doses of asthma/allergy medicaments which ordinarily induce side effects can be administered without inducing the side effects as long as the subject also receives an immunostimulatory nucleic acid. The type and extent of the side effects ordinarily induced by the asthma/allergy medicament will depend on the particular asthma/allergy medicament used.[0175]
• In other embodiments of the invention, the immunostimulatory nucleic acid is administered on a routine schedule. The asthma/allergy medicament may also be administered on a routine schedule, but alternatively, may be administered as symptoms arise. A “routine schedule” as used herein, refers to a predetermined designated period of time. The routine schedule may encompass periods of time which are identical or which differ in length, as long as the schedule is predetermined. For instance, the routine schedule may involve administration of the immunostimulatory nucleic acid on a daily basis, every two days, every three days, every four days, every five days, every six days, a weekly basis, a bi-weekly basis, a monthly basis, a bimonthly basis or any set number of days or weeks there-between, every two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, etc. Alternatively, the predetermined routine schedule may involve administration of the immunostimulatory nucleic acid on a daily basis for the first week, followed by a monthly basis for several months, and then every three months after that. Any particular combination would be covered by the routine schedule as long as it is determined ahead of time that the appropriate schedule involves administration on a certain day.[0176]
• In some aspects of the invention, the immunostimulatory nucleic acid is administered to the subject in anticipation of an asthmatic or allergic event in order to prevent an asthmatic or allergic event. The asthmatic or allergic event may be, but need not be limited to, an asthma attack, seasonal allergic rhinitis (e.g., hay-fever, pollen, ragweed hypersensitivity) or perennial allergic rhinitis (e.g., hypersensitivity to allergens such as those described herein)., In some instances, the immunostimulatory nucleic acid is administered substantially prior to, an asthmatic or an allergic event. As used herein, “substantially prior” means at least six months, at least five months, at least four months, at least three months, at least two months, at least one month, at least three weeks, at least two weeks, at least one week, at least 5 days, or at least 2 days prior to the asthmatic or allergic event.[0177]
• Similarly, the asthma/allergy medicament may be administered immediately-prior to the asthmatic or allergic event (e.g., within 48 hours, within 24 hours, within 12 hours, within 6 hours, within 4 hours, within 3 hours, within 2 hours, within 1 hour, within 30 minutes or within 10 minutes of an asthmatic or allergic event), substantially simultaneously with the asthmatic or allergic event (e.g., during the time the subject is in contact with the allergen or is experiencing the asthma or allergy symptoms) or following the asthmatic or allergic event.[0178]
• In some embodiments, the immunostimulatory nucleic acid and the asthma/allergy medicament are both administered to a subject. The timing of administration of both may vary. In some embodiments, it is preferred that the asthma/allergy medicament be administered subsequent to the administration of the immunostimulatory nucleic acid. In some embodiments, the immunostimulatory nucleic acid is administered to the subject prior to as well as either substantially simultaneously with or following the administration of the asthma/allergy medicament. The administration of the immunostimulatory nucleic acid and the asthma/allergy medicament may also be mutually exclusive of each other so that at any given time during the treatment period, only one of these agents is active in the subject. Alternatively, and preferably in some instances, the administration of the two agents overlaps such that both agents are active in the subject at the same time.[0179]
• In some embodiments, the immunostimulatory nucleic acid is administered on a weekly or biweekly basis and the asthma/allergy medicament is administered more frequently (e.g., on a daily basis). However, if the dose of immunostimulatory nucleic acid is reduced sufficiently, it is possible that the immunostimulatory nucleic acid is administered as frequently as the asthma/allergy medicament, albeit at a reduced dose.[0180]
• In other aspects, the invention relates to kits that are useful in the treatment of asthma and/or allergy. One kit of the invention includes a sustained release vehicle containing an immunostimulatory nucleic acid and a container housing an asthma/allergy medicament and instructions for timing of administration of the immunostimulatory nucleic acid in the asthma/allergy medicament. A sustained release vehicle is used herein in accordance with its prior art meaning of any device which slowly releases the immunostimulatory nucleic acid.[0181]
• Such systems can avoid repeated administrations of the compounds, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. They include polymer base systems such as poly(lactide-glycolide), copolyoxalates, polycaprolactones, polyesteramides, polyorthoesters, polyhydroxybutyric acid, and polyanhydrides. Microcapsules of the foregoing polymers containing drugs are described in, for example, U.S. Pat. No. 5,075,109. Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-di- and tri-glycerides; hydrogel release systems; sylastic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients; partially fused implants; and the like. Specific examples include, but are not limited to: (a) erosional systems in which an agent of the invention is contained in a form within a matrix such as those described in U.S. U.S. Pat. Nos. 4,452,775, 4,675,189, and 5,736,152, and (b) diffusional systems in which an active component permeates at a controlled rate from a polymer such as described in U.S. Pat. Nos. 3,854,480, 5,133,974 and 5,407,686. In addition, pump-based hardware delivery systems can be used, some of which are adapted for implantation.[0182]
• The asthma/allergy medicament is housed in at least one container. The container may be a single container housing all of the asthma/allergy medicament together or it may be multiple containers or chambers housing individual dosages of the asthma/allergy medicament, such as a blister pack. The kit also has instructions for timing of administration of the asthma/allergy medicament. The instructions would direct the subject having asthma/allergy or at risk of asthma/allergy to take the asthma/allergy medicament at the appropriate time. For instance, the appropriate time for delivery of the medicament may be as the symptoms occur. Alternatively, the appropriate time for administration of the medicament may be on a routine schedule such as monthly or yearly.[0183]
• Another kit of the invention includes at least one container housing an immunostimulatory nucleic acid and at least one container housing an asthma/allergy medicament and instructions for administering the compositions ineffective amounts for inducing a synergistic immune response in the subject. The immunostimulatory nucleic acid and asthma/allergy medicament may be housed in single containers or in separate compartments or containers, such as single dose compartments. The instructions in the kit direct the subject to take the immunostimulatory nucleic acid and the asthma/allergy medicament in amounts which will produce a synergistic immune response. The drugs may be administered simultaneously or separately as long as they are administered close enough in time to produce a synergistic response.[0184]
• In other aspects of the invention, a composition is provided. The composition-includes an immunostimulatory nucleic and an asthma/allergy medicament formulated in a pharmaceutically-acceptable carrier and present in the composition in an effective amount for preventing or treating an immune or inflammatory response associated with exposure to a mediator of asthma or allergy. The effective amount for preventing or treating an immune or inflammatory response is that amount which prevents, inhibits completely or partially the induction of the immune or inflammatory response or prevents an increase in the immune or inflammatory response associated with asthma or allergy. An immune or inflammatory response associated with asthma or allergy includes an induction in IgE, an increase in Th2 cytokines, etc. A mediator of asthma or allergy includes asthma initiators and allergens. An example of a composition is one which comprises an immunostimulatory nucleic acid, such as a CpG nucleic acid, and an asthma/allergy medicament, such as an anti-IgE agent (e.g., an anti-IgE antibody or antibody fragment). Such a composition can be administered to a subject on a routine basis such as monthly, bimonthly, or quarterly.[0185]
• For any compound described herein a therapeutically effective amount can be initially determined from cell culture assays. For instance the effective amount of immunostimulatory nucleic acid useful for inducing B cell activation can be-assessed using the in vitro assays with respect to stimulation index in comparison to known immunostimulatory acids. The stimulation index can be used to determine an effective amount of the particular oligonucleotide for the particular subject, and the dosage can be adjusted upwards or downwards to achieve the desired levels in the subject. Therapeutically effective amounts can also be determined from animal models. A therapeutically effective dose can also be determined from human data for immunostimulatory nucleic acids which have been tested in humans (human clinical trials have been initiated) and for compounds which are known to exhibit similar pharmacological activities, such as other adjuvants, e.g., LT and other antigens for vaccination purposes. The applied dose can be adjusted based on the relative bioavailability and potency of the administered compound. Adjusting the dose to achieve maximal efficacy based on the methods described above and other methods as are well-known in the art is well within the capabilities of the ordinarily skilled artisan. Most of the asthma/allergy medicaments have been identified. These amounts can be adjusted when they are combined with immuno-stimulatory nucleic acids by routine experimentation.[0186]
• The formulations of the invention are administered in pharmaceutically acceptable solutions, which may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, adjuvants, and optionally other therapeutic ingredients.[0187]
• Asthma/allergy medicaments and immunostimulatory nucleic acids can be administered by any ordinary route for administering medications. Preferably, they are inhaled, ingested or administered by local routes (such as nasal drops) or by systemic routes. Systemic routes include oral and parenteral. Inhaled medications are preferred in some embodiments because of the direct delivery to the lung, the site of inflammation, primarily in asthmatic patients. Several types of metered dose inhalers are regularly used for administration by inhalation. These types of devices include metered dose inhalers (MDI), breath-actuated MDI, dry powder inhaler (DPI), spacer/holding chambers in combination with MDI, and nebulizers. As used herein, delivery to the nasal passages or the lungs via nasal drops or inhalation are referred to as local administration. Although it is possible that delivery to the lung (e.g., via inhalation) can eventually result in systemic delivery of the agent, the administration is still considered “local” in the sense that the majority of the agent is initially presented to the lung tissue or the nasal passages, prior to any secondary systemic effects. In some preferred embodiments, the immunostimulatory nucleic acid is administered locally, such as for example by nasal drops or inhalation.[0188]
• For use in therapy, an effective amount of the immunostimulatory nucleic acid can be administered to a subject by any mode that delivers the nucleic acid to the desired surface, e.g., mucosal, systemic. “Administering” the pharmaceutical composition of the present invention may be accomplished by any means known to the skilled artisan. Preferred routes of administration include but are not limited to oral, parenteral, intramuscular, intranasal, intratracheal, inhalation, ocular, vaginal, and rectal.[0189]
• For oral administration, the compounds (i.e., immunostimulatory nucleic acids, asthma/allergy medicament, other therapeutic agent) can be formulated readily by combining the active compound(s) with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as-tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated. Pharmaceutical preparations for oral use can be obtained as solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including, lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Optionally the oral formulations may also be formulated in saline or buffers for neutralizing internal acid conditions or may be administered without any carriers.[0190]
• Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.[0191]
• Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.[0192]
• In addition, stabilizers may be added. Microspheres formulated for oral administration may also be used. Such microspheres have been well defined in the art. All formulations for oral administration should be in dosages suitable for such administration.[0193]
• For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.[0194]
• For administration by inhalation, the compounds for use according to the present invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch. Techniques for preparing aerosol delivery systems are well known to those of skill in the art. Generally, such systems should utilize components which will not significantly impair the biological properties of the therapeutic, such as the immunostimulatory capacity of the nucleic acids (see, for example, Sciarra and Cutie, “Aerosols,” in[0195]Remington's Pharmaceutical Sciences,18th edition, 1990, pp 1694-1712; incorporated by reference). Those of skill in the art can readily determine the various parameters and conditions for producing aerosols without resort to undue experimentation.
• The compounds, when it is desirable to deliver them systemically, may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.[0196]
• Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic so solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid: esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.[0197]
• Alternatively, the active compounds may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.[0198]
• The compounds may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.[0199]
• In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.[0200]
• The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.[0201]
• Suitable liquid or solid pharmaceutical preparation forms are, for example, aqueous or saline solutions for inhalation, microencapsulated, encochleated; coated onto microscopic gold particles, contained in liposomes, nebulized, aerosols, pellets for implantation into the skin, or dried onto a sharp object to be scratched into the skin. The pharmaceutical compositions also include granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, drops or preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customarily used as described above. The pharmaceutical compositions are suitable for use in a variety of drug delivery systems. For a brief review of methods for drug delivery, see Langer,[0202]Science249:1527-1533, 1990, which is incorporated herein by reference.
• The immunostimulatory nucleic acids and asthma/allergy medicament may be administered per se (neat) or in the form of a pharmaceutically acceptable salt. When used in medicine the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof. Such salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulphuric, nitric, phosphoric, maleic, acetic, salicylic, p-toluene sulphonic, tartaric, citric, methane sulphonic, formic, malonic, succinic, naphthalene-2-sulphonic, and benzene sulphonic. Also, such salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.[0203]
• Suitable buffering agents include: acetic acid and a salt (1-2% w/v); citric acid and a salt (1-3% w/v); boric acid and a salt (0.5-2.5% w/v); and phosphoric acid and a salt (0.8-2% w/v). Suitable preservatives include benzalkonium chloride (0.003-0.03% w/v); chlorobutanol (0.3-0.9% w/v); parabens (0.01-0.25% w/v) and thimerosal (0.004-0.02% w/v).[0204]
• The pharmaceutical compositions of the invention contain an effective amount of an immunostimulatory nucleic acid and optionally asthma/allergy medicament and/or other therapeutic agents optionally included in a pharmaceutically-acceptable carrier. The term “pharmaceutically-acceptable carrier” means one or more compatible solid or liquid filler, dilutants or encapsulating substances which are suitable for administration to a human or other vertebrate animal. The term “carrier” denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being commingled with the compounds of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficiency.[0205]
• The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages and objects of the invention are not necessarily encompassed by each embodiment of the invention.[0206]
• All references, patents and patent publications that are recited in this application are incorporated in their entirety herein by reference.[0207]
• 11093118DNAArtificial SequenceSynthetic Sequence 1 tctcccagcg tgcgccat 18220DNAArtificial SequenceSynthetic Sequence 2 ataatccagc ttgaaccaag 20320DNAArtificial SequenceSynthetic Sequence 3 ataatcgacg ttcaagcaag 20418DNAArtificial SequenceSynthetic Sequence 4 taccgcgtgc gaccctct 1859DNAArtificial SequenceSynthetic Sequence 5 ggggagggt 969DNAArtificial SequenceSynthetic Sequence 6 ggggagggg 979DNAArtificial SequenceSynthetic Sequence 7 ggtgaggtg 9820DNAArtificial Sequencemodified_base(8)...(8)m5c 8 tccatgtngt tcctgatgct 20915DNAArtificial Sequencemodified_base(11)...(11)m5c 9 gctaccttag ngtga 151020DNAArtificial Sequencemodified_base(8)...(8)m5c 10 tccatgangt tcctgatgct 201120DNAArtificial Sequencemodified_base(13)...(13)m5c 11 tccatgacgt tcntgatgct 201215DNAArtificial Sequencemodified_base(7)...(7)m5c 12 gctagangtt agtgt 151319DNAArtificial SequenceSynthetic Sequence 13 agctccatgg tgctcactg 191420DNAArtificial SequenceSynthetic Sequence 14 ccacgtcgac cctcaggcga 201520DNAArtificial SequenceSynthetic Sequence 15 gcacatcgtc ccgcagccga 201619DNAArtificial SequenceSynthetic Sequence 16 gtcactcgtg gtacctcga 191725DNAArtificial SequenceSynthetic Sequence 17 gttggataca ggccagactt tgttg 251825DNAArtificial SequenceSynthetic Sequence 18 gattcaactt gcgctcatct taggc 251924DNAArtificial SequenceSynthetic Sequence 19 accatggacg aactgtttcc cctc 242024DNAArtificial SequenceSynthetic Sequence 20 accatggacg agctgtttcc cctc 242124DNAArtificial SequenceSynthetic Sequence 21 accatggacg acctgtttcc cctc 242224DNAArtificial SequenceSynthetic Sequence 22 accatggacg tactgtttcc cctc 242324DNAArtificial SequenceSynthetic Sequence 23 accatggacg gtctgtttcc cctc 242424DNAArtificial SequenceSynthetic Sequence 24 accatggacg ttctgtttcc cctc 242525DNAArtificial SequenceSynthetic Sequence 25 ccactcacat ctgctgctcc acaag 252625DNAArtificial SequenceSynthetic Sequence 26 acttctcata gtccctttgg tccag 252720DNAArtificial SequenceSynthetic Sequence 27 tccatgagct tcctgagtct 202820DNAArtificial SequenceSynthetic Sequence 28 gaggaaggng nggangacgt 202920DNAArtificial SequenceSynthetic Sequence 29 gtgaatncgt tcncgggnct 20306DNAArtificial SequenceSynthetic Sequence 30 aaaaaa 6316DNAArtificial SequenceSynthetic Sequence 31 cccccc 6326DNAArtificial SequenceSynthetic Sequence 32 ctgtca 6336DNAArtificial SequenceSynthetic Sequence 33 tcgtag 6346DNAArtificial SequenceSynthetic Sequence 34 tcgtgg 6356DNAArtificial SequenceSynthetic Sequence 35 cgtcgt 63620DNAArtificial SequenceSynthetic Sequence 36 tccatgtcgg tcctgagtct 203720DNAArtificial SequenceSynthetic Sequence 37 tccatgccgg tcctgagtct 203820DNAArtificial SequenceSynthetic Sequence 38 tccatgacgg tcctgagtct 203920DNAArtificial SequenceSynthetic Sequence 39 tccatgacgg tcctgagtct 204020DNAArtificial SequenceSynthetic Sequence 40 tccatgtcga tcctgagtct 204120DNAArtificial SequenceSynthetic Sequence 41 tccatgtcgc tcctgagtct 204220DNAArtificial SequenceSynthetic Sequence 42 tccatgtcgt tcctgagtct 204320DNAArtificial SequenceSynthetic Sequence 43 tccatgacgt tcctgagtct 204420DNAArtificial SequenceSynthetic Sequence 44 tccataacgt tcctgagtct 204520DNAArtificial SequenceSynthetic Sequence 45 tccatgacgt ccctgagtct 204620DNAArtificial SequenceSynthetic Sequence 46 tccatcacgt gcctgagtct 204720DNAArtificial SequenceSynthetic Sequence 47 tccatgctgg tcctgagtct 204820DNAArtificial Sequencemodified_base(8)...(8)m5c 48 tccatgtngg tcctgagtct 204939DNAArtificial SequenceSynthetic Sequence 49 ccgcttcctc cagatgagct catgggtttc tccaccaag 395039DNAArtificial SequenceSynthetic Sequence 50 cttggtggag aaacccatga gctcatctgg aggaagcgg 395120DNAArtificial SequenceSynthetic Sequence 51 ccccaaaggg atgagaagtt 205220DNAArtificial SequenceSynthetic Sequence 52 agatagcaaa tcggctgacg 205320DNAArtificial SequenceSynthetic Sequence 53 ggttcacgtg ctcatggctg 205418DNAArtificial SequenceSynthetic Sequence 54 tctcccagcg tgcgccat 185518DNAArtificial SequenceSynthetic Sequence 55 tctcccagcg tgcgccat 185618DNAArtificial SequenceSynthetic Sequence 56 taccgcgtgc gaccctct 185720DNAArtificial SequenceSynthetic Sequence 57 ataatccagc ttgaaccaag 205820DNAArtificial SequenceSynthetic Sequence 58 ataatcgacg ttcaagcaag 205920DNAArtificial SequenceSynthetic Sequence 59 tccatgattt tcctgatttt 206024DNAArtificial SequenceSynthetic Sequence 60 ttgttttttt gtttttttgt tttt 246122DNAArtificial SequenceSynthetic Sequence 61 ttttttttgt ttttttgttt tt 226224DNAArtificial SequenceSynthetic Sequence 62 tgctgctttt gtgcttttgt gctt 246322DNAArtificial SequenceSynthetic Sequence 63 tgctgcttgt gcttttgtgc tt 226423DNAArtificial SequenceSynthetic Sequence 64 gcattcatca ggcgggcaag aat 236523DNAArtificial SequenceSynthetic Sequence 65 taccgagctt cgacgagatt tca 236615DNAArtificial SequenceSynthetic Sequence 66 gcatgacgtt gagct 156715DNAArtificial SequenceSynthetic Sequence 67 cacgttgagg ggcat 156815DNAArtificial SequenceSynthetic Sequence 68 ctgctgagac tggag 156920DNAArtificial SequenceSynthetic Sequence 69 tccatgacgt tcctgacgtt 207017DNAArtificial SequenceSynthetic Sequence 70 gcatgagctt gagctga 177112DNAArtificial SequenceSynthetic Sequence 71 tcagcgtgcg cc 127217DNAArtificial SequenceSynthetic Sequence 72 atgacgttcc tgacgtt 177320DNAArtificial SequenceSynthetic Sequence 73 ttttggggtt ttggggtttt 207420DNAArtificial SequenceSynthetic Sequence 74 tctaggcttt ttaggcttcc 207520DNAArtificial SequenceSynthetic Sequence 75 tgcatttttt aggccaccat 207622DNAArtificial SequenceSynthetic Sequence 76 tctcccagcg tgcgtgcgcc at 227717DNAArtificial SequenceSynthetic Sequence 77 tctcccagcg ggcgcat 177818DNAArtificial SequenceSynthetic Sequence 78 tctcccagcg agcgccat 187918DNAArtificial SequenceSynthetic Sequence 79 tctcccagcg cgcgccat 188019DNAArtificial SequenceSynthetic Sequence 80 ggggtgacgt tcagggggg 198124DNAArtificial SequenceSynthetic Sequence 81 ggggtccagc gtgcgccatg gggg 248219DNAArtificial SequenceSynthetic Sequence 82 ggggtgtcgt tcagggggg 198320DNAArtificial SequenceSynthetic Sequence 83 tccatgtcgt tcctgtcgtt 208420DNAArtificial SequenceSynthetic Sequence 84 tccatagcgt tcctagcgtt 208521DNAArtificial SequenceSynthetic Sequence 85 tcgtcgctgt ctccgcttct t 218615DNAArtificial SequenceSynthetic Sequence 86 gcatgacgtt gagct 158720DNAArtificial SequenceSynthetic Sequence 87 tctcccagcg tgcgccatat 208820DNAArtificial Sequencemodified_base(8)...(8)m5c 88 tccatgangt tcctgangtt 208915DNAArtificial Sequencemodified_base(7)...(7)m5c 89 gcatgangtt gagct 159016DNAArtificial SequenceSynthetic Sequence 90 tccagcgtgc gccata 169118DNAArtificial SequenceSynthetic Sequence 91 tctcccagcg tgcgccat 189220DNAArtificial SequenceSynthetic Sequence 92 tccatgagct tcctgagtct 209315DNAArtificial SequenceSynthetic Sequence 93 gcatgtcgtt gagct 159419DNAArtificial SequenceSynthetic Sequence 94 tcctgacgtt cctgacgtt 199515DNAArtificial SequenceSynthetic Sequence 95 gcatgatgtt gagct 159615DNAArtificial SequenceSynthetic Sequence 96 gcatttcgag gagct 159715DNAArtificial SequenceSynthetic Sequence 97 gcatgtagct gagct 159820DNAArtificial SequenceSynthetic Sequence 98 tccaggacgt tcctagttct 209920DNAArtificial SequenceSynthetic Sequence 99 tccaggagct tcctagttct 2010020DNAArtificial SequenceSynthetic Sequence 100 tccaggatgt tcctagttct 2010120DNAArtificial SequenceSynthetic Sequence 101 tccagtctag gcctagttct 2010220DNAArtificial SequenceSynthetic Sequence 102 tccagttcga gcctagttct 2010315DNAArtificial SequenceSynthetic Sequence 103 gcatggcgtt gagct 1510415DNAArtificial SequenceSynthetic Sequence 104 gcatagcgtt gagct 1510515DNAArtificial SequenceSynthetic Sequence 105 gcattgcgtt gagct 1510615DNAArtificial SequenceSynthetic Sequence 106 gcttgcgttg cgttt 1510721DNAArtificial SequenceSynthetic Sequence 107 tctcccagcg ttgcgccata t 2110820DNAArtificial SequenceSynthetic Sequence 108 tctcccagcg tgcgttatat 2010920DNAArtificial SequenceSynthetic Sequence 109 tctccctgcg tgcgccatat 2011020DNAArtificial SequenceSynthetic Sequence 110 tctgcgtgcg tgcgccatat 2011120DNAArtificial SequenceSynthetic Sequence 111 tctcctagcg tgcgccatat 2011220DNAArtificial SequenceSynthetic Sequence 112 tctcccagcg tgcgcctttt 2011313DNAArtificial SequenceSynthetic Sequence 113 gctandcghh agc 1311413DNAArtificial SequenceSynthetic Sequence 114 tcctgacgtt ccc 1311513DNAArtificial SequenceSynthetic Sequence 115 ggaagacgtt aga 1311613DNAArtificial SequenceSynthetic Sequence 116 tcctgacgtt aga 1311727DNAArtificial SequenceSynthetic Sequence 117 tcagaccagc tggtcgggtg ttcctga 2711827DNAArtificial SequenceSynthetic Sequence 118 tcaggaacac ccgaccagct ggtctga 2711913DNAArtificial SequenceSynthetic Sequence 119 gctagtcgat agc 1312013DNAArtificial SequenceSynthetic Sequence 120 gctagtcgct agc 1312114DNAArtificial SequenceSynthetic Sequence 121 gcttgacgtc tagc 1412214DNAArtificial SequenceSynthetic Sequence 122 gcttgacgtt tagc 1412314DNAArtificial SequenceSynthetic Sequence 123 gcttgacgtc aagc 1412414DNAArtificial SequenceSynthetic Sequence 124 gctagacgtt tagc 1412520DNAArtificial SequenceSynthetic Sequence 125 tccatgacat tcctgatgct 2012614DNAArtificial SequenceSynthetic Sequence 126 gctagacgtc tagc 1412719DNAArtificial SequenceSynthetic Sequence 127 ggctatgtcg ttcctagcc 1912819DNAArtificial SequenceSynthetic Sequence 128 ggctatgtcg atcctagcc 1912921DNAArtificial SequenceSynthetic Sequence 129 ctcatgggtt tctccaccaa g 2113021DNAArtificial SequenceSynthetic Sequence 130 cttggtggag aaacccatga g 2113120DNAArtificial SequenceSynthetic Sequence 131 tccatgacgt tcctagttct 2013224DNAArtificial SequenceSynthetic Sequence 132 ccgcttcctc cagatgagct catg 2413324DNAArtificial SequenceSynthetic Sequence 133 catgagctca tctggaggaa gcgg 2413424DNAArtificial SequenceSynthetic Sequence 134 ccagatgagc tcatgggttt ctcc 2413524DNAArtificial SequenceSynthetic Sequence 135 ggagaaaccc atgagctcat ctgg 2413620DNAArtificial SequenceSynthetic Sequence 136 agcatcagga acgacatgga 2013720DNAArtificial SequenceSynthetic Sequence 137 tccatgacgt tcctgacgtt 2013819DNAArtificial SequenceSynthetic Sequence 138 gcgcgcgcgc gcgcgcgcg 1913920DNAArtificial SequenceSynthetic Sequence 139 ccggccggcc ggccggccgg 2014043DNAArtificial SequenceSynthetic Sequence 140 ttccaatcag ccccacccgc tctggcccca ccctcaccct cca 4314143DNAArtificial SequenceSynthetic Sequence 141 tggagggtga gggtggggcc agagcgggtg gggctgattg gaa 4314227DNAArtificial SequenceSynthetic Sequence 142 tcaaatgtgg gattttccca tgagtct 2714327DNAArtificial SequenceSynthetic Sequence 143 agactcatgg gaaaatccca catttga 2714427DNAArtificial SequenceSynthetic Sequence 144 tgccaagtgc tgagtcacta ataaaga 2714527DNAArtificial SequenceSynthetic Sequence 145 tctttattag tgactcagca cttggca 2714631DNAArtificial SequenceSynthetic Sequence 146 tgcaggaagt ccgggttttc cccaaccccc c 3114731DNAArtificial SequenceSynthetic Sequence 147 ggggggttgg ggaaaacccg gacttcctgc a 3114838DNAArtificial SequenceSynthetic Sequence 148 ggggactttc cgctggggac tttccagggg gactttcc 3814945DNAArtificial SequenceSynthetic Sequence 149 tccatgacgt tcctctccat gacgttcctc tccatgacgt tcctc 4515045DNAArtificial SequenceSynthetic Sequence 150 gaggaacgtc atggagagga acgtcatgga gaggaacgtc atgga 4515120DNAArtificial SequenceSynthetic Sequence 151 ataatagagc ttcaagcaag 2015220DNAArtificial SequenceSynthetic Sequence 152 tccatgacgt tcctgacgtt 2015320DNAArtificial SequenceSynthetic Sequence 153 tccatgacgt tcctgacgtt 2015420DNAArtificial SequenceSynthetic Sequence 154 tccaggactt tcctcaggtt 2015545DNAArtificial SequenceSynthetic Sequence 155 tcttgcgatg ctaaaggacg tcacattgca caatcttaat aaggt 4515645DNAArtificial SequenceSynthetic Sequence 156 accttattaa gattgtgcaa tgtgacgtcc tttagcatcg caaga 4515728DNAArtificial SequenceSynthetic Sequence 157 tcctgacgtt cctggcggtc ctgtcgct 2815819DNAArtificial SequenceSynthetic Sequence 158 tcctgtcgct cctgtcgct 1915915DNAArtificial SequenceSynthetic Sequence 159 tcctgacgtt gaagt 1516015DNAArtificial SequenceSynthetic Sequence 160 tcctgtcgtt gaagt 1516115DNAArtificial SequenceSynthetic Sequence 161 tcctggcgtt gaagt 1516215DNAArtificial SequenceSynthetic Sequence 162 tcctgccgtt gaagt 1516315DNAArtificial SequenceSynthetic Sequence 163 tccttacgtt gaagt 1516415DNAArtificial SequenceSynthetic Sequence 164 tcctaacgtt gaagt 1516515DNAArtificial SequenceSynthetic Sequence 165 tcctcacgtt gaagt 1516615DNAArtificial SequenceSynthetic Sequence 166 tcctgacgat gaagt 1516715DNAArtificial SequenceSynthetic Sequence 167 tcctgacgct gaagt 1516815DNAArtificial SequenceSynthetic Sequence 168 tcctgacggt gaagt 1516915DNAArtificial SequenceSynthetic Sequence 169 tcctgacgta gaagt 1517015DNAArtificial SequenceSynthetic Sequence 170 tcctgacgtc gaagt 1517115DNAArtificial SequenceSynthetic Sequence 171 tcctgacgtg gaagt 1517215DNAArtificial SequenceSynthetic Sequence 172 tcctgagctt gaagt 1517315DNAArtificial SequenceSynthetic Sequence 173 gggggacgtt ggggg 1517415DNAArtificial SequenceSynthetic Sequence 174 tcctgacgtt ccttc 1517522DNAArtificial SequenceSynthetic Sequence 175 tctcccagcg agcgagcgcc at 2217632DNAArtificial SequenceSynthetic Sequence 176 tcctgacgtt cccctggcgg tcccctgtcg ct 3217728DNAArtificial SequenceSynthetic Sequence 177 tcctgtcgct cctgtcgctc ctgtcgct 2817815DNAArtificial SequenceSynthetic Sequence 178 tcctggcggg gaagt 1517915DNAArtificial Sequencemodified_base(7)...(7)m5c 179 tcctgangtt gaagt 1518015DNAArtificial Sequencemodified_base(3)...(3)m5c 180 tcntgacgtt gaagt 1518115DNAArtificial SequenceSynthetic Sequence 181 tcctagcgtt gaagt 1518215DNAArtificial SequenceSynthetic Sequence 182 tccagacgtt gaagt 1518315DNAArtificial SequenceSynthetic Sequence 183 tcctgacggg gaagt 1518415DNAArtificial SequenceSynthetic Sequence 184 tcctggcggt gaagt 1518527DNAArtificial SequenceSynthetic Sequence 185 ggctccgggg agggaatttt tgtctat 2718627DNAArtificial SequenceSynthetic Sequence 186 atagacaaaa attccctccc cggagcc 2718721DNAArtificial SequenceSynthetic Sequence 187 tccatgagct tccttgagtc t 2118821DNAArtificial SequenceSynthetic Sequence 188 tcgtcgctgt ctccgcttct t 2118921DNAArtificial SequenceSynthetic Sequence 189 tcgtcgctgt ctccgcttct t 2119023DNAArtificial SequenceSynthetic Sequence 190 tcgagacatt gcacaatcat ctg 2319120DNAArtificial SequenceSynthetic Sequence 191 cagattgtgc aatgtctcga 2019220DNAArtificial SequenceSynthetic Sequence 192 tccatgtcgt tcctgatgcg 2019320DNAArtificial SequenceSynthetic Sequence 193 gcgatgtcgt tcctgatgct 2019420DNAArtificial SequenceSynthetic Sequence 194 gcgatgtcgt tcctgatgcg 2019520DNAArtificial SequenceSynthetic Sequence 195 tccatgtcgt tccgcgcgcg 2019620DNAArtificial SequenceSynthetic Sequence 196 tccatgtcgt tcctgccgct 2019720DNAArtificial SequenceSynthetic Sequence 197 tccatgtcgt tcctgtagct 2019820DNAArtificial SequenceSynthetic Sequence 198 gcggcgggcg gcgcgcgccc 2019921DNAArtificial SequenceSynthetic Sequence 199 atcaggaacg tcatgggaag c 2120020DNAArtificial SequenceSynthetic Sequence 200 tccatgagct tcctgagtct 202018DNAArtificial SequenceSynthetic Sequence 201 tcaacgtt 82028DNAArtificial SequenceSynthetic Sequence 202 tcaagctt 820319DNAArtificial SequenceSynthetic Sequence 203 tcctgtcgtt cctgtcgtt 1920420DNAArtificial SequenceSynthetic Sequence 204 tccatgtcgt ttttgtcgtt 2020520DNAArtificial SequenceSynthetic Sequence 205 tcctgtcgtt ccttgtcgtt 2020620DNAArtificial SequenceSynthetic Sequence 206 tccttgtcgt tcctgtcgtt 2020729DNAArtificial Sequencemisc_feature(1)...(3)Conjugated to biotin moiety. 207 tccattccat gacgttcctg atgcttcca 2920820DNAArtificial SequenceSynthetic Sequence 208 tcctgtcgtt ttttgtcgtt 2020921DNAArtificial SequenceSynthetic Sequence 209 tcgtcgctgt ctccgcttct t 2121021DNAArtificial SequenceSynthetic Sequence 210 tcgtcgctgt ctgcccttct t 2121121DNAArtificial SequenceSynthetic Sequence 211 tcgtcgctgt tgtcgtttct t 2121230DNAArtificial SequenceSynthetic Sequence 212 tcctgtcgtt cctgtcgttg gaacgacagg 3021340DNAArtificial SequenceSynthetic Sequence 213 tcctgtcgtt cctgtcgttt caacgtcagg aacgacagga 4021421DNAArtificial SequenceSynthetic Sequence 214 ggggtctgtc gttttggggg g 2121521DNAArtificial SequenceSynthetic Sequence 215 ggggtctgtg cttttggggg g 2121615DNAArtificial SequenceSynthetic Sequence 216 tccggccgtt gaagt 1521715DNAArtificial SequenceSynthetic Sequence 217 tccggacggt gaagt 1521815DNAArtificial SequenceSynthetic Sequence 218 tcccgccgtt gaagt 1521915DNAArtificial SequenceSynthetic Sequence 219 tccagacggt gaagt 1522015DNAArtificial SequenceSynthetic Sequence 220 tcccgacggt gaagt 1522115DNAArtificial SequenceSynthetic Sequence 221 tccagagctt gaagt 1522220DNAArtificial Sequencemodified_base(8)...(8)m5c 222 tccatgtngt tcctgtngtt 2022320DNAArtificial SequenceSynthetic Sequence 223 tccatgacgt tcctgacgtt 2022420DNAArtificial SequenceSynthetic Sequence 224 ggggttgacg ttttgggggg 2022520DNAArtificial SequenceSynthetic Sequence 225 tccaggactt ctctcaggtt 2022620DNAArtificial SequenceSynthetic Sequence 226 tttttttttt tttttttttt 2022720DNAArtificial SequenceSynthetic Sequence 227 tccatgccgt tcctgccgtt 2022820DNAArtificial SequenceSynthetic Sequence 228 tccatggcgg gcctggcggg 2022920DNAArtificial SequenceSynthetic Sequence 229 tccatgacgt tcctgccgtt 2023020DNAArtificial SequenceSynthetic Sequence 230 tccatgacgt tcctggcggg 2023120DNAArtificial SequenceSynthetic Sequence 231 tccatgacgt tcctgcgttt 2023220DNAArtificial SequenceSynthetic Sequence 232 tccatgacgg tcctgacggt 2023320DNAArtificial SequenceSynthetic Sequence 233 tccatgcgtg cgtgcgtttt 2023420DNAArtificial SequenceSynthetic Sequence 234 tccatgcgtt gcgttgcgtt 2023530DNAArtificial Sequencemisc_feature(1)...(3)Conjugated to biotin moiety. 235 tccattccat tctaggcctg agtcttccat 3023620DNAArtificial SequenceSynthetic Sequence 236 tccatagcgt tcctagcgtt 2023720DNAArtificial SequenceSynthetic Sequence 237 tccatgtcgt tcctgtcgtt 2023820DNAArtificial SequenceSynthetic Sequence 238 tccatagcga tcctagcgat 2023920DNAArtificial SequenceSynthetic Sequence 239 tccattgcgt tccttgcgtt 2024020DNAArtificial SequenceSynthetic Sequence 240 tccatagcgg tcctagcggt 2024129DNAArtificial SequenceSynthetic Sequence 241 tccatgattt tcctgcagtt cctgatttt 2924229DNAArtificial SequenceSynthetic Sequence 242 tccatgacgt tcctgcagtt cctgacgtt 2924320DNAArtificial SequenceSynthetic Sequence 243 ggcggcggcg gcggcggcgg 2024420DNAArtificial SequenceSynthetic Sequence 244 tccacgacgt tttcgacgtt 2024520DNAArtificial SequenceSynthetic Sequence 245 tcgtcgttgt cgttgtcgtt 2024624DNAArtificial SequenceSynthetic Sequence 246 tcgtcgtttt gtcgttttgt cgtt 2424722DNAArtificial SequenceSynthetic Sequence 247 tcgtcgttgt cgttttgtcg tt 2224821DNAArtificial SequenceSynthetic Sequence 248 gcgtgcgttg tcgttgtcgt t 2124919DNAArtificial SequenceSynthetic Sequence 249 cnggcnggcn gggcnccgg 1925020DNAArtificial SequenceSynthetic Sequence 250 gcggcgggcg gcgcgcgccc 2025120DNAArtificial SequenceSynthetic Sequence 251 agncccgnga acgnattcac 2025221DNAArtificial SequenceSynthetic Sequence 252 tgtcgtttgt cgtttgtcgt t 2125325DNAArtificial SequenceSynthetic Sequence 253 tgtcgttgtc gttgtcgttg tcgtt 2525425DNAArtificial SequenceSynthetic Sequence 254 tgtcgttgtc gttgtcgttg tcgtt 2525514DNAArtificial SequenceSynthetic Sequence 255 tcgtcgtcgt cgtt 1425613DNAArtificial SequenceSynthetic Sequence 256 tgtcgttgtc gtt 1325720DNAArtificial SequenceSynthetic Sequence 257 cccccccccc cccccccccc 2025820DNAArtificial SequenceSynthetic Sequence 258 tctagcgttt ttagcgttcc 2025920DNAArtificial SequenceSynthetic Sequence 259 tgcatccccc aggccaccat 2026023DNAArtificial SequenceSynthetic Sequence 260 tcgtcgtcgt cgtcgtcgtc gtt 2326120DNAArtificial SequenceSynthetic Sequence 261 tcgtcgttgt cgttgtcgtt 2026224DNAArtificial SequenceSynthetic Sequence 262 tcgtcgtttt gtcgttttgt cgtt 2426322DNAArtificial SequenceSynthetic Sequence 263 tcgtcgttgt cgttttgtcg tt 2226439DNAArtificial SequenceSynthetic Sequence 264 ggggagggag gaacttctta aaattccccc agaatgttt 3926539DNAArtificial SequenceSynthetic Sequence 265 aaacattctg ggggaatttt aagaagttcc tccctcccc 3926633DNAArtificial SequenceSynthetic Sequence 266 atgtttactt cttaaaattc ccccagaatg ttt 3326733DNAArtificial SequenceSynthetic Sequence 267 aaacattctg ggggaatttt aagaagtaaa cat 3326833DNAArtificial SequenceSynthetic Sequence 268 atgtttacta gacaaaattc ccccagaatg ttt 3326933DNAArtificial SequenceSynthetic Sequence 269 aaacattctg ggggaatttt gtctagtaaa cat 3327020DNAArtificial SequenceSynthetic Sequence 270 aaaattgacg ttttaaaaaa 2027120DNAArtificial SequenceSynthetic Sequence 271 ccccttgacg ttttcccccc 2027220DNAArtificial SequenceSynthetic Sequence 272 ttttcgttgt ttttgtcgtt 2027324DNAArtificial SequenceSynthetic Sequence 273 tcgtcgtttt gtcgttttgt cgtt 2427414DNAArtificial SequenceSynthetic Sequence 274 ctgcagcctg ggac 1427525DNAArtificial SequenceSynthetic Sequence 275 acccgtcgta attatagtaa aaccc 2527621DNAArtificial SequenceSynthetic Sequence 276 ggtacctgtg gggacattgt g 2127718DNAArtificial SequenceSynthetic Sequence 277 agcaccgaac gtgagagg 1827820DNAArtificial SequenceSynthetic Sequence 278 tccatgccgt tcctgccgtt 2027920DNAArtificial SequenceSynthetic Sequence 279 tccatgacgg tcctgacggt 2028020DNAArtificial SequenceSynthetic Sequence 280 tccatgccgg tcctgccggt 2028120DNAArtificial SequenceSynthetic Sequence 281 tccatgcgcg tcctgcgcgt 2028224DNAArtificial SequenceSynthetic Sequence 282 ctggtctttc tggttttttt ctgg 2428320DNAArtificial SequenceSynthetic Sequence 283 tcaggggtgg ggggaacctt 2028420DNAArtificial Sequencemodified_base(8)...(8)m5c 284 tccatgangt tcctagttct 2028520DNAArtificial SequenceSynthetic Sequence 285 tccatgatgt tcctagttct 2028626DNAArtificial SequenceSynthetic Sequence 286 cccgaagtca tttcctctta acctgg 2628726DNAArtificial SequenceSynthetic Sequence 287 ccaggttaag aggaaatgac ttcggg 2628815DNAArtificial Sequencemodified_base(7)...(7)m5c 288 tcctggnggg gaagt 1528920DNAArtificial Sequencemodified_base(2)...(2)m5c 289 gnggngggng gngngngccc 2029020DNAArtificial SequenceSynthetic Sequence 290 tccatgtgct tcctgatgct 2029120DNAArtificial SequenceSynthetic Sequence 291 tccatgtcct tcctgatgct 2029220DNAArtificial SequenceSynthetic Sequence 292 tccatgtcgt tcctagttct 2029320DNAArtificial SequenceSynthetic Sequence 293 tccaagtagt tcctagttct 2029420DNAArtificial SequenceSynthetic Sequence 294 tccatgtagt tcctagttct 2029520DNAArtificial SequenceSynthetic Sequence 295 tcccgcgcgt tccgcgcgtt 2029620DNAArtificial SequenceSynthetic Sequence 296 tcctggcggt cctggcggtt 2029715DNAArtificial SequenceSynthetic Sequence 297 tcctggaggg gaagt 1529815DNAArtificial SequenceSynthetic Sequence 298 tcctgggggg gaagt 1529915DNAArtificial SequenceSynthetic Sequence 299 tcctggtggg gaagt 1530024DNAArtificial SequenceSynthetic Sequence 300 tcgtcgtttt gtcgttttgt cgtt 2430124DNAArtificial SequenceSynthetic Sequence 301 ctggtctttc tggttttttt ctgg 2430220DNAArtificial SequenceSynthetic Sequence 302 tccatgacgt tcctgacgtt 2030320DNAArtificial SequenceSynthetic Sequence 303 tccaggactt ctctcaggtt 2030424DNAArtificial SequenceSynthetic Sequence 304 tngtngtttt gtngttttgt ngtt 2430529DNAArtificial Sequencemisc_feature(1)...(3)Conjugated to biotin moiety. 305 tcgtcgtttt gtcgttttgt cgttttttt 2930618DNAArtificial SequenceSynthetic Sequence 306 gctatgacgt tccaaggg 183078DNAArtificial SequenceSynthetic Sequence 307 tcaacgtt 830820DNAArtificial SequenceSynthetic Sequence 308 tccaggactt tcctcaggtt 2030920DNAArtificial SequenceSynthetic Sequence 309 ctctctgtag gcccgcttgg 2031020DNAArtificial SequenceSynthetic Sequence 310 ctttccgttg gacccctggg 2031120DNAArtificial SequenceSynthetic Sequence 311 gtccgggcca ggccaaagtc 2031220DNAArtificial SequenceSynthetic Sequence 312 gtgcgcgcga gcccgaaatc 2031320DNAArtificial Sequencemodified_base(8)...(8)I 313 tccatgangt tcctgangtt 2031420DNAArtificial SequenceSynthetic Sequence 314 aatagtcgcc ataacaaaac 2031520DNAArtificial SequenceSynthetic Sequence 315 aatagtcgcc atggcggggc 2031628DNAArtificial Sequencemisc_difference(1)...(3)Biotin moiety attached at 5′ end of sequence. 316 tttttccatg tcgttcctga tgcttttt 2831720DNAArtificial SequenceSynthetic Sequence 317 tcctgtcgtt gaagtttttt 2031824DNAArtificial SequenceSynthetic Sequence 318 gctagcttta gagctttaga gctt 2431920DNAArtificial SequenceSynthetic Sequence 319 tgctgcttcc cccccccccc 2032020DNAArtificial SequenceSynthetic Sequence 320 tcgacgttcc cccccccccc 2032120DNAArtificial SequenceSynthetic Sequence 321 tcgtcgttcc cccccccccc 2032220DNAArtificial SequenceSynthetic Sequence 322 tcgtcgttcc cccccccccc 2032320DNAArtificial SequenceSynthetic Sequence 323 tcgccgttcc cccccccccc 2032420DNAArtificial SequenceSynthetic Sequence 324 tcgtcgatcc cccccccccc 2032515DNAArtificial SequenceSynthetic Sequence 325 tcctgacgtt gaagt 1532615DNAArtificial SequenceSynthetic Sequence 326 tcctgccgtt gaagt 1532715DNAArtificial SequenceSynthetic Sequence 327 tcctgacggt gaagt 1532815DNAArtificial SequenceSynthetic Sequence 328 tcctgagctt gaagt 1532915DNAArtificial SequenceSynthetic Sequence 329 tcctggcggg gaagt 1533021DNAArtificial SequenceSynthetic Sequence 330 aaaatctgtg cttttaaaaa a 2133133DNAArtificial SequenceSynthetic Sequence 331 gatccagtca cagtgacctg gcagaatctg gat 3333233DNAArtificial SequenceSynthetic Sequence 332 gatccagatt ctgccaggtc actgtgactg gat 3333333DNAArtificial SequenceSynthetic Sequence 333 gatccagtca cagtgactca gcagaatctg gat 3333433DNAArtificial SequenceSynthetic Sequence 334 gatccagatt ctgctgagtc actgtgactg gat 3333520DNAArtificial Sequencemodified_base(16)...(16)m5c 335 tcgtcgttcc cccccncccc 2033620DNAArtificial Sequencemodified_base(2)...(2)m5c 336 tngtngttcc cccccccccc 2033720DNAArtificial Sequencemodified_base(2)...(2)m5c 337 tngtcgttcc cccccccccc 2033820DNAArtificial Sequencemodified_base(5)...(5)m5c 338 tcgtngttcc cccccccccc 2033920DNAArtificial SequenceSynthetic Sequence 339 tcgtcgctcc cccccccccc 2034020DNAArtificial SequenceSynthetic Sequence 340 tcgtcggtcc cccccccccc 2034120DNAArtificial SequenceSynthetic Sequence 341 tcggcgttcc cccccccccc 2034220DNAArtificial SequenceSynthetic Sequence 342 ggccttttcc cccccccccc 2034324DNAArtificial SequenceSynthetic Sequence 343 tcgtcgtttt gacgttttgt cgtt 2434424DNAArtificial SequenceSynthetic Sequence 344 tcgtcgtttt gacgttttga cgtt 2434520DNAArtificial SequenceSynthetic Sequence 345 ccgtcgttcc cccccccccc 2034620DNAArtificial SequenceSynthetic Sequence 346 gcgtcgttcc cccccccccc 2034720DNAArtificial SequenceSynthetic Sequence 347 tcgtcattcc cccccccccc 2034820DNAArtificial SequenceSynthetic Sequence 348 acgtcgttcc cccccccccc 2034920DNAArtificial SequenceSynthetic Sequence 349 ctgtcgttcc cccccccccc 2035024DNAArtificial Sequencemisc_feature(1)...(3)Biotin moiety attached at 5′ end of sequence. 350 tttttcgtcg ttcccccccc cccc 2435120DNAArtificial Sequencemisc_feature(18)...(20)Biotin moiety attached at 3′ end of sequence. 351 tcgtcgttcc cccccccccc 2035224DNAArtificial Sequencemisc_feature(22)...(24)Biotin moiety attached at 3′ end of sequence. 352 tcgtcgtttt gtcgttttgt cgtt 2435320DNAArtificial SequenceSynthetic Sequence 353 tccagttcct tcctcagtct 2035424DNAArtificial Sequencemodified_base(2)...(2)m5c 354 tngtcgtttt gtcgttttgt cgtt 2435515DNAArtificial SequenceSynthetic Sequence 355 tcctggaggg gaagt 1535615DNAArtificial SequenceSynthetic Sequence 356 tcctgaaaag gaagt 1535717DNAArtificial SequenceSynthetic Sequence 357 tcgtcgttcc ccccccc 1735824DNAArtificial SequenceSynthetic Sequence 358 tngtngtttt gtngttttgt ngtt 2435920DNAArtificial SequenceSynthetic Sequence 359 ggggtcaagc ttgagggggg 2036020DNAArtificial SequenceSynthetic Sequence 360 tgctgcttcc cccccccccc 2036114DNAArtificial SequenceSynthetic Sequence 361 tcgtcgtcgt cgtt 1436214DNAArtificial SequenceSynthetic Sequence 362 tcgtcgtcgt cgtt 1436314DNAArtificial SequenceSynthetic Sequence 363 tcgtcgtcgt cgtt 1436410DNAArtificial SequenceSynthetic Sequence 364 tcaacgttga 103658DNAArtificial SequenceSynthetic Sequence 365 tcaacgtt 836620DNAArtificial SequenceSynthetic Sequence 366 atagttttcc atttttttac 2036720DNAArtificial SequenceSynthetic Sequence 367 aatagtcgcc atcgcgcgac 2036820DNAArtificial SequenceSynthetic Sequence 368 aatagtcgcc atcccgggac 2036920DNAArtificial SequenceSynthetic Sequence 369 aatagtcgcc atcccccccc 2037024DNAArtificial SequenceSynthetic Sequence 370 tgctgctttt gtgcttttgt gctt 2437124DNAArtificial SequenceSynthetic Sequence 371 ctgtgctttc tgtgtttttc tgtg 2437224DNAArtificial SequenceSynthetic Sequence 372 ctaatctttc taattttttt ctaa 2437326DNAArtificial SequenceSynthetic Sequence 373 tcgtcgttgg tgtcgttggt gtcgtt 2637424DNAArtificial SequenceSynthetic Sequence 374 tcgtcgttgg ttgtcgtttt ggtt 2437524DNAArtificial SequenceSynthetic Sequence 375 accatggacg agctgtttcc cctc 2437620DNAArtificial SequenceSynthetic Sequence 376 tcgtcgtttt gcgtgcgttt 2037720DNAArtificial SequenceSynthetic Sequence 377 ctgtaagtga gcttggagag 2037818DNAArtificial SequenceSynthetic Sequence 378 gagaacgctg gaccttcc 1837920DNAArtificial SequenceSynthetic Sequence 379 cgggcgactc agtctatcgg 2038037DNAArtificial SequenceSynthetic Sequence 380 gttctcagat aaagcggaac cagcaacaga cacagaa 3738137DNAArtificial SequenceSynthetic Sequence 381 ttctgtgtct gttgctggtt ccgctttatc tgagaac 3738223DNAArtificial SequenceSynthetic Sequence 382 cagacacaga agcccgatag acg 2338320DNAArtificial SequenceSynthetic Sequence 383 agacagacac gaaacgaccg 2038420DNAArtificial SequenceSynthetic Sequence 384 gtctgtccca tgatctcgaa 2038520DNAArtificial SequenceSynthetic Sequence 385 gctggccagc ttacctcccg 2038621DNAArtificial SequenceSynthetic Sequence 386 ggggcctcta tacaacctgg g 2138718DNAArtificial SequenceSynthetic Sequence 387 ggggtccctg agactgcc 1838820DNAArtificial SequenceSynthetic Sequence 388 gagaacgctg gaccttccat 2038920DNAArtificial SequenceSynthetic Sequence 389 tccatgtcgg tcctgatgct 2039020DNAArtificial SequenceSynthetic Sequence 390 ctcttgcgac ctggaaggta 2039120DNAArtificial SequenceSynthetic Sequence 391 aggtacagcc aggactacga 2039224DNAArtificial SequenceSynthetic Sequence 392 accatggacg acctgtttcc cctc 2439324DNAArtificial SequenceSynthetic Sequence 393 accatggatt acctttttcc cctt 2439420DNAArtificial SequenceSynthetic Sequence 394 atggaaggtc cagcgttctc 2039520DNAArtificial SequenceSynthetic Sequence 395 agcatcagga ccgacatgga 2039620DNAArtificial SequenceSynthetic Sequence 396 ctctccaagc tcacttacag 2039721DNAArtificial SequenceSynthetic Sequence 397 tccctgagac tgccccacct t 2139820DNAArtificial SequenceSynthetic Sequence 398 gccaccaaaa cttgtccatg 2039920DNAArtificial SequenceSynthetic Sequence 399 gtccatggcg tgcgggatga 2040019DNAArtificial SequenceSynthetic Sequence 400 cctctataca acctgggac 1940120DNAArtificial SequenceSynthetic Sequence 401 cgggcgactc agtctatcgg 2040220DNAArtificial SequenceSynthetic Sequence 402 gcgctaccgg tagcctgagt 2040335DNAArtificial SequenceSynthetic Sequence 403 cgactgccga acaggatatc ggtgatcagc actgg 3540435DNAArtificial SequenceSynthetic Sequence 404 ccagtgctga tcaccgatat cctgttcggc agtcg 3540517DNAArtificial SequenceSynthetic Sequence 405 ccaggttgta tagaggc 1740618DNAArtificial SequenceSynthetic Sequence 406 tctcccagcg tacgccat 1840718DNAArtificial SequenceSynthetic Sequence 407 tctcccagcg tgcgtttt 1840818DNAArtificial SequenceSynthetic Sequence 408 tctcccgacg tgcgccat 1840918DNAArtificial SequenceSynthetic Sequence 409 tctcccgtcg tgcgccat 1841020DNAArtificial SequenceSynthetic Sequence 410 ataatcgtcg ttcaagcaag 2041123DNAArtificial SequenceSynthetic Sequence 411 tcgtcgtttt gtcgttttgt cgt 2341224DNAArtificial SequenceSynthetic Sequence 412 tcgtcgtttt gtcgttttgt cgtt 2441324DNAArtificial SequenceSynthetic Sequence 413 tcgtcgtttt gtcgttttgt cgtt 2441424DNAArtificial Sequencemisc_difference(3)...(3)n is a or c or g or t/u 414 tcntcgtntt ntcgtnttnt cgtn 2441517DNAArtificial SequenceSynthetic Sequence 415 tctcccagcg tcgccat 1741617DNAArtificial SequenceSynthetic Sequence 416 tctcccatcg tcgccat 1741721DNAArtificial SequenceSynthetic Sequence 417 ataatcgtgc gttcaagaaa g 2141820DNAArtificial SequenceSynthetic Sequence 418 ataatcgacg ttcccccccc 2041920DNAArtificial SequenceSynthetic Sequence 419 tctatcgacg ttcaagcaag 2042014DNAArtificial SequenceSynthetic Sequence 420 tcctgacggg gagt 1442119DNAArtificial SequenceSynthetic Sequence 421 tccatgacgt tcctgatcc 1942219DNAArtificial SequenceSynthetic Sequence 422 tccatgacgt tcctgatcc 1942319DNAArtificial SequenceSynthetic Sequence 423 tccatgacgt tcctgatcc 1942415DNAArtificial SequenceSynthetic Sequence 424 tcctggcgtg gaagt 1542519DNAArtificial SequenceSynthetic Sequence 425 tccatgacgt tcctgatcc 1942621DNAArtificial SequenceSynthetic Sequence 426 tcgtcgctgt tgtcgtttct t 2142724DNAArtificial SequenceSynthetic Sequence 427 agcagcttta gagctttaga gctt 2442824DNAArtificial SequenceSynthetic Sequence 428 cccccccccc cccccccccc cccc 2442932DNAArtificial SequenceSynthetic Sequence 429 tcgtcgtttt gtcgttttgt cgttttgtcg tt 3243028DNAArtificial SequenceSynthetic Sequence 430 tcgtcgtttt ttgtcgtttt ttgtcgtt 2843120DNAArtificial SequenceSynthetic Sequence 431 tcgtcgtttt tttttttttt 2043220DNAArtificial SequenceSynthetic Sequence 432 tttttcaacg ttgatttttt 2043324DNAArtificial SequenceSynthetic Sequence 433 tttttttttt tttttttttt tttt 2443420DNAArtificial SequenceSynthetic Sequence 434 ggggtcgtcg ttttgggggg 2043524DNAArtificial SequenceSynthetic Sequence 435 tcgtcgtttt gtcgttttgg gggg 2443627DNAArtificial SequenceSynthetic Sequence 436 tcgtcgctgt ctccgcttct tcttgcc 2743715DNAArtificial SequenceSynthetic Sequence 437 tcgtcgctgt ctccg 1543820DNAArtificial SequenceSynthetic Sequence 438 ctgtaagtga gcttggagag 2043920DNAArtificial SequenceSynthetic Sequence 439 gagaacgctg gaccttccat 2044017DNAArtificial SequenceSynthetic Sequence 440 ccaggttgta tagaggc 1744117DNAArtificial SequenceSynthetic Sequence 441 gctagacgtt agcgtga 1744220DNAArtificial SequenceSynthetic Sequence 442 ggagctcttc gaacgccata 2044320DNAArtificial SequenceSynthetic Sequence 443 tctccatgat ggttttatcg 2044421DNAArtificial SequenceSynthetic Sequence 444 aaggtggggc agtctcaggg a 2144520DNAArtificial SequenceSynthetic Sequence 445 atcggaggac tggcgcgccg 2044620DNAArtificial SequenceSynthetic Sequence 446 ttaggacaag gtctagggtg 2044720DNAArtificial SequenceSynthetic Sequence 447 accacaacga gaggaacgca 2044820DNAArtificial SequenceSynthetic Sequence 448 ggcagtgcag gctcaccggg 2044917DNAArtificial SequenceSynthetic Sequence 449 gaaccttcca tgctgtt 1745017DNAArtificial SequenceSynthetic Sequence 450 gctagacgtt agcgtga 1745120DNAArtificial SequenceSynthetic Sequence 451 gcttggaggg cctgtaagtg 2045212DNAArtificial SequenceSynthetic Sequence 452 gtagccttcc ta 1245314DNAArtificial SequenceSynthetic Sequence 453 cggtagcctt ccta 1445416DNAArtificial SequenceSynthetic Sequence 454 cacggtagcc ttccta 1645518DNAArtificial SequenceSynthetic Sequence 455 agcacggtag ccttccta 1845618DNAArtificial SequenceSynthetic Sequence 456 gaacgctgga ccttccat 1845710DNAArtificial SequenceSynthetic Sequence 457 gaccttccat 1045812DNAArtificial SequenceSynthetic Sequence 458 tggaccttcc at 1245914DNAArtificial SequenceSynthetic Sequence 459 gctggacctt ccat 1446016DNAArtificial SequenceSynthetic Sequence 460 acgctggacc ttccat 1646120DNAArtificial SequenceSynthetic Sequence 461 taagctctgt caacgccagg 2046222DNAArtificial SequenceSynthetic Sequence 462 gagaacgctg gaccttccat gt 2246320DNAArtificial SequenceSynthetic Sequence 463 tccatgtcgg tcctgatgct 2046421DNAArtificial SequenceSynthetic Sequence 464 ttcatgcctt gcaaaatggc g 2146520DNAArtificial SequenceSynthetic Sequence 465 tgctagctgt gcctgtacct 2046620DNAArtificial SequenceSynthetic Sequence 466 agcatcagga ccgacatgga 2046722DNAArtificial SequenceSynthetic Sequence 467 gaccttccat gtcggtcctg at 2246820DNAArtificial SequenceSynthetic Sequence 468 acaaccacga gaacgggaac 2046920DNAArtificial SequenceSynthetic Sequence 469 gaaccttcca tgctgttccg 2047020DNAArtificial SequenceSynthetic Sequence 470 caatcaatct gaggagaccc 2047120DNAArtificial SequenceSynthetic Sequence 471 tcagctctgg tactttttca 2047220DNAArtificial SequenceSynthetic Sequence 472 tggttacggt ctgtcccatg 2047320DNAArtificial SequenceSynthetic Sequence 473 gtctatcgga ggactggcgc 2047420DNAArtificial SequenceSynthetic Sequence 474 cattttacgg gcgggcgggc 2047520DNAArtificial SequenceSynthetic Sequence 475 gaggggacca ttttacgggc 2047620DNAArtificial SequenceSynthetic Sequence 476 tgtccagccg aggggaccat 2047720DNAArtificial SequenceSynthetic Sequence 477 cgggcttacg gcggatgctg 2047820DNAArtificial SequenceSynthetic Sequence 478 tggaccttct atgtcggtcc 2047920DNAArtificial SequenceSynthetic Sequence 479 tgtcccatgt ttttagaagc 2048020DNAArtificial SequenceSynthetic Sequence 480 gtggttacgg tcgtgcccat 2048120DNAArtificial SequenceSynthetic Sequence 481 cctccaaatg aaagaccccc 2048220DNAArtificial SequenceSynthetic Sequence 482 ttgtactctc catgatggtt 2048320DNAArtificial SequenceSynthetic Sequence 483 ttccatgctg ttccggctgg 2048420DNAArtificial SequenceSynthetic Sequence 484 gaccttctat gtcggtcctg 2048520DNAArtificial SequenceSynthetic Sequence 485 gagaccgctc gaccttcgat 2048620DNAArtificial SequenceSynthetic Sequence 486 ttgccccata ttttagaaac 2048718DNAArtificial SequenceSynthetic Sequence 487 ttgaaactga ggtgggac 1848821DNAArtificial SequenceSynthetic Sequence 488 ctatcggagg actggcgcgc c 2148920DNAArtificial SequenceSynthetic Sequence 489 cttggagggc ctcccggcgg 2049020DNAArtificial SequenceSynthetic Sequence 490 gctgaacctt ccatgctgtt 2049132DNAArtificial SequenceSynthetic Sequence 491 tagaaacagc attcttcttt tagggcagca ca 3249224DNAArtificial SequenceSynthetic Sequence 492 agatggttct cagataaagc ggaa 2449324DNAArtificial SequenceSynthetic Sequence 493 ttccgcttta tctgagaacc atct 2449423DNAArtificial SequenceSynthetic Sequence 494 gtcccaggtt gtatagaggc tgc 2349520DNAArtificial SequenceSynthetic Sequence 495 gcgccagtcc tccgatagac 2049620DNAArtificial SequenceSynthetic Sequence 496 atcggaggac tggcgcgccg 2049720DNAArtificial SequenceSynthetic Sequence 497 ggtctgtccc atatttttag 2049820DNAArtificial SequenceSynthetic Sequence 498 tttttcaacg ttgagggggg 2049921DNAArtificial SequenceSynthetic Sequence 499 tttttcaagc gttgattttt t 2150020DNAArtificial SequenceSynthetic Sequence 500 ggggtcaacg ttgatttttt 2050125DNAArtificial SequenceSynthetic Sequence 501 ggggttttca acgttttgag ggggg 2550220DNAArtificial SequenceSynthetic Sequence 502 ggttacggtc tgtcccatat 2050320DNAArtificial SequenceSynthetic Sequence 503 ctgtcccata tttttagaca 2050420DNAArtificial SequenceSynthetic Sequence 504 accatcctga ggccattcgg 2050523DNAArtificial SequenceSynthetic Sequence 505 cgtctatcgg gcttctgtgt ctg 2350621DNAArtificial SequenceSynthetic Sequence 506 ggccatccca cattgaaagt t 2150722DNAArtificial SequenceSynthetic Sequence 507 ccaaatatcg gtggtcaagc ac 2250822DNAArtificial SequenceSynthetic Sequence 508 gtgcttgacc accgatattt gg 2250926DNAArtificial SequenceSynthetic Sequence 509 gtgctgatca ccgatatcct gttcgg 2651027DNAArtificial SequenceSynthetic Sequence 510 ggccaacttt caatgtggga tggcctc 2751127DNAArtificial SequenceSynthetic Sequence 511 ttccgccgaa tggcctcagg atggtac 2751236DNAArtificial SequenceSynthetic Sequence 512 tatagtccct gagactgccc caccttctca acaacc 3651327DNAArtificial SequenceSynthetic Sequence 513 gcagcctcta tacaacctgg gacggga 2751422DNAArtificial SequenceSynthetic Sequence 514 ctatcggagg actggcgcgc cg 2251521DNAArtificial SequenceSynthetic Sequence 515 tatcggagga ctggcgcgcc g 2151621DNAArtificial SequenceSynthetic Sequence 516 gatcggagga ctggcgcgcc g 2151726DNAArtificial SequenceSynthetic Sequence 517 ccgaacagga tatcggtgat cagcac 2651824DNAArtificial SequenceSynthetic Sequence 518 ttttggggtc aacgttgagg gggg 2451920DNAArtificial SequenceSynthetic Sequence 519 ggggtcaacg ttgagggggg 2052020DNAArtificial SequenceSynthetic Sequence 520 cgcgcgcgcg cgcgcgcgcg 2052120DNAArtificial SequenceSynthetic Sequence 521 ggggcatgac gttcgggggg 2052220DNAArtificial SequenceSynthetic Sequence 522 ggggcatgac gttcaaaaaa 2052320DNAArtificial SequenceSynthetic Sequence 523 ggggcatgag cttcgggggg 2052420DNAArtificial SequenceSynthetic Sequence 524 ggggcatgac gttcgggggg 2052520DNAArtificial SequenceSynthetic Sequence 525 aaaacatgac gttcaaaaaa 2052620DNAArtificial SequenceSynthetic Sequence 526 aaaacatgac gttcgggggg 2052720DNAArtificial SequenceSynthetic Sequence 527 ggggcatgac gttcaaaaaa 2052824DNAArtificial SequenceSynthetic Sequence 528 accatggacg atctgtttcc cctc 2452924DNAArtificial SequenceSynthetic Sequence 529 gccatggacg aactgttccc cctc 2453020DNAArtificial SequenceSynthetic Sequence 530 cccccccccc cccccccccc 2053120DNAArtificial SequenceSynthetic Sequence 531 gggggggggg gggggggggg 2053220DNAArtificial SequenceSynthetic Sequence 532 gctgtaaaat gaatcggccg 2053320DNAArtificial SequenceSynthetic Sequence 533 ttcgggcgga ctcctccatt 2053420DNAArtificial SequenceSynthetic Sequence 534 tatgccgcgc ccggacttat 2053520DNAArtificial SequenceSynthetic Sequence 535 ggggtaatcg atcagggggg 2053620DNAArtificial SequenceSynthetic Sequence 536 tttgagaacg ctggaccttc 2053720DNAArtificial SequenceSynthetic Sequence 537 gatcgctgat ctaatgctcg 2053820DNAArtificial SequenceSynthetic Sequence 538 gtcggtcctg atgctgttcc 2053920DNAArtificial SequenceSynthetic Sequence 539 tcgtcgtcag ttcgctgtcg 2054018DNAArtificial SequenceSynthetic Sequence 540 ctggaccttc catgtcgg 1854117DNAArtificial SequenceSynthetic Sequence 541 gctcgttcag cgcgtct 1754216DNAArtificial SequenceSynthetic Sequence 542 ctggaccttc catgtc 1654316DNAArtificial SequenceSynthetic Sequence 543 cactgtcctt cgtcga 1654420DNAArtificial SequenceSynthetic Sequence 544 cgctggacct tccatgtcgg 2054520DNAArtificial SequenceSynthetic Sequence 545 gctgagctca tgccgtctgc 2054620DNAArtificial SequenceSynthetic Sequence 546 aacgctggac cttccatgtc 2054720DNAArtificial SequenceSynthetic Sequence 547 tgcatgccgt acacagctct 2054820DNAArtificial SequenceSynthetic Sequence 548 ccttccatgt cggtcctgat 2054920DNAArtificial SequenceSynthetic Sequence 549 tactcttcgg atcccttgcg 2055018DNAArtificial SequenceSynthetic Sequence 550 ttccatgtcg gtcctgat 1855118DNAArtificial SequenceSynthetic Sequence 551 ctgattgctc tctcgtga 1855220DNAArtificial SequenceSynthetic Sequence 552 ggcgttattc ctgactcgcc 2055322DNAArtificial SequenceSynthetic Sequence 553 cctacgttgt atgcgcccag ct 2255420DNAArtificial SequenceSynthetic Sequence 554 ggggtaatcg atgagggggg 2055520DNAArtificial SequenceSynthetic Sequence 555 ttcgggcgga ctcctccatt 2055620DNAArtificial SequenceSynthetic Sequence 556 tttttttttt tttttttttt 2055720DNAArtificial SequenceSynthetic Sequence 557 gggggttttt tttttggggg 2055820DNAArtificial SequenceSynthetic Sequence 558 tttttggggg gggggttttt 2055919DNAArtificial SequenceSynthetic Sequence 559 gggggggggg ggggggggt 1956020DNAArtificial SequenceSynthetic Sequence 560 aaaaaaaaaa aaaaaaaaaa 2056120DNAArtificial SequenceSynthetic Sequence 561 cccccaaaaa aaaaaccccc 2056220DNAArtificial SequenceSynthetic Sequence 562 aaaaaccccc cccccaaaaa 2056327DNAArtificial SequenceSynthetic Sequence 563 tttgaattca ggactggtga ggttgag 2756427DNAArtificial SequenceSynthetic Sequence 564 tttgaatcct cagcggtctc cagtggc 2756545DNAArtificial SequenceSynthetic Sequence 565 aattctctat cggggcttct gtgtctgttg ctggttccgc tttat 4556645DNAArtificial SequenceSynthetic Sequence 566 ctagataaag cggaaccagc aacagacaca gaagccccga tagag 4556728DNAArtificial SequenceSynthetic Sequence 567 ttttctagag aggtgcacaa tgctctgg 2856829DNAArtificial SequenceSynthetic Sequence 568 tttgaattcc gtgtacagaa gcgagaagc 2956931DNAArtificial SequenceSynthetic Sequence 569 tttgcggccg ctagacttaa cctgagagat a 3157029DNAArtificial SequenceSynthetic Sequence 570 tttgggccca cgagagacag agacacttc 2957129DNAArtificial SequenceSynthetic Sequence 571 tttgggcccg cttctcgctt ctgtacacg 2957220DNAArtificial SequenceSynthetic Sequence 572 gagaacgctg gaccttccat 2057320DNAArtificial SequenceSynthetic Sequence 573 tccatgtcgg tcctgatgct 205746DNAArtificial SequenceSynthetic Sequence 574 ctgtcg 65756DNAArtificial SequenceSynthetic Sequence 575 tcgtga 65766DNAArtificial SequenceSynthetic Sequence 576 cgtcga 65776DNAArtificial SequenceSynthetic Sequence 577 agtgct 65786DNAArtificial SequenceSynthetic Sequence 578 ctgtcg 65796DNAArtificial SequenceSynthetic Sequence 579 agtgct 65806DNAArtificial SequenceSynthetic Sequence 580 cgtcga 65816DNAArtificial SequenceSynthetic Sequence 581 tcgtga 658220DNAArtificial SequenceSynthetic Sequence 582 gagaacgctc cagcttcgat 2058317DNAArtificial SequenceSynthetic Sequence 583 gctagacgta agcgtga 1758420DNAArtificial SequenceSynthetic Sequence 584 gagaacgctc gaccttccat 2058521DNAArtificial SequenceSynthetic Sequence 585 gagaacgctg gacctatcca t 2158617DNAArtificial SequenceSynthetic Sequence 586 gctagaggtt agcgtga 1758719DNAArtificial SequenceSynthetic Sequence 587 gagaacgctg gacttccat 1958817DNAArtificial SequenceSynthetic Sequence 588 tcacgctaac gtctagc 1758917DNAArtificial Sequencemisc_feature(1)...(3)Conjugated to biotin moiety. 589 gctagacgtt agcgtga 1759020DNAArtificial SequenceSynthetic Sequence 590 atggaaggtc gagcgttctc 2059120DNAArtificial SequenceSynthetic Sequence 591 gagaacgctg gaccttcgat 2059220DNAArtificial SequenceSynthetic Sequence 592 gagaacgatg gaccttccat 2059317DNAArtificial SequenceSynthetic Sequence 593 gagaacgctg gatccat 1759420DNAArtificial SequenceSynthetic Sequence 594 gagaacgctc cagcactgat 2059520DNAArtificial SequenceSynthetic Sequence 595 tccatgtcgg tcctgctgat 2059620DNAArtificial SequenceSynthetic Sequence 596 atgtcctcgg tcctgatgct 2059720DNAArtificial SequenceSynthetic Sequence 597 gagaacgctc caccttccat 2059820DNAArtificial SequenceSynthetic Sequence 598 gagaacgctg gaccttcgta 2059920DNAArtificial Sequencemisc_feature(1)...(3)Conjugated to biotin moiety. 599 atggaaggtc cagcgttctc 206006DNAArtificial SequenceSynthetic Sequence 600 tcctga 66018DNAArtificial SequenceSynthetic Sequence 601 tcaacgtt 86026DNAArtificial SequenceSynthetic Sequence 602 aacgtt 66038DNAArtificial SequenceSynthetic Sequence 603 aacgttga 860417DNAArtificial SequenceSynthetic Sequence 604 tcacgctaac ctctagc 1760520DNAArtificial SequenceSynthetic Sequence 605 gagaacgctg gaccttgcat 2060614DNAArtificial SequenceSynthetic Sequence 606 gctggacctt ccat 1460722DNAArtificial SequenceSynthetic Sequence 607 gagaacgctg gacctcatcc at 2260823DNAArtificial SequenceSynthetic Sequence 608 gagaacgctg gacgctcatc cat 2360915DNAArtificial SequenceSynthetic Sequence 609 aacgttgagg ggcat 1561015DNAArtificial SequenceSynthetic Sequence 610 atgcccctca acgtt 1561110DNAArtificial SequenceSynthetic Sequence 611 tcaacgttga 1061214DNAArtificial SequenceSynthetic Sequence 612 gctggacctt ccat 146137DNAArtificial SequenceSynthetic Sequence 613 caacgtt 761410DNAArtificial SequenceSynthetic Sequence 614 acaacgttga 106156DNAArtificial SequenceSynthetic Sequence 615 tcacgt 66168DNAArtificial SequenceSynthetic Sequence 616 tcaagctt 86176DNAArtificial SequenceSynthetic Sequence 617 tcgtca 66188DNAArtificial SequenceSynthetic Sequence 618 aggatatc 86198DNAArtificial SequenceSynthetic Sequence 619 tagacgtc 86208DNAArtificial SequenceSynthetic Sequence 620 gacgtcat 86218DNAArtificial SequenceSynthetic Sequence 621 ccatcgat 86228DNAArtificial SequenceSynthetic Sequence 622 atcgatgt 86238DNAArtificial SequenceSynthetic Sequence 623 atgcatgt 86248DNAArtificial SequenceSynthetic Sequence 624 ccatgcat 86258DNAArtificial SequenceSynthetic Sequence 625 agcgctga 86268DNAArtificial SequenceSynthetic Sequence 626 tcagcgct 86278DNAArtificial SequenceSynthetic Sequence 627 ccttcgat 862818DNAArtificial SequenceSynthetic Sequence 628 gtgccggggt ctccgggc 1862918DNAArtificial SequenceSynthetic Sequence 629 gctgtggggc ggctcctg 186308DNAArtificial Sequencemisc_feature(1)...(3)Conjugated to biotin moiety. 630 tcaacgtt 86318DNAArtificial Sequencemisc_feature(1)...(3)Conjugated to FITC moiety. 631 tcaacgtt 86328DNAArtificial Sequencemisc_feature(1)...(3)Conjugated to FITC moiety. 632 aacgttga 86337DNAArtificial SequenceSynthetic Sequence 633 tcaacgt 76347DNAArtificial SequenceSynthetic Sequence 634 aacgttg 76356DNAArtificial SequenceSynthetic Sequence 635 cgacga 66368DNAArtificial SequenceSynthetic Sequence 636 tcaacgtt 86375DNAArtificial SequenceSynthetic Sequence 637 tcgga 56388DNAArtificial SequenceSynthetic Sequence 638 agaacgtt 86398DNAArtificial SequenceSynthetic Sequence 639 tcatcgat 86408DNAArtificial SequenceSynthetic Sequence 640 taaacgtt 86418DNAArtificial SequenceSynthetic Sequence 641 ccaacgtt 86426DNAArtificial SequenceSynthetic Sequence 642 gctcga 66436DNAArtificial SequenceSynthetic Sequence 643 cgacgt 66446DNAArtificial SequenceSynthetic Sequence 644 cgtcgt 66456DNAArtificial SequenceSynthetic Sequence 645 acgtgt 66466DNAArtificial SequenceSynthetic Sequence 646 cgttcg 664720DNAArtificial SequenceSynthetic Sequence 647 gagcaagctg gaccttccat 206486DNAArtificial SequenceSynthetic Sequence 648 cgcgta 66496DNAArtificial SequenceSynthetic Sequence 649 cgtacg 66508DNAArtificial SequenceSynthetic Sequence 650 tcaccggt 865120DNAArtificial SequenceSynthetic Sequence 651 caagagatgc taacaatgca 2065220DNAArtificial SequenceSynthetic Sequence 652 acccatcaat agctctgtgc 206538DNAArtificial SequenceSynthetic Sequence 653 ccatcgat 86548DNAArtificial SequenceSynthetic Sequence 654 tcgacgtc 86558DNAArtificial SequenceSynthetic Sequence 655 ctagcgct 86568DNAArtificial SequenceSynthetic Sequence 656 taagcgct 865713DNAArtificial SequenceSynthetic Sequence 657 tcgcgaattc gcg 1365819DNAArtificial SequenceSynthetic Sequence 658 atggaaggtc cagcgttct 1965917DNAArtificial SequenceSynthetic Sequence 659 actggacgtt agcgtga 1766018DNAArtificial SequenceSynthetic Sequence 660 cgcctggggc tggtctgg 1866118DNAArtificial SequenceSynthetic Sequence 661 gtgtcggggt ctccgggc 1866218DNAArtificial SequenceSynthetic Sequence 662 gtgccggggt ctccgggc 1866318DNAArtificial SequenceSynthetic Sequence 663 cgccgtcgcg gcggttgg 1866421DNAArtificial SequenceSynthetic Sequence 664 gaagttcacg ttgaggggca t 2166521DNAArtificial SequenceSynthetic Sequence 665 atctggtgag ggcaagctat g 2166621DNAArtificial SequenceSynthetic Sequence 666 gttgaaaccc gagaacatca t 216678DNAArtificial SequenceSynthetic Sequence 667 gcaacgtt 86688DNAArtificial SequenceSynthetic Sequence 668 gtaacgtt 86698DNAArtificial SequenceSynthetic Sequence 669 cgaacgtt 86708DNAArtificial SequenceSynthetic Sequence 670 gaaacgtt 86718DNAArtificial SequenceSynthetic Sequence 671 caaacgtt 86728DNAArtificial SequenceSynthetic Sequence 672 ctaacgtt 86738DNAArtificial SequenceSynthetic Sequence 673 ggaacgtt 86748DNAArtificial SequenceSynthetic Sequence 674 tgaacgtt 86758DNAArtificial SequenceSynthetic Sequence 675 acaacgtt 86768DNAArtificial SequenceSynthetic Sequence 676 ttaacgtt 86778DNAArtificial SequenceSynthetic Sequence 677 aaaacgtt 86788DNAArtificial SequenceSynthetic Sequence 678 ataacgtt 86798DNAArtificial SequenceSynthetic Sequence 679 aacgttct 86808DNAArtificial SequenceSynthetic Sequence 680 tccgatcg 86818DNAArtificial SequenceSynthetic Sequence 681 tccgtacg 868217DNAArtificial SequenceSynthetic Sequence 682 gctagacgct agcgtga 1768325DNAArtificial SequenceSynthetic Sequence 683 gagaacgctg gacctcatca tccat 2568420DNAArtificial SequenceSynthetic Sequence 684 gagaacgcta gaccttctat 2068517DNAArtificial SequenceSynthetic Sequence 685 actagacgtt agtgtga 1768622DNAArtificial SequenceSynthetic Sequence 686 cacaccttgg tcaatgtcac gt 2268722DNAArtificial SequenceSynthetic Sequence 687 tctccatcct atggttttat cg 2268815DNAArtificial SequenceSynthetic Sequence 688 cgctggacct tccat 1568923DNAArtificial SequenceSynthetic Sequence 689 caccaccttg gtcaatgtca cgt 2369017DNAArtificial SequenceSynthetic Sequence 690 gctagacgtt agctgga 1769117DNAArtificial SequenceSynthetic Sequence 691 agtgcgattg cagatcg 1769224DNAArtificial SequenceSynthetic Sequence 692 ttttcgtttt gtggttttgt ggtt 2469323DNAArtificial SequenceSynthetic Sequence 693 ttttcgtttg tcgttttgtc gtt 2369424DNAArtificial SequenceSynthetic Sequence 694 tttttgtttt gtggttttgt ggtt 2469520DNAArtificial SequenceSynthetic Sequence 695 accgcatgga ttctaggcca 2069615DNAArtificial SequenceSynthetic Sequence 696 gctagacgtt agcgt 1569717DNAArtificial SequenceSynthetic Sequence 697 aacgctggac cttccat 176988DNAArtificial Sequencemodified_base(5)...(5)m5c 698 tcaangtt 86998DNAArtificial SequenceSynthetic Sequence 699 ccttcgat 870017DNAArtificial SequenceSynthetic Sequence 700 actagacgtt agtgtga 1770117DNAArtificial SequenceSynthetic Sequence 701 gctagaggtt agcgtga 1770220DNAArtificial SequenceSynthetic Sequence 702 atggactctc cagcgttctc 2070320DNAArtificial SequenceSynthetic Sequence 703 atcgactctc gagcgttctc 2070413DNAArtificial SequenceSynthetic Sequence 704 gctagacgtt agc 137059DNAArtificial SequenceSynthetic Sequence 705 gctagacgt 970617DNAArtificial SequenceSynthetic Sequence 706 agtgcgattc gagatcg 177078DNAArtificial Sequencemodified_base(5)...(5)m5c 707 tcagngct 870818DNAArtificial SequenceSynthetic Sequence 708 ctgattgctc tctcgtga 187098DNAArtificial Sequencemodified_base(2)...(2)m5c 709 tnaacgtt 871020DNAArtificial Sequencemodified_base(6)...(6)m5c 710 gagaangctg gaccttccat 2071117DNAArtificial SequenceSynthetic Sequence 711 gctagacgtt aggctga 1771214DNAArtificial SequenceSynthetic Sequence 712 gctacttagc gtga 1471315DNAArtificial SequenceSynthetic Sequence 713 gctaccttag cgtga 1571419DNAArtificial SequenceSynthetic Sequence 714 atcgacttcg agcgttctc 1971520DNAArtificial SequenceSynthetic Sequence 715 atgcactctg cagcgttctc 2071620DNAArtificial SequenceSynthetic Sequence 716 agtgactctc cagcgttctc 2071717DNAArtificial SequenceSynthetic Sequence 717 gccagatgtt agctgga 1771818DNAArtificial SequenceSynthetic Sequence 718 atcgactcga gcgttctc 1871917DNAArtificial SequenceSynthetic Sequence 719 atcgatcgag cgttctc 1772020DNAArtificial Sequencemisc_feature(1)...(3)Conjugated to biotin moiety. 720 gagaacgctc gaccttcgat 2072117DNAArtificial SequenceSynthetic Sequence 721 gctagacgtt agctgga 1772220DNAArtificial SequenceSynthetic Sequence 722 atcgactctc gagcgttctc 2072315DNAArtificial SequenceSynthetic Sequence 723 tagacgttag cgtga 1572418DNAArtificial SequenceSynthetic Sequence 724 cgactctcga gcgttctc 1872521DNAArtificial SequenceSynthetic Sequence 725 ggggtcgacc ttggaggggg g 2172616DNAArtificial SequenceSynthetic Sequence 726 gctaacgtta gcgtga 167279DNAArtificial SequenceSynthetic Sequence 727 cgtcgtcgt 972820DNAArtificial Sequencemodified_base(14)...(14)m5c 728 gagaacgctg gacnttccat 2072920DNAArtificial Sequencemodified_base(18)...(18)m5c 729 atcgacctac gtgcgttntc 2073020DNAArtificial Sequencemodified_base(3)...(3)m5c 730 atngacctac gtgcgttctc 2073115DNAArtificial Sequencemodified_base(7)...(7)m5c 731 gctagangtt agcgt 1573220DNAArtificial Sequencemodified_base(14)...(14)m5c 732 atcgactctc gagngttctc 2073320DNAArtificial SequenceSynthetic Sequence 733 ggggtaatgc atcagggggg 2073420DNAArtificial SequenceSynthetic Sequence 734 ggctgtattc ctgactgccc 2073517DNAArtificial SequenceSynthetic Sequence 735 ccatgctaac ctctagc 1773617DNAArtificial SequenceSynthetic Sequence 736 gctagatgtt agcgtga 1773715DNAArtificial SequenceSynthetic Sequence 737 cgtaccttac ggtga 1573820DNAArtificial SequenceSynthetic Sequence 738 tccatgctgg tcctgatgct 2073922DNAArtificial SequenceSynthetic Sequence 739 atcgactctc tcgagcgttc tc 2274017DNAArtificial SequenceSynthetic Sequence 740 gctagagctt agcgtga 1774120DNAArtificial SequenceSynthetic Sequence 741 atcgactctc gagtgttctc 2074217DNAArtificial SequenceSynthetic Sequence 742 aacgctcgac cttcgat 1774320DNAArtificial SequenceSynthetic Sequence 743 ctcaacgctg gaccttccat 2074420DNAArtificial SequenceSynthetic Sequence 744 atcgacctac gtgcgttctc 2074520DNAArtificial SequenceSynthetic Sequence 745 gagaatgctg gaccttccat 2074617DNAArtificial SequenceSynthetic Sequence 746 tcacgctaac ctctgac 1774720DNAArtificial Sequencemisc_feature(1)...(3)Conjugated to biotin moiety. 747 gagaacgctc cagcactgat 2074820DNAArtificial Sequencemisc_feature(1)...(3)Biotin moiety attached at 5′ end of sequence. 748 gagcaagctg gaccttccat 2074918DNAArtificial SequenceSynthetic Sequence 749 cgctagaggt tagcgtga 1875015DNAArtificial SequenceSynthetic Sequence 750 gctagatgtt aacgt 1575119DNAArtificial SequenceSynthetic Sequence 751 atggaaggtc cacgttctc 1975215DNAArtificial SequenceSynthetic Sequence 752 gctagatgtt agcgt 1575315DNAArtificial SequenceSynthetic Sequence 753 gctagacgtt agtgt 1575420DNAArtificial SequenceSynthetic Sequence 754 tccatgacgg tcctgatgct 2075520DNAArtificial SequenceSynthetic Sequence 755 tccatggcgg tcctgatgct 2075615DNAArtificial SequenceSynthetic Sequence 756 gctagacgat agcgt 1575715DNAArtificial SequenceSynthetic Sequence 757 gctagtcgat agcgt 1575820DNAArtificial SequenceSynthetic Sequence 758 tccatgacgt tcctgatgct 2075920DNAArtificial SequenceSynthetic Sequence 759 tccatgtcgt tcctgatgct 2076015DNAArtificial Sequencemodified_base(13)...(13)m5c 760 gctagacgtt agngt 1576115DNAArtificial SequenceSynthetic Sequence 761 gctaggcgtt agcgt 1576220DNAArtificial Sequencemodified_base(8)...(8)m5c 762 tccatgtngg tcctgatgct 2076320DNAArtificial Sequencemodified_base(12)...(12)m5c 763 tccatgtcgg tnctgatgct 2076420DNAArtificial SequenceSynthetic Sequence 764 atngactctn gagngttctc 2076520DNAArtificial SequenceSynthetic Sequence 765 atggaaggtc cagtgttctc 2076615DNAArtificial SequenceSynthetic Sequence 766 gcatgacgtt gagct 1576720DNAArtificial SequenceSynthetic Sequence 767 ggggtcaacg ttgagggggg 2076820DNAArtificial SequenceSynthetic Sequence 768 ggggtcaagt ctgagggggg 2076920DNAArtificial SequenceSynthetic Sequence 769 cgcgcgcgcg cgcgcgcgcg 2077028DNAArtificial SequenceSynthetic Sequence 770 cccccccccc cccccccccc cccccccc 2877135DNAArtificial SequenceSynthetic Sequence 771 cccccccccc cccccccccc cccccccccc ccccc 3577220DNAArtificial SequenceSynthetic Sequence 772 tccatgtcgc tcctgatcct 2077315DNAArtificial SequenceSynthetic Sequence 773 gctaaacgtt agcgt 1577420DNAArtificial SequenceSynthetic Sequence 774 tccatgtcga tcctgatgct 2077520DNAArtificial SequenceSynthetic Sequence 775 tccatgccgg tcctgatgct 2077620DNAArtificial SequenceSynthetic Sequence 776 aaaatcaacg ttgaaaaaaa 2077720DNAArtificial SequenceSynthetic Sequence 777 tccataacgt tcctgatgct 2077823DNAArtificial SequenceSynthetic Sequence 778 tggaggtccc accgagatcg gag 2377921DNAArtificial SequenceSynthetic Sequence 779 cgtcgtcgtc gtcgtcgtcg t 2178021DNAArtificial SequenceSynthetic Sequence 780 ctgctgctgc tgctgctgct g 2178121DNAArtificial SequenceSynthetic Sequence 781 gagaacgctc cgaccttcga t 2178215DNAArtificial SequenceSynthetic Sequence 782 gctagatgtt agcgt 1578315DNAArtificial SequenceSynthetic Sequence 783 gcatgacgtt gagct 1578410DNAArtificial Sequencemisc_feature(8)...(10)Conjugated to FITC moiety. 784 tcaatgctga 1078510DNAArtificial Sequencemisc_feature(8)...(10)Conjugated to FITC moiety. 785 tcaacgttga 1078610DNAArtificial Sequencemisc_feature(8)...(10)Conjugated to biotin moiety. 786 tcaacgttga 1078710DNAArtificial Sequencemisc_feature(8)...(10)Conjugated to biotin moiety. 787 gcaatattgc 1078810DNAArtificial Sequencemisc_feature(8)...(10)Conjugated to FITC moiety. 788 gcaatattgc 1078910DNAArtificial SequenceSynthetic Sequence 789 agttgcaact 107908DNAArtificial SequenceSynthetic Sequence 790 tcttcgaa 87918DNAArtificial SequenceSynthetic Sequence 791 tcaacgtc 879219DNAArtificial SequenceSynthetic Sequence 792 ccatgtcggt cctgatgct 1979318DNAArtificial SequenceSynthetic Sequence 793 gtttttatat aatttggg 1879423DNAArtificial SequenceSynthetic Sequence 794 tttttgtttg tcgttttgtc gtt 2379512DNAArtificial SequenceSynthetic Sequence 795 ttgggggggg tt 1279613DNAArtificial SequenceSynthetic Sequence 796 ggggttgggg gtt 1379717DNAArtificial SequenceSynthetic Sequence 797 ggtggtgtag gttttgg 1779820DNAArtificial Sequencemisc_feature(1)...(3)Conjugated to biotin moiety. 798 gagaangctc gaccttcgat 2079920DNAArtificial SequenceSynthetic Sequence 799 tcaacgttaa cgttaacgtt 2080020DNAArtificial Sequencemisc_feature(1)...(3)Conjugated to biotin moiety. 800 gagcaagntg gaccttccat 2080120DNAArtificial Sequencemisc_feature(1)...(3)Conjugated to biotin moiety. 801 gagaangctc cagcactgat 2080210DNAArtificial Sequencemodified_base(5)...(5)m5c 802 tcaangttga 1080310DNAArtificial Sequencemodified_base(2)...(2)m5c 803 gnaatattgc 1080424DNAArtificial SequenceSynthetic Sequence 804 tgctgctttt gtcgttttgt gctt 2480522DNAArtificial SequenceSynthetic Sequence 805 ctgcgttagc aatttaactg tg 2280620DNAArtificial SequenceSynthetic Sequence 806 tccatgacgt tcctgatgct 2080728DNAArtificial SequenceSynthetic Sequence 807 tgcatgccgt gcatccgtac acagctct 2880820DNAArtificial SequenceSynthetic Sequence 808 tgcatgccgt acacagctct 2080912DNAArtificial SequenceSynthetic Sequence 809 tgcatcagct ct 128108DNAArtificial SequenceSynthetic Sequence 810 tgcgctct 881120DNAArtificial SequenceSynthetic Sequence 811 cccccccccc cccccccccc 2081212DNAArtificial SequenceSynthetic Sequence 812 cccccccccc cc 128138DNAArtificial SequenceSynthetic Sequence 813 cccccccc 881412DNAArtificial SequenceSynthetic Sequence 814 tgcatcagct ct 1281520DNAArtificial SequenceSynthetic Sequence 815 tgcatgccgt acacagctct 2081620DNAArtificial SequenceSynthetic Sequence 816 gagcaagctg gaccttccat 2081732DNAArtificial SequenceSynthetic Sequence 817 tcaacgttaa cgttaacgtt aacgttaacg tt 3281820DNAArtificial SequenceSynthetic Sequence 818 gagaacgctc gaccttcgat 2081925DNAArtificial SequenceSynthetic Sequence 819 gtccccattt cccagaggag gaaat 2582025DNAArtificial SequenceSynthetic Sequence 820 ctagcggctg acgtcatcaa gctag 2582125DNAArtificial SequenceSynthetic Sequence 821 ctagcttgat gacgtcagcc gctag 2582216DNAArtificial SequenceSynthetic Sequence 822 cggctgacgt catcaa 168238DNAArtificial SequenceSynthetic Sequence 823 ctgacgtg 882410DNAArtificial SequenceSynthetic Sequence 824 ctgacgtcat 1082521DNAArtificial SequenceSynthetic Sequence 825 attcgatcgg ggcggggcga g 2182621DNAArtificial SequenceSynthetic Sequence 826 ctcgccccgc cccgatcgaa t 2182715DNAArtificial SequenceSynthetic Sequence 827 gactgacgtc agcgt 1582826DNAArtificial SequenceSynthetic Sequence 828 ctagcggctg acgtcataaa gctagc 2682926DNAArtificial SequenceSynthetic Sequence 829 ctagctttat gacgtcagcc gctagc 2683026DNAArtificial SequenceSynthetic Sequence 830 ctagcggctg agctcataaa gctagc 2683125DNAArtificial SequenceSynthetic Sequence 831 ctagtggctg acgtcatcaa gctag 2583220DNAArtificial SequenceSynthetic Sequence 832 tccaccacgt ggtctatgct 2083324DNAArtificial SequenceSynthetic Sequence 833 gggaatgaaa gattttatta taag 2483426DNAArtificial SequenceSynthetic Sequence 834 tctaaaaacc atctattctt aaccct 2683515DNAArtificial SequenceSynthetic Sequence 835 agctcaacgt catgc 1583624DNAArtificial SequenceSynthetic Sequence 836 ttaacggtgg tagcggtatt ggtc 2483724DNAArtificial SequenceSynthetic Sequence 837 ttaagaccaa taccgctacc accg 2483825DNAArtificial SequenceSynthetic Sequence 838 gatctagtga tgagtcagcc ggatc 2583925DNAArtificial SequenceSynthetic Sequence 839 gatccggctg actcatcact agatc 2584020DNAArtificial SequenceSynthetic Sequence 840 tccaagacgt tcctgatgct 2084120DNAArtificial SequenceSynthetic Sequence 841 tccatgacgt ccctgatgct 2084220DNAArtificial SequenceSynthetic Sequence 842 tccaccacgt ggctgatgct 2084317DNAArtificial SequenceSynthetic Sequence 843 ccacgtggac ctctagc 1784427DNAArtificial SequenceSynthetic Sequence 844 tcagaccacg tggtcgggtg ttcctga 2784527DNAArtificial SequenceSynthetic Sequence 845 tcaggaacac ccgaccacgt ggtctga 2784618DNAArtificial SequenceSynthetic Sequence 846 catttccacg atttccca 1884719DNAArtificial SequenceSynthetic Sequence 847 ttcctctctg caagagact 1984819DNAArtificial SequenceSynthetic Sequence 848 tgtatctctc tgaaggact 1984925DNAArtificial SequenceSynthetic Sequence 849 ataaagcgaa actagcagca gtttc 2585025DNAArtificial SequenceSynthetic Sequence 850 gaaactgctg ctagtttcgc tttat 2585130DNAArtificial SequenceSynthetic Sequence 851 tgcccaaaga ggaaaatttg tttcatacag 3085230DNAArtificial SequenceSynthetic Sequence 852 ctgtatgaaa caaattttcc tctttgggca 3085320DNAArtificial SequenceSynthetic Sequence 853 ttagggttag ggttagggtt 2085420DNAArtificial SequenceSynthetic Sequence 854 tccatgagct tcctgatgct 2085520DNAArtificial SequenceSynthetic Sequence 855 aaaacatgac gttcaaaaaa 2085620DNAArtificial SequenceSynthetic Sequence 856 aaaacatgac gttcgggggg 2085720DNAArtificial SequenceSynthetic Sequence 857 ggggcatgag cttcgggggg 2085824DNAArtificial SequenceSynthetic Sequence 858 ctaggctgac gtcatcaagc tagt 2485930DNAArtificial SequenceSynthetic Sequence 859 tctgacgtca tctgacgttg gctgacgtct 3086025DNAArtificial SequenceSynthetic Sequence 860 ggaattagta atagatatag aagtt 2586130DNAArtificial SequenceSynthetic Sequence 861 tttacctttt ataaacataa ctaaaacaaa 3086215DNAArtificial SequenceSynthetic Sequence 862 gcgttttttt ttgcg 1586324DNAArtificial SequenceSynthetic Sequence 863 atatctaatc aaaacattaa caaa 2486424DNAArtificial SequenceSynthetic Sequence 864 tctatcccag gtggttcctg ttag 2486520DNAArtificial Sequencemisc_feature(1)...(3)Conjugated to biotin moiety. 865 tccatgacgt tcctgatgct 2086620DNAArtificial Sequencemisc_feature(1)...(3)Conjugated to biotin moiety. 866 tccatgagct tcctgatgct 2086713DNAArtificial Sequencemisc_feature(11)...(13)Conjugated to FITC moiety. 867 tttttttttt ttt 1386813DNAArtificial Sequencemisc_feature(11)...(13)Conjugated to biotin moiety. 868 tttttttttt ttt 1386925DNAArtificial SequenceSynthetic Sequence 869 ctagcttgat gagctcagcc gctag 2587025DNAArtificial SequenceSynthetic Sequence 870 ttcagttgtc ttgctgctta gctaa 2587120DNAArtificial SequenceSynthetic Sequence 871 tccatgagct tcctgagtct 2087225DNAArtificial SequenceSynthetic Sequence 872 ctagcggctg acgtcatcaa tctag 2587320DNAArtificial SequenceSynthetic Sequence 873 tgctagctgt gcctgtacct 2087423DNAArtificial SequenceSynthetic Sequence 874 atgctaaagg acgtcacatt gca 2387523DNAArtificial SequenceSynthetic Sequence 875 tgcaatgtga cgtcctttag cat 2387631DNAArtificial SequenceSynthetic Sequence 876 gtaggggact ttccgagctc gagatcctat g 3187731DNAArtificial SequenceSynthetic Sequence 877 cataggatct cgagctcgga aagtccccta c 3187822DNAArtificial SequenceSynthetic Sequence 878 ctgtcaggaa ctgcaggtaa gg 2287927DNAArtificial SequenceSynthetic Sequence 879 cataacatag gaatatttac tcctcgc 2788021DNAArtificial SequenceSynthetic Sequence 880 ctccagctcc aagaaaggac g 2188121DNAArtificial SequenceSynthetic Sequence 881 gaagtttctg gtaagtcttc g 2188224DNAArtificial SequenceSynthetic Sequence 882 tgctgctttt gtgcttttgt gctt 2488324DNAArtificial SequenceSynthetic Sequence 883 tcgtcgtttt gtggttttgt ggtt 2488423DNAArtificial SequenceSynthetic Sequence 884 tcgtcgtttg tcgttttgtc gtt 2388522DNAArtificial SequenceSynthetic Sequence 885 tcctgacgtt cggcgcgcgc cc 2288624DNAArtificial SequenceSynthetic Sequence 886 tgctgctttt gtgcttttgt gctt 2488720DNAArtificial SequenceSynthetic Sequence 887 tccatgagct tcctgagctt 2088824DNAArtificial SequenceSynthetic Sequence 888 tcgtcgtttc gtcgttttga cgtt 2488926DNAArtificial SequenceSynthetic Sequence 889 tcgtcgtttg cgtgcgtttc gtcgtt 2689027DNAArtificial SequenceSynthetic Sequence 890 tcgcgtgcgt tttgtcgttt tgacgtt 2789125DNAArtificial SequenceSynthetic Sequence 891 ttcgtcgttt tgtcgttttg tcgtt 2589215DNAArtificial SequenceSynthetic Sequence 892 tcctgacggg gaagt 1589315DNAArtificial SequenceSynthetic Sequence 893 tcctggcgtg gaagt 1589415DNAArtificial SequenceSynthetic Sequence 894 tcctggcggt gaagt 1589515DNAArtificial SequenceSynthetic Sequence 895 tcctggcgtt gaagt 1589615DNAArtificial SequenceSynthetic Sequence 896 tcctgacgtg gaagt 1589720DNAArtificial SequenceSynthetic Sequence 897 gcgacgttcg gcgcgcgccc 2089820DNAArtificial SequenceSynthetic Sequence 898 gcgacgggcg gcgcgcgccc 2089920DNAArtificial SequenceSynthetic Sequence 899 gcggcgtgcg gcgcgcgccc 2090020DNAArtificial SequenceSynthetic Sequence 900 gcggcggtcg gcgcgcgccc 2090120DNAArtificial SequenceSynthetic Sequence 901 gcgacggtcg gcgcgcgccc 2090220DNAArtificial SequenceSynthetic Sequence 902 gcggcgttcg gcgcgcgccc 2090320DNAArtificial SequenceSynthetic Sequence 903 gcgacgtgcg gcgcgcgccc 2090415DNAArtificial SequenceSynthetic Sequence 904 tcgtcgctgt ctccg 1590520DNAArtificial SequenceSynthetic Sequence 905 tgtgggggtt ttggttttgg 2090620DNAArtificial SequenceSynthetic Sequence 906 aggggagggg aggggagggg 2090721DNAArtificial SequenceSynthetic Sequence 907 tgtgtgtgtg tgtgtgtgtg t 2190822DNAArtificial SequenceSynthetic Sequence 908 ctctctctct ctctctctct ct 2290920DNAArtificial SequenceSynthetic Sequence 909 ggggtcgacg tcgagggggg 2091022DNAArtificial SequenceSynthetic Sequence 910 atatatatat atatatatat at 2291127DNAArtificial SequenceSynthetic Sequence 911 tttttttttt tttttttttt ttttttt 2791221DNAArtificial SequenceSynthetic Sequence 912 tttttttttt tttttttttt t 2191318DNAArtificial SequenceSynthetic Sequence 913 tttttttttt tttttttt 1891415DNAArtificial SequenceSynthetic Sequence 914 gctagagggg agggt 1591515DNAArtificial SequenceSynthetic Sequence 915 gctagatgtt agggg 1591615DNAArtificial SequenceSynthetic Sequence 916 gcatgagggg gagct 1591720DNAArtificial SequenceSynthetic Sequence 917 atggaaggtc cagggggctc 2091820DNAArtificial SequenceSynthetic Sequence 918 atggactctg gagggggctc 2091920DNAArtificial SequenceSynthetic Sequence 919 atggaaggtc caaggggctc 2092020DNAArtificial SequenceSynthetic Sequence 920 gagaaggggg gaccttggat 2092120DNAArtificial SequenceSynthetic Sequence 921 gagaaggggg gaccttccat 2092220DNAArtificial SequenceSynthetic Sequence 922 gagaaggggc cagcactgat 2092320DNAArtificial SequenceSynthetic Sequence 923 tccatgtggg gcctgatgct 2092420DNAArtificial SequenceSynthetic Sequence 924 tccatgaggg gcctgatgct 2092520DNAArtificial SequenceSynthetic Sequence 925 tccatgtggg gcctgctgat 2092620DNAArtificial SequenceSynthetic Sequence 926 atggactctc cggggttctc 2092720DNAArtificial SequenceSynthetic Sequence 927 atggaaggtc cggggttctc 2092820DNAArtificial SequenceSynthetic Sequence 928 atggactctg gaggggtctc 2092920DNAArtificial SequenceSynthetic Sequence 929 atggaggctc catggggctc 2093020DNAArtificial SequenceSynthetic Sequence 930 atggactctg gggggttctc 2093120DNAArtificial SequenceSynthetic Sequence 931 tccatgtggg tggggatgct 2093220DNAArtificial SequenceSynthetic Sequence 932 tccatgcggg tggggatgct 2093320DNAArtificial SequenceSynthetic Sequence 933 tccatggggg tcctgatgct 2093420DNAArtificial SequenceSynthetic Sequence 934 tccatggggt ccctgatgct 2093520DNAArtificial SequenceSynthetic Sequence 935 tccatggggt gcctgatgct 2093620DNAArtificial SequenceSynthetic Sequence 936 tccatggggt tcctgatgct 2093720DNAArtificial SequenceSynthetic Sequence 937 tccatcgggg gcctgatgct 2093814DNAArtificial SequenceSynthetic Sequence 938 gctagaggga gtgt 1493918DNAArtificial SequenceSynthetic Sequence 939 tttttttttt tttttttt 1894021DNAArtificial Sequencemisc_difference(2)...(2)m is a or c 940 gmggtcaacg ttgagggmgg g 2194121DNAArtificial SequenceSynthetic Sequence 941 ggggagttcg ttgagggggg g 2194220DNAArtificial SequenceSynthetic Sequence 942 tcgtcgtttc cccccccccc 2094325DNAArtificial SequenceSynthetic Sequence 943 ttggggggtt tttttttttt ttttt 2594423DNAArtificial SequenceSynthetic Sequence 944 tttaaatttt aaaatttaaa ata 2394524DNAArtificial SequenceSynthetic Sequence 945 ttggtttttt tggttttttt ttgg 2494624DNAArtificial SequenceSynthetic Sequence 946 tttccctttt ccccttttcc cctc 2494721DNAArtificial Sequencemisc_difference(21)...(21)s is g or c 947 ggggtcatcg atgagggggg s 2194820DNAArtificial SequenceSynthetic Sequence 948 tccatgacgt tcctgacgtt 2094920DNAArtificial SequenceSynthetic Sequence 949 tccatgacgt tcctgacgtt 2095020DNAArtificial SequenceSynthetic Sequence 950 tccatgacgt tcctgacgtt 2095120DNAArtificial SequenceSynthetic Sequence 951 tccatgacgt tcctgacgtt 2095220DNAArtificial SequenceSynthetic Sequence 952 tccatgacgt tcctgacgtt 2095320DNAArtificial SequenceSynthetic Sequence 953 tccatgacgt tcctgacgtt 2095420DNAArtificial SequenceSynthetic Sequence 954 tccatgacgt tcctgacgtt 2095520DNAArtificial SequenceSynthetic Sequence 955 tccatgacgt tcctgacgtt 2095620DNAArtificial SequenceSynthetic Sequence 956 tccatgacgt tcctgacgtt 2095720DNAArtificial SequenceSynthetic Sequence 957 tccatgacgt tcctgacgtt 2095820DNAArtificial SequenceSynthetic Sequence 958 tccatgacgt tcctgacgtt 2095919DNAArtificial SequenceSynthetic Sequence 959 gggggacgat cgtcggggg 1996020DNAArtificial SequenceSynthetic Sequence 960 gggggtcgta cgacgggggg 2096124DNAArtificial SequenceSynthetic Sequence 961 tttttttttt tttttttttt tttt 2496224DNAArtificial SequenceSynthetic Sequence 962 aaaaaaaaaa aaaaaaaaaa aaaa 2496324DNAArtificial SequenceSynthetic Sequence 963 cccccccccc cccccccccc cccc 2496424DNAArtificial SequenceSynthetic Sequence 964 tcgtcgtttt gtcgttttgt cgtt 2496524DNAArtificial SequenceSynthetic Sequence 965 tcgtcgtttt gtcgttttgt cgtt 2496624DNAArtificial SequenceSynthetic Sequence 966 tcgtcgtttt gtcgttttgt cgtt 2496724DNAArtificial SequenceSynthetic Sequence 967 tcgtcgtttt gtcgttttgt cgtt 2496820DNAArtificial SequenceSynthetic Sequence 968 ggggtcaacg ttgagggggg 2096920DNAArtificial SequenceSynthetic Sequence 969 ggggtcaacg ttgagggggg 2097020DNAArtificial SequenceSynthetic Sequence 970 ggggtcaagc ttgagggggg 2097120DNAArtificial SequenceSynthetic Sequence 971 tgctgcttcc cccccccccc 2097220DNAArtificial SequenceSynthetic Sequence 972 ggggacgtcg acgtgggggg 2097320DNAArtificial SequenceSynthetic Sequence 973 ggggtcgtcg acgagggggg 2097424DNAArtificial SequenceSynthetic Sequence 974 ggggtcgacg tacgtcgagg gggg 2497522DNAArtificial SequenceSynthetic Sequence 975 ggggaccggt accggtgggg gg 2297619DNAArtificial SequenceSynthetic Sequence 976 gggtcgacgt cgagggggg 1997719DNAArtificial SequenceSynthetic Sequence 977 ggggtcgacg tcgaggggg 1997822DNAArtificial SequenceSynthetic Sequence 978 ggggaacgtt aacgttgggg gg 2297920DNAArtificial SequenceSynthetic Sequence 979 ggggtcaccg gtgagggggg 2098022DNAArtificial SequenceSynthetic Sequence 980 ggggtcgttc gaacgagggg gg 2298122DNAArtificial SequenceSynthetic Sequence 981 ggggacgttc gaacgtgggg gg 2298210DNAArtificial SequenceSynthetic Sequence 982 tcaactttga 1098310DNAArtificial SequenceSynthetic Sequence 983 tcaagcttga 1098412DNAArtificial SequenceSynthetic Sequence 984 tcacgatcgt ga 1298512DNAArtificial SequenceSynthetic Sequence 985 tcagcatgct ga 1298620DNAArtificial SequenceSynthetic Sequence 986 gggggagcat gctggggggg 2098720DNAArtificial SequenceSynthetic Sequence 987 gggggggggg gggggggggg 2098822DNAArtificial SequenceSynthetic Sequence 988 gggggacgat atcgtcgggg gg 2298922DNAArtificial SequenceSynthetic Sequence 989 gggggacgac gtcgtcgggg gg 2299022DNAArtificial SequenceSynthetic Sequence 990 gggggacgag ctcgtcgggg gg 2299120DNAArtificial SequenceSynthetic Sequence 991 gggggacgta cgtcgggggg 209928DNAArtificial SequenceSynthetic Sequence 992 tcaacgtt 899320DNAArtificial SequenceSynthetic Sequence 993 tccataccgg tcctgatgct 2099420DNAArtificial SequenceSynthetic Sequence 994 tccataccgg tcctaccggt 2099520DNAArtificial SequenceSynthetic Sequence 995 gggggacgat cgttgggggg 2099620DNAArtificial SequenceSynthetic Sequence 996 ggggaacgat cgtcgggggg 2099721DNAArtificial SequenceSynthetic Sequence 997 ggggggacga tcgtcggggg g 2199821DNAArtificial SequenceSynthetic Sequence 998 gggggacgat cgtcgggggg g 2199912DNAArtificial SequenceSynthetic Sequence 999 aaagacgtta aa 12100012DNAArtificial SequenceSynthetic Sequence 1000 aaagagctta aa 12100112DNAArtificial Sequencemodified_base(6)...(6)m5c 1001 aaagangtta aa 12100212DNAArtificial SequenceSynthetic Sequence 1002 aaattcggaa aa 12100321DNAArtificial SequenceSynthetic Sequence 1003 gggggtcatc gatgaggggg g 21100421DNAArtificial SequenceSynthetic Sequence 1004 gggggtcaac gttgaggggg g 21100520DNAArtificial SequenceSynthetic Sequence 1005 atgtagctta ataacaaagc 20100620DNAArtificial SequenceSynthetic Sequence 1006 ggatcccttg agttacttct 20100720DNAArtificial SequenceSynthetic Sequence 1007 ccattccact tctgattacc 20100820DNAArtificial SequenceSynthetic Sequence 1008 tatgtattat catgtagata 20100920DNAArtificial SequenceSynthetic Sequence 1009 agcctacgta ttcaccctcc 20101020DNAArtificial SequenceSynthetic Sequence 1010 ttcctgcaac tactattgta 20101120DNAArtificial SequenceSynthetic Sequence 1011 atagaaggcc ctacaccagt 20101220DNAArtificial SequenceSynthetic Sequence 1012 ttacaccggt ctatggaggt 20101320DNAArtificial SequenceSynthetic Sequence 1013 ctaaccagat caagtctagg 20101420DNAArtificial SequenceSynthetic Sequence 1014 cctagacttg atctggttag 20101520DNAArtificial SequenceSynthetic Sequence 1015 tataagcctc gtccgacatg 20101620DNAArtificial SequenceSynthetic Sequence 1016 catgtcggac gaggcttata 20101720DNAArtificial SequenceSynthetic Sequence 1017 tggtggtggg gagtaagctc 20101820DNAArtificial SequenceSynthetic Sequence 1018 gagctactcc cccaccacca 20101920DNAArtificial SequenceSynthetic Sequence 1019 gccttcgatc ttcgttggga 20102020DNAArtificial SequenceSynthetic Sequence 1020 tggacttctc tttgccgtct 20102120DNAArtificial SequenceSynthetic Sequence 1021 atgctgtagc ccagcgataa 20102220DNAArtificial SequenceSynthetic Sequence 1022 accgaatcag cggaaagtga 20102320DNAArtificial SequenceSynthetic Sequence 1023 tccatgacgt tcctgacgtt 20102424DNAArtificial SequenceSynthetic Sequence 1024 ggagaaaccc atgagctcat ctgg 24102520DNAArtificial SequenceSynthetic Sequence 1025 accacagacc agcaggcaga 20102620DNAArtificial SequenceSynthetic Sequence 1026 gagcgtgaac tgcgcgaaga 20102720DNAArtificial SequenceSynthetic Sequence 1027 tcggtaccct tgcagcggtt 20102820DNAArtificial SequenceSynthetic Sequence 1028 ctggagccct agccaaggat 20102920DNAArtificial SequenceSynthetic Sequence 1029 gcgactccat caccagcgat 20103021DNAArtificial SequenceSynthetic Sequence 1030 cctgaagtaa gaaccagatg t 21103121DNAArtificial SequenceSynthetic Sequence 1031 ctgtgttatc tgacatacac c 21103221DNAArtificial SequenceSynthetic Sequence 1032 aattagcctt aggtgattgg g 21103321DNAArtificial SequenceSynthetic Sequence 1033 acatctggtt cttacttcag g 21103423DNAArtificial SequenceSynthetic Sequence 1034 ataagtcata ttttgggaac tac 23103521DNAArtificial SequenceSynthetic Sequence 1035 cccaatcacc taaggctaat t 21103620DNAArtificial SequenceSynthetic Sequence 1036 ggggtcgtcg acgagggggg 20103722DNAArtificial SequenceSynthetic Sequence 1037 ggggtcgttc gaacgagggg gg 22103822DNAArtificial SequenceSynthetic Sequence 1038 ggggacgttc gaacgtgggg gg 22103915DNAArtificial Sequencemodified_base(9)...(9)n is 5-methylcytosine. 1039 tcctggcgng gaagt 15104022DNAArtificial SequenceSynthetic Sequence 1040 ggggaacgac gtcgttgggg gg 22104120DNAArtificial SequenceSynthetic Sequence 1041 ggggaacgta cgtcgggggg 20104224DNAArtificial SequenceSynthetic Sequence 1042 ggggaacgta cgtacgttgg gggg 24104320DNAArtificial SequenceSynthetic Sequence 1043 ggggtcaccg gtgagggggg 20104424DNAArtificial SequenceSynthetic Sequence 1044 ggggtcgacg tacgtcgagg gggg 24104522DNAArtificial SequenceSynthetic Sequence 1045 ggggaccggt accggtgggg gg 22104619DNAArtificial SequenceSynthetic Sequence 1046 gggtcgacgt cgagggggg 19104718DNAArtificial SequenceSynthetic Sequence 1047 ggggtcgacg tcgagggg 18104822DNAArtificial SequenceSynthetic Sequence 1048 ggggaacgtt aacgttgggg gg 22104919DNAArtificial SequenceSynthetic Sequence 1049 ggggacgtcg acgtggggg 19105034DNAArtificial SequenceSynthetic Sequence 1050 gcactcttcg aagctacagc cggcagcctc tgat 34105132DNAArtificial SequenceSynthetic Sequence 1051 cggctcttcc atgaggtctt tgctaatctt gg 32105235DNAArtificial SequenceSynthetic Sequence 1052 cggctcttcc atgaaagtct ttggacgatg tgagc 35105315DNAArtificial SequenceSynthetic Sequence 1053 tcctgcaggt taagt 15105420DNAArtificial SequenceSynthetic Sequence 1054 gggggtcgtt cgttgggggg 20105520DNAArtificial SequenceSynthetic Sequence 1055 gggggatgat tgttgggggg 20105620DNAArtificial Sequencemodified_base(7)...(7)m5c 1056 gggggangat ngttgggggg 20105720DNAArtificial SequenceSynthetic Sequence 1057 gggggagcta gcttgggggg 20105820DNAArtificial SequenceSynthetic Sequence 1058 ggttcttttg gtccttgtct 20105920DNAArtificial SequenceSynthetic Sequence 1059 ggttcttttg gtcctcgtct 20106020DNAArtificial SequenceSynthetic Sequence 1060 ggttcttttg gtccttatct 20106120DNAArtificial SequenceSynthetic Sequence 1061 ggttcttggt ttccttgtct 20106220DNAArtificial SequenceSynthetic Sequence 1062 tggtcttttg gtccttgtct 20106320DNAArtificial SequenceSynthetic Sequence 1063 ggttcaaatg gtccttgtct 20106420DNAArtificial SequenceSynthetic Sequence 1064 gggtcttttg ggccttgtct 20106524DNAArtificial SequenceSynthetic Sequence 1065 tccaggactt ctctcaggtt tttt 24106620DNAArtificial SequenceSynthetic Sequence 1066 tccaaaactt ctctcaaatt 20106724DNAArtificial SequenceSynthetic Sequence 1067 tactactttt atacttttat actt 24106824DNAArtificial SequenceSynthetic Sequence 1068 tgtgtgtgtg tgtgtgtgtg tgtg 24106925DNAArtificial SequenceSynthetic Sequence 1069 ttgttgttgt tgtttgttgt tgttg 25107027DNAArtificial SequenceSynthetic Sequence 1070 ggctccgggg agggaatttt tgtctat 27107119DNAArtificial SequenceSynthetic Sequence 1071 gggacgatcg tcggggggg 19107220DNAArtificial SequenceSynthetic Sequence 1072 gggtcgtcga cgaggggggg 20107319DNAArtificial SequenceSynthetic Sequence 1073 ggtcgtcgac gaggggggg 19107420DNAArtificial SequenceSynthetic Sequence 1074 gggtcgtcgt cgtggggggg 20107520DNAArtificial SequenceSynthetic Sequence 1075 ggggacgatc gtcggggggg 20107620DNAArtificial SequenceSynthetic Sequence 1076 ggggacgtcg tcgtgggggg 20107727DNAArtificial SequenceSynthetic Sequence 1077 ggggtcgacg tcgacgtcga ggggggg 27107821DNAArtificial SequenceSynthetic Sequence 1078 ggggaaccgc ggttgggggg g 21107921DNAArtificial SequenceSynthetic Sequence 1079 ggggacgacg tcgtgggggg g 21108023DNAArtificial SequenceSynthetic Sequence 1080 tcgtcgtcgt cgtcgtgggg ggg 23108115DNAArtificial SequenceSynthetic Sequence 1081 tcctgccggg gaagt 15108215DNAArtificial SequenceSynthetic Sequence 1082 tcctgcaggg gaagt 15108315DNAArtificial SequenceSynthetic Sequence 1083 tcctgaaggg gaagt 15108415DNAArtificial SequenceSynthetic Sequence 1084 tcctggcggg caagt 15108515DNAArtificial SequenceSynthetic Sequence 1085 tcctggcggg taagt 15108615DNAArtificial SequenceSynthetic Sequence 1086 tcctggcggg aaagt 15108715DNAArtificial SequenceSynthetic Sequence 1087 tccgggcggg gaagt 15108815DNAArtificial SequenceSynthetic Sequence 1088 tcggggcggg gaagt 15108915DNAArtificial SequenceSynthetic Sequence 1089 tcccggcggg gaagt 15109015DNAArtificial SequenceSynthetic Sequence 1090 gggggacgtt ggggg 15109120DNAArtificial SequenceSynthetic Sequence 1091 ggggtttttt ttttgggggg 20109220DNAArtificial SequenceSynthetic Sequence 1092 ggggcccccc ccccgggggg 20109321DNAArtificial SequenceSynthetic Sequence 1093 ggggttgttg ttgttggggg g 21

Claims (21)

We claim:

1-36. (Canceled)

37. A method of suppressing a symptom of an allergic response in a subject, the method comprising: administering to the subject a first dose of an immunostimulatory nucleic acid; and administering to the subject a second dose of an immunostimulatory nucleic acid, wherein the immunostimulatory nucleic acid comprises a nucleotide sequence comprising 5′-CG-3′, and wherein the second dose is administered from about 1 day to about 8 weeks after the first dose.

38. The method ofclaim 37, wherein the second dose is administered from about 1 day to about 7 days after the first dose.

39. The method ofclaim 37, wherein the second dose is administered from about 1 week to about 2 weeks after the first dose.

40. The method ofclaim 37, wherein the second dose is administered from about 2 weeks to about 4 weeks after the first dose.

41. The method ofclaim 37, wherein the first dose is co-administered with an antigen.

42. The method ofclaim 37, wherein the second dose is co-administered with an antigen.

43. The method ofclaim 37, wherein the first dose and second dose are co-administered with an antigen.

44. The method ofclaim 37, wherein the subject is a human.

45. The method ofclaim 37, wherein the first and the second doses are administered by inhalation.

46. A method for maintaining suppression of a Th2 immune response in a subject, the method comprising: administering to a subject a first dose of an immunostimulatory nucleic acid; and administering to the subject a second dose of an immunostimulatory nucleic acid, wherein the immunostimulatory nucleic acid comprises a nucleotide sequence comprising 5′-CG-3′, and wherein the second dose is administered from about 1 day to about 8 weeks after the first dose.

47. The method ofclaim 46, wherein the second dose is administered from about 1 day to about 7 days after the first dose.

48. The method ofclaim 46, wherein the second dose is administered from about 1 week to about 2 weeks after the first dose.

49. The method ofclaim 46, wherein the second dose is administered from about 2 weeks to about 4 weeks after the first dose.

50. The method ofclaim 46, wherein the subject is a human.

51. The method ofclaim 46, wherein the first and the second doses are administered by inhalation.

52. A method for maintaining stimulation of a Th1 immune response in a subject, the method comprising: administering to a subject a first dose of an immunostimulatory nucleic acid; and administering to the subject a second dose of an immunostimulatory nucleic acid, wherein the immunostimulatory nucleic acid comprises a nucleotide sequence comprising 5′-CG-3′, and wherein the second dose is administered from about 1 day to about 8 weeks after the first dose.

53. The method ofclaim 52, wherein the second dose is administered from about 1 day to about 7 days after the first dose.

54. The method ofclaim 52, wherein the second dose is administered from about 1 week to about 2 weeks after the first dose.

55. The method ofclaim 52, wherein the second dose is administered from about 2 weeks to about 4 weeks after the first dose.

56. The method ofclaim 52, wherein the subject is a human.